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ABSTRACT
The studies described in this thesis set out to investigate three
areas of LHRH action:- (1) Identification of the factors regulating LHRH
receptor concentrations in pituitary and ovary; (2) Investigation of the
nature of the short-term effects of LHRH on follicular steroidogenesis;
(3) Assessment of the relevance of direct ovarian actions of LHRH in the
human.
An LHRH receptor assay capable of quantitative determination of LHRH
receptor numbers in individual rat anterior pituitary glands and ovaries
was validated and used to investigate receptor changes under a number of
reproductive states. In the male, active immunization against
testosterone or castration resulted in increased pituitary LHRH receptor
concentrations whereas hyperprolactinaemia or removal of endogenous LHRH
by active or passive immunization against LHRH was associated with
decreased receptors. In the female, ovariectomy or active immunization
against LH raised receptors. Active immunization against LHRH decreased
receptors. During the oestrous cycle passive immunoneutralization of
LHRH, but not LH, prevented the pro-oestrous receptor rise but neither
regime prevented the fall to oestrous levels.
It v/as concluded from these observations that pituitary LHRH
receptors are primarily under positive autoregulatory control.
Specific LHRH receptors were characterized and localized by
autoradiography in ovarian tissue. Receptor concentrations were increased
after active immunization against LH or LHRH and in rats exposed to
constant light. Ovarian LHRH receptors were concluded not to be
controlled concurrently with those of pituitary.
(iv)
Basal steroidogenesis was specifically stimulated in a dose dependent
manner by LHRH and LHRH agonist in isolated rat pre-ovulatory follicles.
Stimulation of progesterone was likely to be mediated by direct granulosa
cell action. Basal androgen levels were stimulated, implicating a direct
thecal action. However an indirect effect via granulosa cell aromatase
could not be excluded.
The question of the existence of an endogenous ovarian LHRH-like
material was assessed by measuring specific displacement in radioreceptor
and radioimmunoassays by ovarian extracts. Results proved inconclusive
due to interference of control tissues and variability of data.
Specific binding of 125i_|_hrh agonist was demonstrated to human
luteal, but not post-menopausal ovarian tissue. Binding was of low
affinity (Ka 3 x 10? M*l) and the physiological significance of the
observed binding is uncertain.
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1.1 BACKGROUND
The isolation, purification and characterization of luteinizing
hormone releasing hormone (LHRH) from bovine and porcine hypothalami
(Schally & Bowers, 1964; Matsuo et al ., 1971; Schally et al ., 1971;
Burgus et al ., 1972) represented a landmark in reproductive biology.
The identity of the stimulatory controlling factor for gonadotrophin
release from the anterior pituitary was now known and the theory of
hypothalamic control of pituitary function (Harris, 1948) confirmed.
LHRH is a decapeptide of molecular weight 1183, its amino acid
sequence (pyro-glu-his-trp-ser-tyr-gly-1eu-arg-pro-gly-NH2) is
highly conserved throughout evolution (King & Millar, 1980)
indicating its vital importance to reproduction.
The essential role of LHRH in the stimulation of both
luteinizing hormone (LH) and follicle stimulating hormone (FSH) was
elegantly demonstrated by neutralization of LHRH by antibodies.
Specific immunoneutral ization of LHRH resulted in immediate abolition
of the stimulus for pituitary control of gonadal function (Fraser &
Gunn, 1973; Koch et al ♦, 1973; see Fraser, 1980 for review). The
availability of antisera to LHRH, together with techniques for
sampling portal blood, subsequently enabled demonstration of
immunoreactive LHRH in the portal blood in rats (Fink A Jamieson,
1974). The physiological importance of endogenously released LHRH in
the induction of the LH surge was confirmed by the demonstration that
a surge of LHRH occurs coincident with increases in LH in rats,
(Sarkar et al ., 1976; Levine & Ramirez, 1982) rhesus monkeys, (Neil 1
et al., 1976) rabbits (Tsou et al., 1977) and ewes (Levine et al .,
1982).
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1.2 REGULATION OF LHRH
Following the identification of LHRH and the development of
sensitive immunoassays for its measurement in portal blood (e.g. Nett
et al ., 1973) major advances were made in the elucidation of its mode
of action (for review see Fink, 1979). Clearly two loci were
available for control of pituitary function, namely the hypothalamus,
as the site of LHRH release, and the pituitary, as the site of
action.
1.2.1 LHRH Release
Gonadotrophin release was known to be under central neural
control (e.g. see Everett, 1964). This release was elegantly shown
to be LHRH-mediated by Fink A Jamieson in 1974, who demonstrated
increased release of LHRH into portal blood after electrical stimula¬
tion of the pre-optic area. In addition, since the LHRH released in
response to stimulation varied during the oestrous cycle (Fink A
Jamieson, 1976) it was likely that peripheral factors could influence
LHRH release. Oestrogen was subsequently shown to increase
responsiveness of neurons releasing LHRH (Sherwood et al♦, 1976) and
to facilitate LHRH release into portal blood (Sarkar A Fink, 1979).
Steroids are capable of modulating the firing rate of hypothalamic
neurons (Hayward, 1977; Fink A Geffen, 1978) making it likely that
LHRH release is effected by common neuronal pathways. The nature of
these pathways is complex and largely a mystery involving
dopaminergic, serotonergic and noradrenergic neurones (review by Fink
& Geffen, 1978; Rarraclough & Wise, 1982).
1.2.2 Pituitary Responsiveness
Numerous studies have shown that pituitary responsiveness to
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Ovariectomy has been shown to result in an increase in portal blood
levels of LHRH in the rat thus confirming the importance of steroids in the
control of LHRH release (Sherwood and Fink, 1980).
LHRH varies under different endocrine environments (reviewed in
Chapter 4). The role of gonadal steroids as both 'negative' and
'positive' feedback regulators of pituitary function is widely
acknowledged (Everett, 1964; Knobil, 1974; Aiyer A Fink, 1974; Fink,
1979), the mechanism for these actions being mediated in part by a
determination of pituitary responsiveness to LHRH (Aiyer A Fink,
1974; Aiyer et a!., 1974a; Fink, 1979 for review).
In addition it was observed that the magnitude of LH released in
response to a given dose of LHRH was dependent on the degree of prior
exposure to LHRH - a phenomenon termed the 'self priming effect'
(Aiyer et al ., 1973, 1974b). This was also observed following LHRH
release induced by stimulation of the preoptic area (Fink et al.,
1976) and was found to be dependent upon protein and mRNA synthesis
(Pickering A Fink, 1976).
There are three potential mechanisms by which gonadal steroids
and LHRH could influence pituitary sensitivity; the first is by
influencing LHRH release (i.e. at a 'pre-receptor' locus), the second
by influencing the number and/or affinity of pituitary receptors for
LHRH (i.e. receptor regulation) and finally by influencing the
storage and release of gonadotropin'ns (i.e. a 'post-receptor locus').
Chapter 4 of this thesis is concerned with an examination of the
second mechanism - namely receptor regulation.
1.3 PARADOXICAL ANTIFERTILITY EFFECTS OF LHRH
With the wealth of data available on the nature and control of
gonadotroph!n release from the pituitary it was postulated that
synthetically produced LHRH would provide a major advance in the
induction of fertility. However, toxicity trials during the mid
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1970's using synthetic LHRH demonstrated the somewhat surprising
findings, that exogenously administered LHRH did not invariably
stimulate gonadal function. Administration of pharmacological doses
of LHRH (1 mg/day) on d 1-7 of pregnancy inhibited pregnancy in rats
(Corbin & Beattie, 1975). In immature male rats, chronic LHRH
treatment resulted in decreased seminal vesicle and ventral prostate
weight in addition to decreased serum testosterone (Oshima et al .,
1975). Consecutive daily administration of LHRH to ewes resulted in
diminished LH responses (Rippel et al ., 1974) and infusion of LHRH
actually inhibited LH release in ovariectomized ewe s (Piper et al .,
1975). Antiferti1ity effects of LHRH were also noted in rabbits
(Rippel A Johnson, 1976a) and hamsters (Windsor et al ., 1977).
Initially these observations were ill understood and largely
ignored until new LHRH analogues were developed. Although a great
deal of effort had been channelled into attempts at synthesizing
antagonist analogues, only relatively recently have potent
antagonists proved effective at blocking fertility (Rivier et al .,
1981; Zarate et al ., 1981). The major advances both in clinical uses
and in understanding the antiferti1ity effects of LHRH, have come
from the development of potent agonist analogues.
In trials designed to test the effectiveness of an antagonist
analogue in inhibiting pregnancy in the rat, the LHRH agonist
'control treatment1 proved more effective than the antagonist, when
administered both pre-(d 1-7) and post-(d 7-12) implantation (Corbin
et al ., 1978; Rex A Corbin, 1981). The first detailed analysis of
antiferti1ity effects of LHRH agonist was the demonstration that
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chronic administration to both immature and adult female rats delayed
vaginal opening, arrested uterine growth and caused oestrcus cycles to
cease (Johnson et al ., 1976a). These observations have subsequently
been confirmed by numerous other studies (Corbin et al., 1978; Rivier
et al ., 1978; Vi 1 chez-Martinez et al ., 1979; Cusan et al ., 1979;
Maynard A Nicholson, 1979)
Similar inhibitory effects were noted in male rats. Following
chronic agonist treatment, testicular weight decreased and
spermatogenesis became impaired (Pelletier et al ., 1978; Rivier et
al., 1979; Cusan et al., 1979) presumably due to decreased
testosterone production (Sandow, 1978b; Labrie et al., 1980).
1.4 CLINICAL USES OF LHRH AND ITS ANALOGUES
From the above discussions manipulation of pituitary exposure to
LHRH clearly has enormous potential in the regulation of human fert¬
ility. The dual uses of LHRH and its analogues either to mimic the
endogenous molecule and thus promote fertility, or to utilize the
paradoxical inhibitory actions, are amply illustrated by the clinical
uses of LHRH.
1.4.1 Restoration of fertility
Pituitary function had been successfully restored in arcuate
nucleus lesioned rhesus monkeys with pulses of LHRH every 1-2 h
(Knobil, 1980) or in rams in the inactive breeding season by pulses
of LHRH (Lincoln S Short, 1980). Pulsatile administration of LHRH
was subsequently used to induce ovulation in infertile women with
LHRH deficiency due to Kallman's Syndrome (Crowley & McArthur 1980).
In addition pulsatile delivery of LHRH every 60-120 minutes
using an automatic portable pump has restored fertility in patients
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suffering from secondary amenorrhea, and pregnancies have been
reported, following treatment (Leyendeker et al ., 1980; Yen, 1983).
The treatment with LHRH of men suffering from infertility due to
impaired gonadotropin' n secretion, has resulted in restoration of
potential fertility (Hoffman & Crowley, 1982).
1.4.2 Contraceptive effects
Following observations that continuous administration of LHRH
agonists causes infertility effects in rodents and sheep (see 1.3),
these findings have been extended to the human. This approach offers
a new method of contraception, devoid of the side effects of steroids
(see Fraser, 1981a and 1982 for reviews). Daily administration of
small doses of LHRH agonist had resulted in the cessation of
menstrual cycles and abolition of ovulation in women, rhesus mokeys
and stumptailed macaques (Ni 11 ius et_al_., 1978; Vickery et al ♦, 1980;
Fraser et al., 1980). Other regimes of LHRH administration were also
reported to interfere with ovarian function. High doses of LHRH
agonist administered during the early follicular phase resulted in
the formation of an inadequate corpus luteum (Sheehan et al ., 1982),
and during the luteal phase induced premature luteolysis (Casper &
Yen, 1979; Lemay et al ., 1979).
The contraceptive use of LHRH agonist in males has been less
encouraging. Although LHRH agonist reversibly inhibited
spermatogenesis the decreased testosterone production resulted in
impotence and decreased libido (Linde et al ♦, 1981).
The ability of LHRH agonist to suppress gonadal function has
important applications in the treatment of hormone-dependent
disorders. Thus "chemical castration" using LHRH agonist has been
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used to delay the onset of puberty in patients with precocious
puberty (Comite et al., 1981) and to reduce gonadal steroid output in
steroid dependent tumours of the breast (Klijn & de Jong, 1982) and
prostate (Rorgmann et al ♦, 1982; Waxman et al ♦, 1983). LHRH agonist
has also been used to relieve patients with endometriosis (Meldrum et
al., 1982; Werlin & Hodgen, 1983; Shaw db at _ . 1983).
The development of antagonist analogues to inhibit LHRH action
has been less promising (Schally et al ., 1980). However, potent
antagonists have recently been shown to inhibit ovulation in the rat
(Nekola et al ., 1982) and in women (Zarate et al ., 1981) as well as
inhibiting pulsatile LH secretion in castrate male monkeys (Pineda et
al_., 1983).
Pulsatile administration of LHRH thus has important clinical
applications in the induction of fertility whilst LHRH agonists have
a wider clinical potential in suppressing pituitary function.
1.5 MECHANISM OF ANTIFERTILITY EFFECTS OF LHRH
Whereas the induction of fertility by LHRH is well understood,
(its rationale being based on the physiology of the endogenous
peptide) the mechanisms by which LHRH administration results in
inhibition of fertility are largely unknown. However, at least three
explanations have been suggested, namely pituitary desensitization,
gonadal desensitization and direct gonadal actions.
1.5.1 Pituitary desensitization
Continuous or repeated stimulation of the pituitary with LHRH
eventually results in a decreased pituitary responsiveness to LHRH
(Belchez et al., 1978; Sandow, 1978a; Sharpe et al ., 1979; Fraser et
al., 1980). This phenomenon of desensitization has been observed for
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a number of peptide hormones (see Catt 1979 for review) and is
generally considered to be due to a decrease in the number of
receptors for that ligand i.e. down-regulation (Raff, 1976; Catt,
1979). It is therefore possible that continuous exposure of the
gonadotroph cells to LHRH or LHRH agonist causes down-regulation of
its receptors and subsequent desensitization, with decreased
gonadotrophin release and impairment of gonadotrophin dependent
functions, such as spermatogensis and ovulation. This possibility is
examined in Chapter 4.
1.5.2 Gonadal desensitization
Since chronic treatment with LHRH agonist initially results in
c
stimulation of supraphysiologilal levels of LH (e.g. Fraser ?• Lincoln,
1980) it has been suggested that gonadal steroidogenic impairment
could be induced by continuously high circulating gonadotrophs
levels following agonist treatment (Auclair et al ., 1977a,b; Cusan et
al., 1979). High LH levels are known to result in desensitization of
the gonad due to receptor down-regulation in males and females
(Sharpe, 1976; Conti et al ., 1976). Chronic administration of LHRH
agonist was associated with 70% inhibition of testicular LH receptors
(Auclair et al ♦, 1977b; Cusan et al ., 1979) and the post coital
antifertil ity effects of LHRH agonist were associated with decreased
ovarian LH receptors (Kledzik et al ., 1978).
However, if this mechanism were of primary importance in
determining the antiferti1ity effects of LHRH it would be expected
that exogenous administration of gonadotrophins would induce similar
antiferti 1 ity effects to those of LHRH agonist. Abnormally high
gonadotrophi n levels have been demonstrated to disrupt both
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follicular development, ovulation (Friedrick et al_., 1975) and
testicular function (Hsueh et al ., 1977) but whereas the effects of
chronic hCG administration are transient, those of LHRH are prolonged
(Cusan et al ., 1979). In addition the LHRH - induced decrease in
progesterone production in pregnant rats could not be repeated with
high LH administration (Yoshinaga, 1979). Moreover, whilst daily
administration of LHRH agonist resulted in inhibition of testosterone
production and decreased secondary sex organ weights, daily PMSG
treatment increased both parameters (Rivier et al ., 1979). These
data suggest therefore that the antiferti 1 ity effects of LHRH cannot
be due entirely to the secondary induction of supraphysiological
levels of LH and subsequent gonadal desensitization.
1.5.3 Direct gonadal actions of LHRH
The above explanations for the mechanism of the paradoxical
antifertility effects of LHRH are based on the premise that LHRH acts
exclusively on the pituitary gland. This assumption was challenged
in 1976 when Pippel & Johnson (1976b) showed that the hCG-induced
ovarian and uterine weight gain in hypophysectomized rats could be
inhibited by concurrent administration of LHRH agonist, thus
implicating a direct ovarian site of action for LHRH agonist. This
important observation went largely unnoticed and it was three years
before direct gonadal effects were re-examined. The findings of
Rippel & Johnson were subsequently confirmed and extended by Ying &
Guillemin (1979a) who in 1979 showed that follicular maturation and
ovulation induced by PMSG in hypophysectomized rats could be
prevented by LHRH agonist in a dose-dependent manner. Exciting
confirmation of direct ovarian actions of LHRH come from in vitro
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experiments showing LHRH inhibition of FSH-induced oestradiol
production in isolated granulosa cells (Hsueh & Erickson 1979a).
This effect was specific for LHRH, being prevented by LHRH
antagonists (Hsueh & Ling, 1979). An important contribution to this
data was the observation that the actions of LHRH were associated
with specific competitive uptake of labelled LHRH agonist by the
ovary, thus suggesting the presence of specific binding sites (Kayar
et al ., 1979). Evidence for the existence of such receptors as well
as a discussion of their regulation is presented in Chapters 3 and
5.
Direct gonadal actions of LHRH were not however confined to the
ovary. LHRH was shown to inhibit FSH-induced increases in testicular
weight and steroidogensis in hypophysectomized male rats (Hsueh &
Erickson, 1979b).
Few studies have attempted to elucidate the relative importance
of pituitary and extrapituitary sites of action in determining the
antifertility effects of LHRH. Since LHRH agonist administration to
hypophysectomized rats results in an inhibition of gonadal LH/hCG
receptors (Arimura et al., 1979; Bambino et al ♦, 1980), gonadal
desensitization following LHRH administration to intact rats could be
due to either direct or pituitary mediated effects. A comparison of
the gonadal LH receptors 48 hrs after a single injection of LHRH
agonist in intact versus hypophysectomized rats (Seguin et al ♦, 1981)
provided interesting data on this question. All treated animals
showed decreased receptors relative to controls. The receptor
decrease was greater in intact than hypophysectomized male rats,
but both intact and hypophysectomized female rats showed similar
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responses. The authors concluded that the major cause of testicular
LH receptor loss was due to down-regulation following hypersecretion
of LH. However in the female, direct gonadal actions were likely to
play a more important role (Seguin et al ., 1981).
In conclusion, the antiferti1ity effects observed after
exogenous administration of LHRH and its analogues are likely to be
due to complex multiple interactions involving pituitary and gonadal
desensitization together with direct gonadal actions. The relative
contribution of each, particularly in the case of the human, remains
uncertain.
1.6 EXTRAPITUITARY ACTIONS OF LHRH
One of the most intriguing observations to emerge from studies
outlined above was that LHRH and its agonists were capable of
directly regulating tissues other than the pituitary. Since further
studies on this theme were a major part of this thesis the following
sections consider the evidence for extrapituitary actions.
1.6.1 Direct Ovarian Actions
1.6.1.1 Granulosa Cells
In vitro studies on the action of LHRH on isolated granulosa
cells have emphasised an inhibitory effect. Thus, LHRH and LHRH
agonist inhibited FSH-induced increases in oestradiol and
progesterone production (Hsueh & Frickson, 1979a; Knecht A Catt,
1981; Ranta et al ., 1982). This inhibition was manifested by doses
of LHRH compatible with the Ka of the ovarian LHRH receptor (see
Chapter 3). Similar inhibition has been observed in hypo-
physectomized rats treated with FSH and LHRH (e.g. Jones and Hsueh,
1981a). These data are not confined to the rat; direct inhibition of
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granulosa cell function has been reported in porcine granulosa cells
treated with LHRH agonist (Massicotte et al ., 1980).
Since FSH-induction of steroidogenesis involved changes in the
activities of a number of steroidogenic enzymes it seemed likely that
LHRH would reverse these changes. This has been demonstrated to be
the case for four such enzymes.
Progesterone release is primarily under the control of three
enzymes: (a) 3J1 hydroxysteroid dehydrogenase (3^HSD) catalysing the
synthesis of progesterone from its immediate precursor, pregnenolone;
(b) 20 oC hydroxysteroid dehydrogenase (20 oi HSD) responsible for the
conversion of active progesterone to its inactive 20 hydroxypregn-4-
en-3-one (20 C< DHP) metabolite; and (c) sidechain cleavage (SCO)
enzyme which determines the availability of pregnenolone from its
precursor cholesterol. LHRH was found to inhibit FSH-induced
increases in 3pHSD (Hsueh & Jones, 1982a; Jones & Hsueh, 1982) and to
stimulate 20 C*. DHP (Jones & Hsueh, 1981b,c) activity. In addition,
since FSH-induced synthesis of pregnenolone from cholesterol was
inhibited by LHRH (Hsueh & Jones, 1981; Jones & Hsueh, 1982) an
effect on SCO enzyme seems likely. Thus LHRH antagonised all three
parameters of FSH-induced changes in progesterone metabolism,
resulting in decreased rate . of synthesis and increased rate of
inactivation.
Oestradiol production is controlled primarily by the
availability of androgen precursor and on the activity of aromatase.
Again LHRH and LHRH agonist have been found to inhibit FSH-induced
increases in aromatase activity (Hsueh et al♦, 1980; Hi 11er et al.,
1981; Gore-Langton et al ♦, 1981). In addition to changes in the V
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max of FSH-dependent enzymes (Hsueh et al., 1980; Jones & Hsueh,
1981), LHRH inhibited the FSH-induced increase in both LH (Hsueh et
al., 1980) and prolactin (PRL) receptors (Navickis et al., 1982).
LHRH and LHRH agonist were also shown to influence granulosa
cell morphology. Both FSH-induced cellular aggregation and
microvillus formation were inhibited by LHRH and LHRH agonist
(Amsterdam et al., 1981; Knecht et al., 1982). Since high resolution
autoradiographic studies have suggested that new receptors are
associated with microvillus formation (Amsterdam et al., 1981) it is
likely that LHRH-induced receptor decreases are mediated by such
morphological changes. Interestingly, LHRH inhibits FSH-induced
increases in membrane fluidity (Strulovici et al., 1981), again
confirming an inhibitory influence on the dynamics of membrane
function.
In conclusion the overall picture to emerge from analysis of the
effects of LHRH and LHRH agonists on granulosa cell function was an
inhibitory one, confirming the antifertility effects discussed
earlier. Some of these inhibitory actions are summarizied in Fig.
1.1 and clearly involve complex effects on both steroidogenic and
morphological responses. However, the majority of studies discussed
have utilized prolonged exposure of isolated cells to LHRH or its
agonist (see Hsueh & Jones, 1981 for review) on gonadotrophs
mediated events. If LHRH plays a physiological role within the ovary
(as suggested in 1.6.7) the short-term effects may be equally, or
perhaps more, important. This hypothesis provided the basis for







FIGURE 1.1 Summary of some of the inhibitory actions of LHRH on ovarian
follicular function, involving inhibition of FSH induced
increases in oestradiol (E2), progesterone (P) and LH




Two in vitro models have been utilized to provide a source of
luteal tissue. The first involved induction of "granulosa-!uteal"
cells with functional LH receptors, following prolonged exposure of
granulosa cells to FSH (Erickson et al., 1979). LH-induced
steroidogenesis and prolactin receptor formation were inhibited by
LHRH both in vitro and in vivo (Jones & Hsueh, 1980). The second
model utilized luteal cells formed in vivo after treatment of
immature rats with PMSG/hCG. This model confirmed the inhibitory
effect of LHRH and LHRH agonist on LH-induced progesterone production
(CIayton et al., 1979a; Harwood et al♦, 1980a; Behrman et al., 1980;
Massicotte et al♦, 1981; Hall & Behrman, 1981).
Interestingly, LHRH agonist administration to hypophysectomized
PMSG/hCG primed rats resulted in decreased LH receptors (Harwood et
al., 1980b; Behrman et al., 1980; Hall & Behrman, 1981). Thus the
LHRH- and LHRH agonist-induced reduction in luteal cell sensitivity
to LH could be mediated by decreasing LH receptor numbers.
An important insight into the mechanism by which such direct
luteal effects could be mediated came with the demonstration of
specific high affinity LHRH receptors on luteal cells (Clayton et
al., 1979; Harwood et al., 1980a)
1.6.1.3 "Interstitial"/"Prepubertal tissue"
Preincubation of collagenase-dispersed cells from 25 day old rat
ovaries with LHRH agonist decreased the progesterone response induced
by hCG, cholera toxin or 8 bromo cAMP in short term culture in vitro
(Reddy et al., 1980). Similar cells from hypophysectomized, 21 day
old rat ovaries incubated in prolonged cultures indicated that LHRH
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inhibited the LH-, cholera toxin-, dibutyryl cAMP or oestrogen -
induced increase in "aromatizable androgen production" (Magoffin et
al., 1981). In addition LHRH agonist inhibited steroidogenesis in
hamster interstitial cells (Silavin & Greenwald, 1982). Thus LHRH
appears to have the potential to influence directly the steroidogenic
output of a number of cell types within the rat ovary.
1.6.2. Direct testicular actions of LHRH
Confirmation of direct testicular effects of LHRH following in
vivo observations in hypophysectomized rats (Hsueh & Erickson, 1979b;
Arimura et al., 1979) came with the demonstration of specific high
affinity LHRH receptors in isolated rat Leydig cells (Sharpe A
Fraser, 1980a) and testicular homogenates (Bourne et al., 1980;
Perrin et al., 1980a). Since these receptors were confined
exclusively to Leydig cells, the direct effects of LHRH and LHRH
agonists on testicular steroidogenesis were mediated entirely through
Leydig cells. These actions were inhibitory, decreasing the
sensitivity of Leydig cells to FSH (Bambino et al ♦, 1980; Hsueh et
al_., 1981).
Little is known about the effects of LHRH on steroidogenic
enzymes within the testis although a decrease in 17 oC hydroxylase
activity has been reported (Bambino et al., 1980). Since LHRH
receptors are absent from Sertoli cells, the lack of effect of LHRH
on FSH- cholera toxin- and dibutyryl cAMP - stimulation of aromatase
activity is therefore not surprising (Gore-Langton et al., 1981;
1982).
Direct testicular actions of LHRH confirmed the antifertility
effects of LHRH observed in male rats (1.3): In contrast to the ovary
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however, LHRH had only one site of action within the testis, namely
the Leydig cell.
1.6.3 Direct Uterine Action
A direct uterine action has been postulated for LHRH (Jones,
1979; Sundaram et al., 1981). However, since no evidence has been
found for specific uterine LHRH receptors (e.g. Clayton & Catt,
1981b) the physiological significance of this hypothesis remains
questionable.
1.6.4. Direct effects on the Placenta
Preliminary evidence suggested that LHRH was present in the
placenta and that LHRH stimulated placental hCG production (Khodr &
Siler-Khodr, 1978a; Siler-Khodr & Khodr, 1981) and released hCG from
trophoblast cells (B'utzow, 1982). However, this result has not been
confirmed by other investigators (e.g. Hussa, 1980) although LHRH
inhibition of progesterone (Wilson & Jawad, 1980) and oestrogen
(Branchaud et al., 1983) have been reported. Specific placental
binding sites have been demonstrated in human placental tissue
(Currie et al., 1981), but these are of low affinity (Ka 5 x 10?
M~l) and render it unlikely that concentrations of LHRH
sufficiently high to activate such receptors, would occur in vivo.
Thus the role of LHRH in the control of placental function has yet to
be adequately elucidated. However, it is of interest that the LHRH
decapeptide has now been characterized from human placenta extracts
(Tan & Rousseau, 1983).
1.6.5 Direct effects on Tumours
The ability of LHRH to inhibit steroid-dependent tumours (De
sombre et al., 1976; Johnson et al., 1976b) was explained
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initially on the basis of its "chemical castration" effects and
reduction of gonadal steroidogenesis. However, this may not be the
sole explanation since there are reports of direct effects of LHRH on
chorionic gonadotrophin release from rat choriocarcinoma cells and
human mammary tumour cells (Teodorczyk-Injeyan et al., 1981). In
addition, LHRH agonist inhibited testosterone release from a
Sertoli-Leydig cell tumour (Lamberts et al ♦, 1982).
1.6.6 LHRH and the Nervous System
LHRH may function as a peptide neurotransmitter influencing the
function of neurons outside the hypothalamic area at least in the
rat (Moss, 1979). For example LHRH has been detected in
extrahypothalamic areas (see Samson^/, 1980). Moreover, centrally-
mediated effects of LHRH on sexual behaviour have been reported (e.g.
Pfaff, 1973; Moss & McCann, 1973; Sakuma & Pfaff, 1980 and see Mauk
et al., 1980 for review). An antagonist analogue of LHRH has also
been shown to suppress sexual behaviour in rats (Dudley et al.,
1980).
In addition to the central nervous system, LHRH has been
detected in sympathetic neurons in the frog (Jan et al., 1979).
However, the presence and role of LHRH in mammalian sympathetic
neural control remains to be demonstrated.
1.6.7 Physiological Significance
Since hypothalamic LHRH is rapidly degraded (e.g. Jeffcoate et
al., 1974) it is unlikely that circulating levels sufficient
to interact with gonadal LHRH receptors, and therefore to exert
effects on gonadal function, are attained. The presence of specific
actions, mediated by high affinity receptors, particularly on gonadal
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cells (see Sharpe, 1982 for review) has led to the suggestion that,
far from being a pharmacological manifestation due to the
administration of high doses of LHRH or LHRH agonist, the direct
gonadal effects are of physiological relevance. Thus the gonads have
been suggested to produce an endogenous LHRH or LHRH-like molecule,
which under normal circumstances would act locally and represents the
true ligand for the receptors (Ying & Guillemin, 1979a).
There is ample evidence for the presence of non-steroidal
regulators of granulosa cell function (see Channing, 1979 for
review). Some of the effects reported for such factors bear a
considerable resemblance to the characteristic inhibition of
gonadotrophin-induced changes by LHRH. For example, LHRH inhibited
the FSH-induced increase in cAMP in isolated porcine granulosa cells
(Massicotte et al., 1980) and a factor present in porcine follicular
fluid also depressed LH-induced cAMP (Ledwitz-Rigby et al., 1977).
In addition LHRH decreased basal progesterone production in porcine
granulosa cells (Massicotte et al., 1980) and fluid from small
porcine follicles has been shown to be inhibitory to basal
progesterone (Ledwitz-Rigby et al ♦, 1977 and see Ledwitz-Rigby A
Rigby, 1931 for review).
It is therefore possible that a gonadal LHRH-like peptide is
present in follicular fluid, regulating follicular function, a
hypothesis which is examined further in Chapter 8. This concept is
particularly important when considering the wide clinical uses of
LHRH (see 1.4). It is not known whether LHRH exerts direct gonadal
actions in the human and, if so, whether the dose regimes used for
contraception (1.4.2) are exerting inhibitory effects directly on
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luteal function. Chapter 6 examines this possibility.
1.7 AIMS OF THESIS
Three main areas of research were seen as being of particular
importance in further developing an understanding of the actions of
LHRH, at the onset of work described in this thesis, namely: (a)
identification of the factors regulating LHRH receptors; (b)
investigation of the nature of the short-term direct actions of LHRH
on follicular steroidogenesis; and (c) assessment of the relevance of
direct gonadal actions of LHRH in the human. Accordingly attention
was focussed on the following objectives:-
1) Development of an LHRH receptor assay capable of quantitative
measurement of receptors in individual anterior pituitary glands
and ovaries (Chapter 3).
2) Utilization of such an assay to examine the regulation of LHRH
receptors, particularly in assessing the role of heterologous
ligand regulation and autoregulation in the determination of
receptors numbers (Chapters 4 and 5).
3) Assessment of whether direct ovarian actions of LHRH occur in
the human by investigation of the ability of 125 j-LHR H
agonist to bind to human ovarian tissue (Chapter 6).
4) Determination of the short-term effects of LHRH and LHRH agonist
on follicular function and in particular, the assessment of
whether LHRH is capable of influencing thecal function (Chapter
7).
5) Extraction of ovarian LHRH-like material and its
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2.1 RADIOLABELLING OF LHRH
2.1.1. Introduction
Radioreceptor and radioimmunoassays are critically dependent on
the availability of a tracer with a high specific activity. The
advantages of tritiated ligands are that the structural integrity of
the molecule is maintained and that the labelled hormone is stable
for storage. Although tritiated LHRH (3H-Pro9LHRH) had been
synthesised (e.g. Grant et al., 1973; Perrin et al., 198Gb) it was
found to produce relatively low yield and low specific activity.
The vast majority of studies now utilize LHRH labelled with one
125 j ocj ine atom at the Tyr position. This preparation has the
advantage of high yield and specific activity. However, the
i ncorporation of a large iodine atom necessarily increases the net
charge and electrophGretic mobility which may decrease the biological
potency of the labelled ligand (Nieman & Sandow, 1973; Terada et al.,
1980). Thus, although 3-25i_lhrj-| agonist is biologically active
in vivo (Sandow, 1978a; 1978b) the activity of the iodinated hormone
was estimated at 5G% of that of the unlabel led hormone (Sandow,
1978a). This figure is in agreement with the estimated maximum
receptor binding ability of the iodinated tracer (Clayton et al.,
1980a; Marshall et al., 1980).
Two methods of iodination have been used for LHRH. The first is
based on that of Greenwood et al., 1963 with Chloramine T as an
oxidizing agent. However, although this method results in the
production of monoiodi^ted LHRH, the specificity is variable (see
Table 2.1). The second method was therefore adopted as the procedure







































































































































1actoperoxidase method utilizing a hydrogen peroxide generating
system as described by Miyachi et al., 1973 and had been shown to
yield monoiodinated LHRH of high specific activity (Sharpe & Fraser,
1980) (Table 2.1) which is stable for up to 14 weeks (Marshall &
Odell, 1975). A glucose/glucose oxidase system provided a continuous
source of hydrogen peroxide thus avoiding high denaturing
concentration of strong oxidising agents (Miyachi et al., 1973).
2.1.2 Iodination of LHRH agonist
Reagents: Bovine serum albumin (BSA) (Sigma Type A6003 Fraction V)
Glucose (BDH Chemicals Ltd., Poole, England)
Glucose oxidase (Miles Labs Inc., U.S.A.,)
Lactoperoxidase (Sigma, Product No. L8503) 1 yjg/10 |il
Sephadex G25 fine (Pharmacia)
Phosphate buffer 0.05 M pH 7.4
Acetic acid buffer 0.01N
Elution buffer 0.01N acetic acid, 0.1% BSA.
Nal25j (Amersham) as carrier free solution in NaOH,
specific activity 100 mCi/ml





To a reaction vessel (63 x 11mm polystyrene tube) was added in
sequence:-
1. 5 jjl LHRH agonist
2. 40 jj! 0.05M phosphate buffer
3. 5 |il lactoperoxidase
4. 5 jjI glucose oxidase
5. 20 )jl Na 125J
6. The reaction was started by adding 20 jul of 0.1%
glucose solution (to activate the glucose oxidase and
provide a source of hydrogen peroxide as oxidizing
agent).
The reaction tube was stoppered, vortexed, and left to
react for 4 minutes.
7. The reaction was terminated by the addition of 300 jj!
of elution buffer and the mixture immediately applied to
a column of Sephadex gel.
Chromatography
Purification of monoiodinated LHRH agonist was achieved by
column adsorption chromatography using Sephadex gel. 12 g of
Sephadex G25 fine were left for 12-24 h to swell in the presence of
an excess (75 mis) of 0.01 N acetic acid. The swollen gel was
carefully poured into a 60 cm x 1 cm glass column and left to settle
to a packed height of 45 cms. The column was coated with 10 mis
0.01N acetic acid 5% BSA, to minimise adsorption of iodinated LHRH,
and washed with 50 mis 0.01N acetic acid, 0.1% BSA elution buffer.












































column using a long Pasteur pipette and allowed to soak into the gel.
The reaction vessel was washed with 300 jj1 of buffer and this was
applied to the column as described. The column was fitted with a
glass reservoir containing elution buffer. Fractions (70 drops) were
collected into glass tubes which had been precoated with 100 |il 0.01
N acetic acid, 5% BSA.
Results
A typical elution profile for iodinated LHRH agonist is shown in
Fig. 2.1. The same pattern is seen also for 125j_i_|-|RH. It has
been shown that the first peak of radioactivity represents unreacted
iodine and subsequent peaks contain iodinated peptides with varying
degrees of immunoreactivity, as assessed by the ability of label to
bind excess LHRH antibody, with the main peak binding 90% of antibody
(Marshall & Odell , 1975; Copeland et al., 1979). The receptor
binding ability for each fraction, as assessed in the Leydig cell
receptor assay, indicated that maximal binding was associated with
the third major peak which was taken to represent the
mono-125j_|_L|RH agonist fraction (Sharpe & Fraser, 1980). The
peak fraction together with the following two fractions from the
third major peak were pooled and stored in 250 jul aliquots at -20°C.
In general the tracer was found to retain binding characteristics for
long periods provided a given aliquot was not thawed and refrozen.
In practice the tracer was used up to eight weeks after storage with
no detectable deterioration in binding ability.
The specific activity of the tracer was assessed by self
displacement in either rat Leydig or rat pituitary radioreceptor
assay (Fig. 2.2). For the calculation it was assumed that at 50%
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CONCENTRATION OF LHRH AGONIST CM)
FIGURE 2.2 Displacement of 125I-LHRH agonist binding to rat pituitary
homogenate by unlabel led LHRH agonist. Each point represents
mean +_ range of duplicate determinations.
The specific activity of the tracer was calculated by assuming that at
50% displacement of binding the concentration of cold hormone (3 x
Iq-IOm) was in equilibrium with and thus equivalent to the amount of
labelled hormone added (100,000cpm). From this premis the number of counts
of labelled hormone equivalent to lmg cold hormone was calculated and
expressed as mCi/mg.
displacement x 10~10 m) the labelled hormone (100,000 cpm) is
in equilibrium with the unlabelled hormone. The specific activity
has been found to range from 900-1200 mCi/mg, figures within the
range reported by others utilizing the lactoperoxidase technique
(Table 2.1). The theoretical specific activity of monoiodinated LHRH
has been calculated to be 1600 jjg/ml (Marshall ft Odell, 1975) and the
range of values obtained using lactoperoxidase are thus consistent
with a monoiodinated ligand.




Elution buffer 0.01M phosphate buffered saline (PBS)
Chioramine T
Rat LH 1-4 NIAMDD, NIH, U.S.A.,
Sodium metabisulphite (Na2S20g) 0.16 mg/ml in 0.05 M
PBS
Potassium iodide (KI) 20 mg/ml in 0.05 M
PBS
Iodination Procedure
To a reaction vessel (63 x 11 mm polystyrene tube) was added in
sequence:-
1. 2 jjg LH
2. 20 /jl 0.05M PBS
3. 200-350 /jCi Nal25i
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4. The reaction was started by adding 10 y~\ Chloramine T
(5 mg/ml in 0.05 M PBS). React for 20 seconds.
5. The reaction was terminated by the addition of 750 jul
Na2S205 and 500 /j! KI as a carrier.
A column (12 x 1 cm) of Sephadex G50 was prepared as described
previously and the contents of the reaction vessel transferred to the
column and eluted with buffer into 1 ml fractions (63 x 11 mm
polystyrene tubes containing 0.1 ml 5% BSA in 0.01 M PBS). A typical
elution profile is given in Table 2.2. In this instance labelled
hormone was eluted in fraction 6 and the free 125 j -jn fractions
13-14. The labelled hormone (specific activity 60-120 mCi/mg) was
stored at 4°C and used within 2-3 weeks of preparation.
2.3 RADIOIMMUNOASSAY OF PROTEIN HORMONES
For a number of experiments described in Chapters 4 and 5, serum
concentrations and pituitary content of LH and FSH were assayed. The
methods used were essentially those described by Fraser & Sandow,
1977 and de Jong & Sharpe, 1977. Some of the assays were performed
by Mrs. M. Swaney.
Reagents: Iodinated rat LH (prepared as described)
Iodinated rat FSH (kindly prepared by Mrs. J. Smith by
Chloramine T iodination)
Assay buffer 0.01 M PBS, 0.01% thiomersalate, 1% BSA pH
7.5




Normal rabbit serum (NRS) Wellcome
Standards Rat LH-RP-1 NIAMDD, NIH, U.S.A.,
Rat FSH-RP-1 NIAMDD, NIH, U.S.A.,
Antisera Anti rat LH-S-4 from NIAMDD
Anti ovine FSH (61911) from Dr. J.M.J. Uilenbroek
Second antibody Donkey-anti-rabbit serum (DARS) Wellcome.
LH Assay Procedure
All additions were made using an automatic dispensing system
(Microlab M) into 63 x 11 mm polystyrene tubes. All incubations were
carried out at 4°C.
Day 1 Duplicate estimations of non-specific binding (NSB), total
binding (Bo), standards (serial dilutions from 0.7-100
ng/0.1 ml) and samples were made to a total volume of
0.4 ml. Subsequent additions were as follows:-
0.1 ml of antiserum (1:8,000 in special buffer).
Day 2 0.1 ml -jn assay buffer (15,000 cpm).
Day 3 0.1 ml (1:15 dilution) DARS.
Day 4 Separation of free from bound hormone was achieved after
dilution with 1 ml saline followed by centrifugation at
3000 rpm for 30 minutes at 4°C.
The pellet was counted and the assay calculated using a
gamma spectrometer attached to a commodore 4032 computer
(Nuclear Enterprises).
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The assay sensitivity was 6 ng/ml and the within assay coefficient of
variation 9%.
FSH Assay Procedure
Assay conditions were identical to those for LH except that
standards ranged from 3.9-500 ng/0.1 ml and the total assay volume
was 0.5 ml.
FSH Antiserum was used at 1:8,000 dilution. The assay
sensitivity was 50 ng/ml and the within-assay coefficient of
variation was 11%.
Pro!actin
Prolactin concentrations were estimated for an experiment
described in Chapter 4 section 4.3.2.2. These samples were assayed
by Dr. A.S. McNeilly (McNei1ly et al., 1978).
2.4 RADIOIMMUNOASSAY OF PEPTIDE HORMONES
Hypothalamic content of LHRH was assessed in Chapter 4,
experiment 4.4.3.
Radioimmunoassays for LHRH and LHRH agonist were utilized for
experiments described in Chapter 8.
Reagents: Iodinated LHRH agonist (prepared as described previously)
Iodinated LHRH
Standards 0.39-400 pg/0.1 ml LHRH agonist (Hoechst A.G.)
0.39-400 pg/0.1 ml LHRH
Assay buffer 0.01 M PBS, 0.01% thiomersalate, 0.1% BSA pH
7.4
Antisera 1. R103 anti-LHRH agonist at 1 in 4,000
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dilution (Fraser et al., 1983a)
2. RO "C-terminal" anti-LHRH at 1 in 15,000
dilution (Jeffcoate, 1976)
3. R42 "conformational" anti-LHRH at 1 in
30,000 dilution (Nett et al., 1973).
Assay Procedure
All additions were made using an automatic dispenser system
(Micro!ab M) into 63 x 11 mm polystyrene tubes. Incubations were at
4°C.
Day 1 Duplicate determinations of NSB, Bo, sample or standards were
made in 0.2 ml total volume, together with 50 ^il of the
relevant antiserum at the appropriate dilution.
Day 2 Addition of 50 jjI labelled hormone (15,000 cpm)
Day 3 Separation of free from bound was achieved at 4°C by addition
of 1.5 ml ice cold ethanol followed by centrifugation at 2500
rpm for 20 minutes at 4°C. The pellet was counted and the
assays calculated as described for LH.
The detection limit for each assay was 5-8 pg and the within
assay coefficient of variation was 9-11%.




Hypothalami were rapidly dissected out after death and placed in
1 ml boiling PBS for 10 minutes. Samples were stored at -40°C until
required for assay. The contents were thawed and homogenized in a
1 ml glass homogenizer. The homogenate was transferred to plastic
63 x 11 mm tubes together with 1 ml 0.2% BSA PBS which had rinsed out
the homogenizer. After centrifugation at 3,000 rpm for 60 minutes at
4°C the supernatant was taken for radioimmunoassay as described.
2.5 RADIOIMMUNOASSAY OF STEROID HORMONES
For the in vitro experiments described in Chapter 7, steroid
hormones were assayed from unextracted culture medium, no difference
having been found between extracted and unextracted medium.
For experiments where serum steroid concentrations were
estimated (Chapters 4 and 5) the following procedure was used prior
to assay.
Extraction of steroids from serum
Estimation of individual recoveries was obtained by incubating
sample aliquots with 1000 cpm of internal standard (^H-steroid) for
30-60 minutes in 125 x 15 mm glass tubes. The extraction procedures
differed for each steroid:-
Testosterone was extracted using 10 volumes of freshly distilled
hexone : diethyl ether (4 : 1 v/v)
Progesterone and oestradiol were extracted using 2 mis petroleum
ether
After vigorous mechanical shaking for 5 minutes using a
multi-vortex shaker (Searle) the organic and aqueous phases were
separated by freezing in a dry ice/methanol mixture. The organic
phase was decanted and evaporated to dryness on a heated block and
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the residue reconstituted in 2(10 |il assay buffer and left for at
least 3 h prior to estimation of tracer recovery and assay.
Assay Reagents






Scintillation fluid 10 g 2,5-diphenyloxazole
0.75 g l,4-Di[2-(5-phenyloxazolyl )] benzene
from Koch Light Labs, dissolved in 2.5 litres
sulphur free toluene (A.X.J. Beveridge) and
1.5 litres Triton-X (A.X.J. Beveridge).
Tracer hormones - were all stored at 4°C in ethanol.
[1,2,6,7 (N)] testosterone )New England
[1,2,6,7 (N)] progesterone )Nuclear,
Androst-4-Ene-3,17,Dione[lB,2B 3h(N)])Boston Moss
[2,4,6,7 3H] oestradiol (Radiochemicals,
Amersham).
Standards
Non-radioactive steroids (Sigma Chemical Co.) were dissolved in
ethanol and stored at 4°C at 1 mg/ml stock solution. Standard
solutions were either made (a) in ethanol at 10 ng and 1 ng/ml (e.g.
y
oestradiol) and the standard cuye obtained by pipetting the ethanol
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and, after drying down, taking up the residue in 0.1 ml PGRS; or
(b) from the stock solution and stored in PGBS at 4°C (e.g.
testosterone 10-640 pg/0.1 ml; androstenedione 10-1000 pg/0.1 ml and
progesterone 10-800 pg/0.1 ml).
Antisera
1. Testosterone: Antiserum E01 (kindly donated by Dr. S. Till son)
was used at a dilution of 1 in 10,000 giving 50-55% specific
binding (Corker & Davidson, 1978).
2. Progesterone: Antiserum 361 was used at a dilution of 1 in 4,000
giving 40-50% specific binding (Scaramuzzi et al ., 1975).
3. Androstenedione: Antiserum IR637 was used at a dilution of 1 in
8,000 giving 40-45% specific binding (Vaughan-Wil1iams et al., 1982).
4. Oestradiol: Antiserum R3 was kindly donated by Dr. H. Dobson and
utilized for assay of culture medium at a dilution of 1 in 8,000
giving 40-45% specific binding (Van Look et al., 1977).
Serum oestradiol levels were measured, after plasma extraction,
utilizing a gamma G antibody (Backstrom et al., 1982) and were
assayed by Mrs. M. Swaney.
The lower detection limits of the assays were 10 pg/0.1 ml for
androstenedione and progesterone and 5 pg/0.1 ml for testosterone and
oestradiol (R3). The detection limit for serum oestradiol assay was
1 pg/0.1 ml.
The within-assay variation was 5-9% and the interassay variation




Duplicate estimations of NSB, Bo, standards or samples (in 0.1
ml) were made. Samples were dispensed into 75 x 10 mm glass tubes
using a Microlab M automatic dispenser. 100 |jl of antiserum (made up
to the appropriate dilution in PGBS) was added, followed by 100 jj!
tracer (6-8,000 cpm). After thorough mixing the assay was left for
12-24 h at 4°C.
Separation of free from bound hormone was achieved on ice using
1 ml freshly made cold dextran coated charcoal (0.25% charcoal -
Sigma Chemicals, 0.025% Dextran T70, Pharmacia, in PGBS). Charcoal
addition was completed within 2-3 minutes and the tubes vortexed and
left for 15 minutes at 4°C prior to centrifugation at 2000 rpm for 15
minutes at 4°C. The supernatant (antibody bound hormone) was then
poured off into 10 mis of Scintillation fluid. Radioactivity was
measured by counting each vial for 4-5 minutes in a counter
(Packard, counting efficiency 50%).
2.6 IMMUNIZATION
Rats were actively immunized against LHRH, LH and testosterone
(Chapter 4).
In order for small molecules such as testosterone or LHRH to be
rendered immunogenic it is necessary to couple the molecule to a
large molecular weight carrier such as serum albumin.
Testosterone was conjugated to BSA at position 15 (Rao & Moore,
1976) by Dr. J.E.T. Corrie.
LHRH was coupled to human serum albumin (HSA) by carbodiimide as
the coupling agent (Fraser etal., 1974).
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Immunization procedure for LHRH
Day 1 To prepare conjugate to immunize 10 rats, 5 mg HSA (Sigma)
were combined with 5 mg LHRH and dissolved in 0.7 ml
distilled water. 100 mg carbodiimide (Sigma) was dissolved
in 0.3 ml distilled water and immediately added to the
HSA-LHRH solution, mixed and left in the dark overnight at
room temperature.
Day 2 Six inches of dialysis tubing was washed in distilled water
and knotted at one end before the conjugate mixture was
added. The top was then knotted and the sac left to dialyse
for 48 h at 4°C against 0.9% saline. Since the dialysis
tubing cut off was at Mr 10,000 and LHRH Mr is approximately
1000 and BSA 50,000, uncoupled LHRH molecules will pass
through the tubing.
Day 4 The contents of the dialysis tubing were then combined with
Freund's complete adjuvant (Gibco Labs, Grand Island
Biological Centre, Grand Island, New York, U.S.A.) in a ratio
of 2:3. An emulsion was then formed by mechanical means
using glass 10 ml syringes (Berlin & McKinney, 1958).
LH is immunogenic without conjugation and was therefore
dissolved in distilled water (100 ^ig/rat) before emulsification in
Freund's complete adjuvant as described.
Animals were immunized by intradermal injections (given under
ether anaesthesia) of 1 ml emulsion distributed between 8-10 sites.
Booster immunizations were given 3-6 months after the initial
injection utilizing Freund's incomplete adjuvant.
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2.7 ANTIBODY TITRE DETERMINATION
Antibody titres for testosterone and LHRH were assessed 3-4
months after immunization (Chapter 4).
The titre of anti-LHRH or anti-testosterone antibodies was
determined by incubation of serial dilutions of serum together with
10,000 cpm 1251_"J abelled LHRH or [^Hl-testosterone using
conditions similar to those described for radioimmunoassay. In each
case the dilution of serum required to bind 33% of the labelled
hormone was taken as the antibody titre.
2.8 DNA AND PROTEIN ASSAYS
Protein estimations were assessed using the method of Lowry jet
al., 1951 with BSA as a standard.
DNA measurements were performed according to the method of
Burton, 1956 and were carried out by Mr. G. Menzies.
2.9 STATISTICAL ANALYSIS
The results obtained in this thesis were analysed using standard
statistical procedures and are expressed as mean +_ S.E.M. The
significance of differences between means has been assessed using
Student's t-test or (where appropriate) two factor analysis of
variance with replication. These were performed using programmes
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3.3 BIOCHEMICAL NATURE OF LHRH RECEPTORS
3.1 PITUITARY LHRH RECEPTORS
3.1.1 Introduction
Although the pituitary gland was known to be the target organ
for hypothalamic LHRH, the demonstration of specific high affinity
receptors proved difficult. Initial studies successfully utilized
iodinated (125 j-LHRH e.g. Spona, 1973; Marshall et al., 1976;
Heber et al., 1978) or tritiated (3h-LHRH e.g. Grant et al., 1973;
Theoleyre et al., 1976) LHRH to demonstrate the presence of specific
pituitary binding sites for LHRH. Analysis of the binding
characteristics, as described by Scatchard plot analysis, indicated
the presence of two separate binding sites, one of low affinity (Ka
of 105_i(]6 M"l) but high capacity and the other of high
affinity (Ka 10^-10^ M~l) but low capacity. This was
observed in both rat (Marshall et al., 1976; Heber et al., 1978;
Clayton et al., 1978) and bovine (Marshall et al., 1976) pituitary
membrane preparations.
Although the high affinity sites represented only a small
percentage of the total bound hormone (e.g. Clayton et al., 1979b)
their affinity was of the range expected from estimations of portal
blood LHRH (40-800 pM). It was suggested therefore that the high
affinity site represented the physiological receptor whereas the low
affinity site represented a membrane-associated degrading enzyme
(Clayton et al., 1979b). Thus if degradation of 125j_j_hrH was
prevented by a peptidase inhibitor aprotinin, a single class of high
affinity receptors was detected (Wagner et al., 1979).
However, with the availability of agonist analogues of LHRH
relatively resistant to degradation (e.g. Swift & Crighton, 1979) the
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need for the inclusion of protease inhibitors has been largely
removed. A major advance in the analysis of LHRH receptors was the
advent of 125i_LHRH agonist analogues which were found to bind
primarily to the high affinity site (Conne et al., 1979), with only
30% degradation occurring after 30 minutes .at 37°C (Clayton et al.,
1979b). The physiological significance of these receptors has been
indicated by the correlation between the relative potencies of
125i_ag0n-jsts and their biological activity, and the ability of
unlabelled LHRH to displace binding of 125j-LHRH agonist (e.g.
see Clayton & Catt, 1981b).
It is important to remember, however, that the 125i_ag0n-jst
or antagonist analogues used in receptor assays are only tools to
detect the high affinity binding sites. The endogenous ligand is
subject to rapid degradation by peptidases (possibly represented by
the low affinity binding site). Therefore control of the rate of
ligand degradation is likely to play an important role in the control
of target organ sensitivity.
3.1.2 Aims
The aim of this study was to develop a radioreceptor assay
capable of measuring pituitary LHRH receptor concentrations in
individual pituitary glands, to enable subsequent characterization of
the factors controlling receptor numbers and to assess their
importance in the regulation of pituitary sensitivity (Chapter 4).
3.1.3 Assessment of LHRH Receptors in individual pituitaries
The method adopted was essentially the 'saturation analysis
method' reported by Clayton, et al., 1980.
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3.1.3.1 Animals
Unless otherwise stated all the rats utilized in this thesis
were of the Sprague Dawley strain, bred in the laboratory colony and
kept under standard conditions (lights on 05.00 h - 19.00 h and with
free access to food and water). Animals were killed using dry ice
CO2 and the anterior pituitary rapidly dissected out following
decapitation.
3.1.3.2 Method
Individual anterior pituitaries were assessed for LHRH receptor
content immediately after removal from the animal, by homogenization
on ice in 400 ^il 10 mM Tris HC1 (pH 7.4) in a 1 ml glass homogenizer.
The homogenate was then filtered through nylon gauze (Simon Precision
textiles, Stockport, Cheshire, U.S., Mesh type N355). Duplicate 50
^1 aliquots of the filtrate were equilibrated with 100,000 - 150,000
cpm 125j_lhrh agonist plus 420 pg unlabelled hormone, giving a
total ligand concentration of 540-600 pg (2.2-2.4 nM). Non-specific
binding (NSB) was assessed in duplicate in the presence of 1Q~5 M
unlabelled LHRH agonist. Incubations were carried out for 80 minutes
at 4°C (conditions found to be optimum for maximal binding). The
reaction was terminated by dilution with 2 mis ice cold 0.01 M
phosphate buffered saline (PBS) followed by immediate filtration
under vacuum through Whatman GF/C glass fibre filters (which had been
presoaked for 12 h in 2% BSA to minimize non-specific tracer
adsorption). After washing with 3 x 2 ml PBS, the dried filters were
counted for estimation of the retained hormone receptor complex.
Specific binding (Bo) was assessed by subtracting the NSB value (2-3%
of total counts added) from the total bound (B).
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The protein content of pituitary glands as assessed by the
method of Lowry et al., 1951, ranged from 1.4 - 2 mg. However, since
expression of the results as fem^tomoles (fm) bound per mg protein
made no significant differences to the relative changes in receptor
numbers seen when the results were expressed as fm/pituitary, the
latter format was adopted for presentation of pituitary receptor
concentrations. In addition no significant differences were found
between receptor numbers assessed from fresh or frozen tissue.
3.1.3.3 Calculation of pituitary LHRH receptor concentration
The bindable activity of the tracer utilized in the receptor
studies calculated from the Leydig cell self displacement curve
(Sharpe & Fraser, 1980a) was 1.2 pg per 1000 cpm. The counts of LHRH
agonist specifically bound (B - NSB) divided by the total amount of
LHRH added (i.e. hot and cold) gave a measure of the pg bound/50 ^1
homogenate. This value was then multiplied by 8 and calculated as fm
bound/gland.
Since a ligand concentration of 1.8 - 2 nM had been shown to
produce about 85% receptor occupancy (Clayton, 1980) it is assumed
that the binding analysis was performed under near saturating
conditions (i.e. in the presence of 2.2-2.4 nM ligand) and therefore
that specific binding is a direct measure of the number of receptors
per aliquot.
This method of calculating receptor numbers has been criticised
since it does not enable measurement of possible changes in receptor
affinity (Ka). Thus, some studies estimate receptor concentrations,
together with Ka, from competition curves and Scatchard analysis.
However, it is necessary to utilize pooled homogenates from a number
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of pituitaries to obtain such data, and the precise determination of
individual pituitary receptors is therefore lost. In addition,
similar changes in receptor concentrations have been observed by both
methods (e.g. Savoy-Moore et al., 1980; CIayton et al ., 1980) and no
evidence has been found to suggest changes in pituitary LHRH receptor
affinity under any endocrine state so far studied. The technique of
saturation analysis was thus utilizied in the assessment of pituitary
LHRH receptors, for the studies presented in Chapter 4.
3.2 OVARIAN LHRH RECEPTORS
3.2.1 Introduction
Initial binding studies utilizing 12 5 j _ |_ h revealed the
presence of specific, but low affinity binding sites in the ovary
similar to those found in the pituitary (Marshall et al., 1976; Heber
et al., 1978). In addition ovarian uptake of 125i_[_hrh agonist
in vivo implicated the presence of specific binding sites (Mayar et
al., 1979). The first conclusive demonstration of high affinity
ovarian LHRH receptors was obtained by incubating labelled LHRH
agonist with homogenates from ovaries of PMSG/hCG-primed immature
rats (CIayton et al., 1979a). The receptors had identical properties
both of affinity (Ka 5 x 10^ M~l) and specificity to those of
the pituitary, although their concentration was markedly lower
(CIayton et al., 1979a).
3.2.2 Aims
The aims of these investigations were threefold:-
1) To characterize and develop conditions suitable for analysis of
LHRH receptors in rat follicular tissue with a view to utilizing the
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radioreceptor assay for the detection of intragonadal LHRH-like
peptides.
2) To develop a method suitable for the estimation of ovarian LHRH
receptor concentrations in individual ovaries.
3) To identify the sites of LHRH binding in ovarian tissue by
autoradiography.
3.2.3 LHRH binding to rat follicular tissue
Since direct effects of LHRH had been shown on follicular as
well as luteal tissue (Chapter 1) and only the receptors on luteal
tissue had been adequately characterized, it was decided to
investigate ovarian LHRH receptors from PMSG-primed immature rats.
3.2.3.1 Animals and Method
Animal s
Immature (26-30 days old) female Sprague Dawley rats from the
laboratory colony were used for these studies. The rats were killed
using dry ice CO2 48 h after induction of follicular development by
s~G tu
subcutaneous injection of^Pregnant Mares Serum Gonadotroph!" n (PMSG)
and the ovaries rapidly dissected out into ice cold 10 mM Tris HC1
(pH 7.5) 0.5 ml/ovary. After homogenization in a 10 ml glass
homogenizer the homogenate was filtered through nylon gauze as
described for pituitary tissue.
Method
150 jul aliquots of filtrate (600-700 jjg protein) were used for
binding assay which was carried out in a total volume of 400 |il of
assay buffer (10 mM Tris HC1 , 0.2% BSA). Total binding was assessed
after incubation in the presence of 100,000 - 120,000 cpm
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FIGURE 3.1 Displacement of 125x_LHRH agonist binding to rat ovarian
homogenates by unlabelled LHRH agonist. Each point represents
mean +_ range of duplicate determinations.
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duplicate in the presence of 10~5 M unlabel led hormone.
3.2.3.2 Separation of free from bound
This was achieved by one of two methods:-
3.2.3.2.1 Filtration
After incubation, 1 ml of ice cold PBS was added to each tube
and the contents immediately filtered through Whatman GF/C
filters, using the conditions described earlier for the pituitary
(3.1.3.2). In practice, pre-soaking the filters in 2% BSA reduced
non-specific binding of the tracer from 5-10% of the total counts to
3% and this figure was reduced to less than 1% following the washing
procedures.
Using this method NSB values were 2-4% of total counts and
specific binding was 10-15% per mg protein. This is a much lower
value than that obtained with pituitary tissue (30-40%/mg protein),
in agreement with the lower concentration of receptors in ovarian
tissue.
A displacement curve was obtained by incubation of ovarian
tissue in the presence of a constant amount of labelled hormone with
varying amounts of unlabelled LHRH agonist (Fig. 3.1). The curve was
found to be identical to that obtained with pituitary tissue (Chapter
2, Fig. 2.2), both binding sites showing 50% displacement of binding
with 3 x 10"*10 h LHRH agonist.
3.2.3.2.2 PEG/IgG Separation
Separation of free from bound hormone using solubilized hCG
receptors can be achieved by a double precipitation procedure with
polyethylene glycol (PEG) in the presence of bovine gamma globulin
(IgG) as a carrier (Dufau et al ♦, 1973). This technique has been
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FIGURE 3.2 Displacement of 125i-LHRH agonist binding to rat ovarian
tissue by unlabelled LHRH agonist following separation of free
from bound by polyethylene glycol precipitation (°—° PEG) or
filtration through Whatman GF/C filters (GF/C*-*). Each point





























utilized for other peptide hormones e.g. insulin (Desbuquois &
Aurbach, 1971) and was suggested as being particularly useful for low
molecular weight substances.
For LHRH receptors, after incubation as described above, the
tubes were placed on ice and diluted with 0.5 ml cold PBS followed by
0.5 ml 0.5% bovine IgG (Bovine Cohn Fraction II, Sigma Chemicals) and
1 ml 25% PEG (w/v) (Approx. Mr. 8000, Sigma Chemicals). After
thorough mixing the tubes were centrifuged at 3000 rpm for 10
minutes at 4°C. The supernatant was aspirated and the pellet
counted. A blank value of 2-3% of total counts was obtained and an
NSB of 4-6%. Total specific binding varied between 15-20%.
A comparison of the two methods of separation is shown in Fig.
3.2. The displacement curves obtained were not significantly
different so it was concluded that either method was suitable for the
separation of free from bound LHRH agonist.
3.2.3.3 Time and temperature dependence of LHRH agonist binding
Optimal conditions for assay incubation were determined by
assessment of specific binding, as described previously, at 0°C or
22°C for various times up to 240 minutes (Fig. 3.3). Binding was
rapid at 20°C, reaching maximal levels after 30 minutes. Binding
then decreased with increased incubation time at 20°C, a phenomenon
likely to be due to instability of the ligand and/or receptor under
these conditions. At 0°C binding reached maximal levels after 120
minutes and was stable for 180 minutes.
Assessment of ovarian LHRH receptors was therefore routinely
achieved after incubation for 120 minutes at 0-4°C.
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FIGURE 3.4. Saturation of 125i-i_hlRH agonist binding to rat ovarian
tissue with a Scatchard plot of the data as inset. Each point representsthe mean of duplicate determinations. The within assay variation for the
duplicates was 10%. Over 10 ovarian receptor assays the intra-assay
coefficient of variation was 13%.
51
3.2.3.4 Scatchard analysis of 125i-LHRH agonist binding
Aliquots of tissue were incubated, as described above, with
increasing concentrations of 125 j-LHP. H agonist. Plotting the
data as bound versus added hormone gave a curvilinear plot indicative
ik-
of saturated binding sites (Fig. 3.4). Expression of the data as the
ratio of bound to free hormone (B/F) against bound (R) hormone
resulted in a linear Scatchard plot indicative of a single class of
receptors with affinity Ka 4 x 109 m-1 (Fig. 3.4).
Although Scatchard analysis was designed to characterize low
affinity binding systems interacting with small soluble molecules
(Scatchard, 1949) and is therefore not ideal for using in the
analysis of hormone-receptor interactions, it is universally used as
an index of receptor affinity. The apparent affinity of
agonist for rat follicular receptors is in agreement
with the value obtained for both rat luteal (Clayton et al ., 1979a)
and pituitary tissue (e.g. Clayton A Catt, 1981b).
Interestingly, whereas the pituitary receptor Ka is greater than
the EP50 value for LM release (which has been suggested to indicate
that a maximum biological response can be achieved with only a
fraction of the receptors occupied (Clayton & Catt, 1981b)) the Ka
and EP50 for ovarian LHRH receptors and direct actions are of the
same order of magnitude (10~9 M).
3.2.3.5 Specificity of ovarian LHRH receptors
The ability of ovarian LHRH receptors to discriminate between
LHRH and unrelated peptides was assessed by performing a binding
assay with 125j-LHRH agonist as the labelled ligand in the


























oxytocin and vasopressin; using the conditions described earlier.
The displacement of binding of 125 j _|_HR H agonist obtained
with each peptide is shown in Fig. 3.5. Native LHRH was capable of
displacing binding but the curve was shifted to the right in
comparison with that of unlabelled LHRH agonist. The lower affinity
of the receptor for LHRH is probably due to its degradation during
incubation. Somatostatin had no effect on binding and TRH and
oxytocin only produced minimal displacement at high concentrations.
The receptor data again emphasises the similarity between the
ovarian and pituitary receptor and is corroborated by biological
data. TRH and somotostatin had no effect in vitro in isolated
fol1icles (Chapter 7).
3.2.3.6 Conclusions
The criteria laid down for the designation of a "physiological
receptor" (Cuatrecasas, 1974 & Cuatrecasas et al., 1975) have largely
been confirmed for LHRH receptors. Binding is (a) tissue specific
for both the pituitary and gonads, (b) ligand specific, only LHRH and
related compounds being capable of receptor binding (Fig. 3.5), (c)
of high affinity (Fig. 3.4), being within the range known to initiate
biological responses (Chapter 7), (d) reversable (Clayton & Catt,
1981b) and (e) saturable (Fig. 3.4).
3.2.4. Assessment of LHRH Receptors in individual ovaries
The concentration of LHRH receptors present in homogenates of
whole ovarian tissue was assessed by saturation analysis using
essentially the same method as that described for the pituitary
(3.1.3). The ovarian assay was incubated for 120 minutes at 4°C and
terminated by filtration through Whatman GF/C filters. Since ovarian
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protein content varied considerably between treatment groups,
according to ovarian size, it was decided to express the receptor
data in terms of fm bound/mg protein rather than fm bound/ovary.
Since ovarian receptors are believed to recognize locally produced
factors (Chapter 1) it is likely that receptor concentration rather
than total number per ovary is the more important parameter.
However, where major differences were obtained by expressing the data
as a concentration, both results are shown (Chapter 5).
Although no attempt was made to assess changes in receptor
affinity, other groups had failed to show this (e.g. Pieper et al.,
1981; Reeves et al., 1982) and it was concluded that ovarian LHRH
receptor affinity was unlikely to be altered and therefore that
saturation analysis provided an adequate means of assessing receptor
regulation.
3.2.5 Localization of LHRH binding by autoradiography
3.2.5.1 Introduction
Relatively few studies have been reported as determining the
cellular location of ovarian LHRH receptors. Although receptors had
been demonstrated in isolated granulosa cells (Jones et al., 1980;
dai
RantaA 1982) and luteal tissue (CIayton et al., 1979a; Pieper et al.,
1981) the possibility of binding to other tissue compartments had not
been established. The aim of this investigation was to compare the
localization of LHRH binding by autoradiography in both pituitary and
ovarian tissue, with particular emphasis on whether LHRH binding
occurred to thecal tissue.
3.2.5.2 Method
Two pro-oestrous rats weighing 250 g were anaesthetized at 12.00
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h with ethyl carbamate (1.75 g/Kg body wt, injected i.p. as a 25%
solution (w/v) BDH Ltd., Poole, Dorset, U.K.) and the right atrium of
each was cannulated. Each rat was given a 1 ml injection of
125j-1abel1ed LH-RH agonist (2.9 x 107 cpm) either alone or
with a 100 fold excess of unlabelled hormone at pH 7, into the atrial
cannula over a period of 2 minutes. The animals were killed 30
minutes later by perfusion with 30 ml heparinized saline and this was
immediately followed by 20 ml 10% neutral buffered formal-saline
solution. The ovaries and pituitary glands were dissected out,
immersed in this fixative solution and counted in a gamma
spectrometer. In the animal injected with 125 j_-| abel 1 ed LH-RH
agonist the ovary count was 2100 cpm/mg, the pituitary 3200 cpm/mg
and the blood count 270,000 cpm/ml. The corresponding values for the
rat injected with 125i_-j abel 1 ed LH-RH agonist and unlabelled
hormone were 100 cpm/mg and 350 and 220,000 cpm/ml.
After fixation for A h the tissues were transferred to 2%
glutaraldehyde (TAAB, Reading, Berks, U.S.) in 0.01 M Hepes Buffer
(pH 7.2) for further fixation overnight at 4°C. The tissues were
then washed with distilled water, snap frozen and sectioned at 12 |jm
with a cryostat. The sections were mounted on acid-cleaned and
gelatin-coated slides and coated with liquid nuclear emulsion (K5,
II ford Ltd., Basildon, Essex, U.K.). Additional tissues from
untreated rats were similarly prepared to control for chemfographic
effects (high background activity and latent image fading). The
slides were exposed in light-proof boxes at 4°C for 33 days. They
were then developed and fixed (D19 developer and Kodafix, Kodak Ltd.,
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PLATE 3.1 Autoradiographic localization of 125j-LHRH agonist binding
by light (A) and dark (B) field illumination in rat pituitary
cells from rats treated with 125j_LHRH agonist. X 500.
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PLATE 3.2 Autoradiographic localization of 125j_LHRH agonist binding
by light (A) and dark (B) field illumination in rat ovarian
tissue from rats treated with 125j-LHRH agonist. Grains
are shown to be located over granulosa (G), thecal (T) and





PLATE 3.3 Autoradiographic localization of 125I-LHRH agonist binding
by light (A) and dark (B) field illumination in control
pituitary tissue from rats treated with an excess of cold LHRH
agonist together with 125j_LHRH ag0nist. X 500.
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PLATE 3.4 Autoradiographic localization of 125j-LHRH agonist binding
by light (A) and dark (P.) field illumination in control
ovarian tissue from rats treated with an excess of cold LHRH
agonist together with 125j-LHRH agonist. X 500.
Granulosa cells (G), thecal cells (T) and luteal cells (L).
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examined microscopically at high power (x 1000) under oil-immersion
and with bright-field and dark-ground illumination.
This experiment was performed in collaboration with Dr. R.
Gosden.
3.2.5.3 Results
Both the ovaries and pituitary showed specific uptake of
labelled 125j-LHRH agonist. Uptake in the control animal, where
binding had been displaced by excess of 'cold' hormone, was
substantially lower.
Silver grains over pituitary tissue were unevenly distributed
amongst cells of the adenohypophysis being primarily localized over
small groups of cells (Plate 3.1). The grains over ovarian tissue
were distributed throughout thecal, granulosa and luteal tissue
(Plate 3.2). In both cases labelling in the control animals was
markedly lower (Plates 3.3 & 3.4).
3.2.5.4 Piscussion
These results emphasise the different binding patterns of LHRH
in rat pituitary and ovarian tissue. In the pituitary, binding was
located in discrete areas (presumably gonadotroph cells) whereas in
the ovary, binding was more diffuse, being distributed throughout all
cell types. Although these observations were based on only two
animals, this pattern of ovarian binding has since been confirmed
(Seguin et al ♦, 1982; Pelletier et al., 1982a) and is in agreement
with biochemical studies implicating direct effects of LHRH at
multiple sites within the ovary (reviewed in Chapters 1 A 6).
That pituitary LHRH binding is confined exclusively to
gonadotroph cells had been demonstrated by an elegant series of
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experiments. The first morphological demonstration of binding
employed ferritin-coupled LHRH (Hopkins A Gregory, 1977) followed by
detailed autoradiographic localization of binding primarily over
cells which stained immunochemically for LH (Duello A Nett, 1980;
Pelletier et al_., 1982b). In addition, enriched populations of
gonadotroph cells prepared by velocity gradient sedimentation at unit
gravity contained 71% of LHRH receptors (Naor et al., 1982).
Although fractionation of purified membrane preparations and
subsequent receptor assay indicated that the majority of pituitary
LHRH receptors were located in the plasma membrane fraction (Marian
A Conn, 1983), pulse chase experiments have indicated that the
LHRH-receptor complex is internalized. Several techniques have been
utilized to confirm the intracellular fate of the LHRH-receptor.
Autoradiography, (utilizing 125 j _lhr H agonist) followed by
electron microscopy has revealed the presence of internalized
receptor-bound hormone (Duello A Nett, 1980; Duello et al ., 1983).
Immunohistochemical techniques have localized LHRH inside gonadotroph
cells (Bauer et al ., 1981). One of the most exciting advances in
this area however, has been the development of a rhodamine-conjugated
LHRH derivative (Naor et al ., 1981; Hazum, 1981a,c). This has
enabled visualization of the 1 igand-receptor interaction by
video-intensified fluorescence microscopy. Binding of rhodamine-
labelled LHRH to dissociated rat pituitary cells was followed by
aggregation along the cell surface (patching), association with
coated pits (capping) and internalization into endocytic vesicles
(Hazum et al ., 1980, 1982a; Naor et al ., 1981) according to the
'receptor mediated endocytosis' sequence reviewed by Goldstein _et
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al_., (1979).
Interestingly however, although receptor internalization
follows LHRH binding it is not a prerequisite for gonadotrophs
release. Thus if internalization was prevented, e.g. using
vinblastin, LHRH-stimulated LH release still occurred (Conn et al.,
1981a; Conn & Hazum, 1981). The observation that a dimer molecule of
LHRH antagonist was converted to a potent agonist upon addition of a
cross reacting antibody (with resultant formation of a divalent
antibody - dimer conjugate (Conn et al♦, 1982a,b)) led to the
suggestion that receptor microaggregation in the lateral plane of the
membrane was an important feature of LHRH action (Blum & Conn,
1982).
The physiological significance of internalized receptor
complexes remains unknown, but is likely to be involved in receptor
turnover (Marian & Conn, 1983) and degradation of LHRH (Duello _et
al_., 1983).
Only limited data is available as yet on the fate of ovarian
LHRH receptors in the different ovarian compartments. However, the
same rhodamine-LHRH derivative has indicated that receptor-mediated-
endocytosis occurred, with internalization of LHRH, in isolated
granulosa cells (Hazum & Nimrod, 1982). Whether this is a
prerequisite for biological action, or a means of receptor turnover,
still remains to be established.
The techniques outlined above have dramatically increased our
understanding of the histological location of LHRH binding and events
subsequent to receptor activation. Knowledge gained so far has
provided the basis for current theories on the mechanism of receptor
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regulation (discussed in Chapter 9).
3.3 BIOCHEMICAL NATURE OF THE LHRH RECEPTOR
From the LHRH binding studies outlined earlier it seemed evident
that gonadal and pituitary LHRH receptors were identical, apart from
the lower receptor concentration in the former. A number of studies
have attempted to characterize the biochemical nature of the
pituitary receptor and it is interesting to review the data available
and compare it with that on gonadal receptors.
The pituitary LHRH receptor is likely to be a glycoprotein with
an important sialic acid moiety, since binding is abolished after
treatment with neuraminidase, trypsin or chymotrypsin (Hazum, 1981c,
1982). A number of groups have attempted to isolate the receptor.
For example, using the rhodamine LHRH derivative, photolabel1ing of
the rat pituitary receptor (after sodium dodecyl sulphate (SPS)
polyacrylamide gel electrophoresis (PAGE)) was found to be associated
with two protein bands; a major component of apparent molecular
weight 60,000, and a minor component of 48,000 daltons (Hazum,
1981c). An identical estimated molecular weight of 60,000 was
obtained by an independent group using receptor protein isolated from
steer pituitaries. The isolated protein showed 125x_lHRH binding
characteristics similar to those of intact membranes (Zolman &
Valenta, 1978). Recent studies have utilized a zwitterionic
detergent, CHAPS (3[(3-cholamidopropyl) dimethyl ammonio]-l-propane
sulphonate) to solubilize pituitary LHRH receptors. A large
molecular weight complex with LHRH binding characteristics identical
to those found in whole tissue has been isolated from bovine anterior
pituitary tissue (Perrin et al., 1983; Winiger et al., 1983) with an
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apparent molecular weight of 80,000 (Winiger et a!., 1983). The
isolated receptor complex was suggested to be composed of aggregated
molecules, and no similar complex could be isolated from rat kidney
tissue (Perrin et al., 1983).
Digestion of pituitary membrane phospholipids and phospholipases
reduces LHRH binding (Hazum et al., 1982b). Since phospholipids are
essential for maintaining structural integrity of the membrane, it is
evident that the fully functional receptor is dependent on plasma
membrane association.
Application of the photol abelling technique for isolating
granulosa cell LHRH receptors led to the identification of two
specific components of molecular weight 60,000 and 54,000 (Hazum &
Nimrod, 1982), the former being identical to the estimate from
pituitary tissue (see above, Hazum, 1981c). However, the 54,000
molecular weight component appears to be specific to the gonad, the
pituitary minor component being estimated at 48,000 daltons. LHRH
receptor sites at the two loci may therefore not be identical. This
hypothesis has also been investigated in the testis. Comparison of
the effects of enzyme treatment on LHRH agonist and antagonist
binding to pituitary and Leydig cells, revealed differences. Whereas
chymotrypsin and trypsin decreased binding in both tissues,
neuraminidase was effective only in decreasing pituitary binding and
actually increased Leydig cell binding (Mi 11ar et al., 1982). This
suggests that a sialic acid residue is important for pituitary, but
not Leydig cell, LHRH binding.
In conclusion, it appears that the binding characteristics as
regards specificity and affinity, of LHRH receptors both in the
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pituitary and gonad, are indistinguishable. The distribution of
receptors differs however, being of greater concentration and on
specific cell types within the pituitary, but being more diffuse in
the ovary (Plates 3.1-3.4). Finally, the biochemical nature of one
of the receptor subunits may differ between pituitary and gonad
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4.1 INTRODUCTION
Regulation of the number and/or affinity of target cell
receptors provides one mechanism by which responsiveness of a target
cell to a particular ligand can be regulated. There are numerous
examples of this in endocrinology (see Roth, 1979; Catt et al.,
1979). Where receptor numbers are limiting, logically it would be
expected that alterations in number would lead to changed magnitude
of the biological response. However, since, for LHRH, occupancy of
only 20% of receptors is required to elicit maximum biological
response (Naor et al., 1980) it is evident that, as with gonadal LH
receptors (Catt & Dufau, 1973) "spare receptors" are present. In the
case of alterations in LH receptor concentrations, receptors have
been shown to correlate with changes in target cell responsiveness
(Harwood et al., 1978 & see Catt et al., 1979); likewise changes in
the numbers of LHRH receptors could, theoretically, influence
pituitary responsiveness.
The previous chapter described methods utilized to measure LHRH
receptor concentrations and discussed the concept of receptor
turnover providing a mechanism for regulating receptor concentration.
This chapter is concerned with identification of some of the
potential molecules regulating pituitary LHRH receptor numbers.
4.2 REVIEW - CORRELATION BETWEEN PITUITARY RESPONSIVENESS AMD LHRH
RECEPTORS
4.2.1 Sexual maturation
Pituitary LHRH receptors show increased concentration from
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birth, reaching peak values at 30 days of age in males and 20 days in
females, falling thereafter to adult levels at 80 and 40 days old
respectively (Dalkin et al., 1981; Chan et al., 1981). These changes
correlate well with the observed alterations in pituitary
responsiveness to LHRH which is maximal at 30-40 days of age in males
and 20 days in females (Rebel juk. et al_., 1972a,b; Ojeda et al_.,
1977). This change in receptors represents a change in
concentration. Since pituitary protein content is increasing with
age, expression of receptor numbers per gland shows a steady increase
which is maintained from day 30 in both sexes (Chan et al., 1981).
It is possible that thcs observation reflects1 alterations in the
number of gonadotroph cells, which are known to change at this time
(Denef et al., 1978), rather than receptor numbers per cell.
4.2.2 Adulthood
Pituitary protein content varies little during adult life so
expression of receptor numbers per gland gives an adequate means of
assessing concentration. Pituitary LHRH receptors do not vary during
adulthood in male rats, and correspondingly there is no evidence for
changes in pituitary responsiveness at this time. However in cycling
female rats it is known that responsiveness shows marked changes
(e.g. Aiyer et al., 1974a). Initial studies of pituitary receptors
during the oestrous cycle indicated that maximum binding occurred at
pro-oestrus (Park et al., 1976), the time of maximum responsiveness
(Aiyer et al_., 1974a). Although this study (Park et al., 1976)
utilized ^-^5 j_lhRH as ligand, the cyclic pattern of receptor
numbers has been confirmed by numerous other studies utilizing
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125i_|_hrh agonist (e.g. Savoy-Moore et al., 1980; Clayton et al.,
1980). The characteristic binding pattern showing high levels at
pro-oestrus and nadir at oestrus, was demonstrated in both isolated
cell (Meidan & Koch, 1981) and tissue homogenates or membrane
preparations (CIayton et al., 1979b; Savoy-Moore et al., 1980; Clayton
et al., 1980). In addition the same binding changes have been found
utilizing 125j_|_hrH antagonist (Meidan & Koch, 1981). No evidence
has been found for changes in receptor affinity (e.g. Savoy-Moore et
al., 1980 Marian et al., 1981; Meidan A Koch, 1981).
These observations were not confined solely to the rat. Similar
cyclic changes in pituitary LHRH receptors were also noted in the
hamster (Adams & Spies, 1981a). In addition, receptor numbers are
elevated during oestrus in ewes (Crowder & Nett, 1982) and following
oestrogen administration to ovariectomized Rhesus monkeys (Adams et
al_., 1981).
4.2.3 Pregnancy and Lactation
Lactation is associated with a decreased pituitary
responsiveness to LHRH (Lu et al., 1976; Smith, 1978) and
measurements of pituitary LHRH receptors have shown a marked
reduction in numbers (but no affinity change) at this time in rats
(Marian et al., 1981; Reeves et al., 1982). Pituitary receptor
numbers were unchanged during pregnancy relative to oestrous levels
in rats (Reeves et al., 1982). Pregnant beef heifers showed receptor
numbers similar to those at oestrus (Schoenemann et al., 1982).
Pseudopregnant rats had fewer LHRH receptors than weanling females
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(Marian et al., 1981); however, since receptor numbers are highest at
this time it is perhaps more meaningful to use adult cycling values
as comparison. It is unlikely therefore that receptor numbers during
pregnancy are significantly different from those of cycling rats.
4.2.4 Castration
Removal of the inhibitory feedback influence of gonadal steroids
on gonadotropin'n release is known to result both in marked increases
in serum LH concentrations and in pituitary responsiveness to LHRH
(O'Conner et al., 1980; Frager et al., 1980). Numbers of pituitary
LHRH receptors are elevated following gonadectomy in both males and
females (e.g. Clayton & Catt, 1981b). In male rats both the LH and
receptor response is rapid, with increased receptors detectable 18-24
h after castration (Frager et al., 1981; Clayton & Catt, 1981b).
However, in the female, both the gonadotroph!n and receptor responses
are slower than in the male, no change being seen until 3 days after
ovariectomy (Frager et al., 1981; Clayton & Catt, 1981b). The reason
for the sex difference is unclear, although adrenal steroids have been
implicated in the case of the female (Clayton & Catt, 1981b). The
important observation though is that in both cases elevated receptor
numbers correlated well with elevated serum LH, whereas receptor
affinity remained unchanged (Clayton & Catt, 1981b).
4.2.5 Assessment of pituitary receptors in anoestrous rats
Ageing is associated with changes in receptor numbers, but not
affinity, for a variety of hormones in rats, mice, dogs and humans
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(Roth, 1979). Since ageing rats show a tendency to enter a state of
constant oestrus and loss of reproductive function (Watkins et al.,
1975) it is possible that this change is associated with altered
pituitary LHRH receptor numbers. Similar loss of reproductive
function can be induced by maintaining female rats in constant light
for periods of 2-3 months. Therefore in the experiment described
receptor numbers were assessed after exposure to constant light. .
Method: 10 regularly cycling female rats were kept in constant light^
for 10 weeks. These animals were then killed, together with 10
cycling rats of the same age, killed either at 10.00 h dioestrus or
at noon pro-oestrus, using dry ice CO2. Anterior pituitaries were
removed and stored at -40°C prior to assaying LHRH binding as described
in Chapter 3.
Results: All animals kept under constant light exhibited constant
oestrous type vaginal smears of cornified cells. Ovarian histology
indicated the presence of cystic follicles (Lawton & Schwartz, 1967;
Reiter & Klein, 1971; see Chapter 5). Pituitary LHRH receptor numbers
are shown in Fig. 4.1. Cycling rats showed the expected increased
receptor numbers at pro-oestrus (P^l_0.05). However receptor numbers
from pituitaries from constant light rats were not significantly
pro-ceStrcuS
different from those of^cycling rats, although they were significantly
raised above the low levels at dioestrus.
Discussion: The absence of changes in LHRH receptor numbers in the
presence of marked alterations in reproductive function is



























FIGURE 4.i Pituitary LHRH receptors in control animals killed at 10.00 h
dioestrus (D) or 12.00 h pro-oestrus (P) and in rats killed
after exposure to constant light for 10 weeks.
Data represent Mean jf S.E.M. (10 constant light, 5 for each
group in controls).
** p«e£0.01 compared to D control value.
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pituitary responsiveness to LHRH does not vary in rats exposed to
constant light (Fink, 1975). Studies on pituitary receptor
concentrations from aged or spontaneously acyclic rats were found to
show decreased receptor numbers compared with immature rats (Marian
et al_., 1981). However, this comparison is misleading due to
elevated receptor concentrations in prepubertal rats (see 4.1) and
when compared with cyclic females, receptor numbers were not
significantly reduced (Marian et al., 1981).
Conclusion: Pituitary LHRH receptor concentration was not altered
from the cyclic range after exposure to constant light. It is
therefore likely that pituitary responsiveness to LHRH at this time
is regulated by other factors e.g. the rate or quantity of LHRH
released.
4.3 REGULATION OF PITUITARY LHRH RECEPTORS IN THE MALE
4.3.1 Introduction, Aims, Models
Introduction
The fact that pituitary receptor numbers correlate well with
changes in pituitary responsiveness to LHRH during sexual maturation
(4.2.1), the oestrous cycle (4.2.2) and lactation (4.2.3), has led to
the suggestion that the relationship is a causal one i.e. that
changes in receptor numbers are responsible for the observed changes
in pituitary responsiveness (Belchez et al_., 1978). Since two
categories of molecule are thought to regulate pituitary
responsiveness, namely heterologous ligands such as gonadal steroids
and LHRH itself (see Chapter 1), the mechanism of action may well
involve changes in LHRH receptors. In order to minimize cyclic
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variation in pituitary responses, studies were initiated in the male.
Aims
1. To investigate the ability of heterologous ligands (gonadal
steroids and prolactin) to alter pituitary LHRH receptors.
2. To investigate the ability of LHRH to autoregulate its own
receptors.
Experimental Models
Receptor changes were investigated after the following
procedures had been utilized to disrupt the hypothalamic-pituitary-
gonadal axis.
i) Specific removal of the negative feedback influence of
testosterone by active immunization against testosterone
(4.3.1.1.) or by castration (4.3.1.2.).
ii) Hyperprolactinaemia induced by transplantation of pituitaries
under the kidney capsule (4.3.1.2.).
iii) Specific removal of endogenous LHRH (and subsequent inhibition
of both gonadotrophs and steroid levels) following either
active (4.3.2.1) or passive (4.3.2.2) immunization against LHRH.
4.3.2 Heterologous ligand regulation
The ability of molecules, other than the ligand responsible for
binding to and initiating a response from a target cell, to influence
receptor numbers for that ligand is not unusual in biological
systems. In the case of the pituitary, responsiveness to thyrotropin
releasing hormone (TRH) is known to be increased by oestradiol and
decreased by prolactin (De Lean et al., 1977b). These changes are
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associated with increased and decreased pituitary TRH receptors
respectively (De Lean et al., 1977a). Since pituitary
responsiveness to LHRH is also regulated by heterologous molecules,
it was decided to investigate the ability of these hormones to alter
receptor numbers.
4.3.2.1 Active Immunization against Testosterone
Introduction: Since pituitary LHRH receptors are raised following
the removal of gonadal steroids (see 4.2.4) it seemed reasonable
to suggest that the negative feedback effects of steroids on
gonadotrophin release could, in part at least, be due to a reduction
in pituitary receptor numbers. In order to assess the inhibitory
role of testosterone, the effects of specific immunization of
testosterone on pituitary LHRH receptors was investigated in intact
rats.
Method: 20 male Sprague Dawley rats (90 days of age) were actively
immunized either against testosterone or against BSA in Freund's
complete adjuvant (see chapter 2). Booster immunizations were given
at 6 and 11 months using Freund's incomplete adjuvant. Rats were
killed one month after the final booster using dry ice CO2 and
blood collected by decapitation, the serum being stored at -20°C
prior to hormone assay and antibody titre determination. Anterior
pituitary glands were used immediately for the binding assay as
described in Chapter 3. Anti-testosterone antibody titre was
determined and serum testosterone was measured after acidification of
serum with an equal volume of 1 M HC1 to release antibody bound







































FIGURE 4.2 Effect of active immunization against testosterone (T)
or HSA (control) on pituitary LHRH receptors, pituitary
content and serum concentrations of LH and FSH in adult male
rats.
Data are Mean +_ S.E.M. (10 animals per group).
** P ^0.05; *** 0.001.
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gonadotropins were measured by radioimmunoassay (see Chapter 2).
Results: In testosterone-immunized rats the titre of antibody varied
between animals from as little as 1:50 to a maximum of 1:4,000, with
the majority of animals exhibiting high titre in the range 1:800 -
1:4,000. Despite this variation, the antibodies were clearly
effective in all the testosterone-immunized animals as evidenced by
the raised (P^C 0.001) serum levels and pituitary contents of LH and
FSH (Fig. 4.2). Serum concentrations of testosterone were markedly
increased in the testosterone-immunized rats (controls 1.2 +_ 0.2
ng/ml; immunized 61.7 _+ 9.6 ng/ml; P 0.001; Mean +_ SEM). There was
a significant increase (P 0.05) in LHRH receptors in the
testosterone-immunized animals (Fig. 4.2).
Discussion: The reduction in available testosterone induced by the
circulating antibodies, led to an increased pituitary content and
serum concentration of LH and FSH, and was associated with a
significant increase in the number of pituitary LHRH receptors.
Since the increases in both parameters were less pronounced than
those following castration (see section 4.3.2.2 and Clayton & Catt,
1981b) it is possible that small amounts of non-antibody-bound
testosterone are present in the immunized rat, whereas castration
completely removes the source of testosterone. The data are
consistent however with the concept of an inhibitory effect of
testosterone on LHRH receptor numbers. This has also been
demonstrated in intact rats by exogenous administration of steroid.
Daily injection of testosterone (500 jjg/day for 11 days) or
implantation of testosterone capsules to intact rats led to a
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reduction in the number of pituitary LHRH receptors (Naess et al.,
1981; Heber et al., 1982).
The majority of studies confirming this concept have come from
examination of the receptor changes following gonadectomy and steroid
replacement therapy. In general, acute testosterone replacement
(administered from the time of castration, or up to 6 days later)
prevents the post-gonadectomy receptor rise in both males and females
(Naess et al_., 1981; Frager et al., 1981; Conne et al., 1982;
Marchetti et al., 1982). Other steroids show similar inhibitory
effects. Oestradiol and progesterone replacement has been reported
to prevent the receptor rise (Naess et al., 1981; Frager et al.,
1981; Conne et al ., 1982). Administration of oestradiol 7 days after
ovariectomy resulted in decreased receptor numbers within 3 h (Marian
et al., 1981). It appears, however, that prolonged gonadectomy
abolishes the receptor response to steroids and thus chronic
administration (more than 7 days after gonadectomy) has no effect on
receptors (Conne et al., 1982; Marchetti et al., 1982).
However, steroids do not always exert inhibitory actions on
pituitary function. Savoy-Moore et al., (1980) noticed a correlation
between the rising receptor numbers during dioestrus to pro-oestrus
of the oestrous cycle, and serum oestradiol levels, and suggested
that part of the positive feedback influence of oestradiol could be
mediated by increased receptor numbers. Oestradiol has since been
found to increase LHRH receptors in isolated pituitary cells (Meidan et
al., 1981). In addition, since the administration of androgens
resulted in decreased receptors in isolated cells (Giguere et al.,
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1981), steroids may have a direct effect on the number of pituitary
LHRH receptors. The pituitary possesses receptors for both
oestradiol and testosterone (Notides, 1970; Naess et al., 1974) thus
providing a means by which steroids could influence receptor
turnover. Moreover, since recent evidence suggests that the isolated
LHRH receptor is capable of specific binding of both oestradiol and
testosterone (Zolman, 1983), a direct effect of steroids on LHRH
receptors cannot be excluded.
Conclusion: Active immunization against testosterone was associated
with a marked increase in pituitary LHRH receptors, consistent with a
negative regulatory influence of testosterone.
4.3.2.2 Effect of hyperprolactinaemia on pituitary LHRH receptors
Since pituitary responsiveness and LHRH receptor numbers are
reduced during lactation (see 4.2.3), a condition associated with
raised prolactin (PRL) levels (McNeilly et al., 1978; McNeilly,
1980),it was decided to assess the ability of PRL to influence
pituitary receptor numbers both in intact and castrate male rats.
Serum prolactin levels were raised by placing pituitary grafts under
the kidney capsule.
Method: Adult male (200-250 g) PVP rats were used both as donors and
recipients of anterior pituitary glands which were allocated at
random to treatment groups. Two pituitary glands were transplanted
under the kidney capsule of 2 groups of 5 rats, while 2 groups of 5
control rats were sham operated. One group of control and one group
of pituitary transplanted rats were castrated 7 weeks later. All
animals were killed 14 weeks after transplant operation by the usual
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procedure and serum analysed as described earlier. Anterior
pituitaries (both the animals' own and the transplanted glands) were
rapidly removed and used immediately for binding assay (Chapter 3).
This study was performed in collaboration with Dr. A.S. McNeilly
who performed the transplant operations. PRL levels were assayed by
Ms. J. Smith.
Results:
Intact Rats: Pituitary transplanted rats demonstrated significant
increases in serum PRL (controls 39 +_ 4 ng/ml; transplants
107 _+ 13 ng/ml; means +_ SEM; P 0.001) indicating the effectiveness
of pituitary transplantation in raising serum PRL. Serum
gonadotropin' ns and pituitary gonadotropin n content were reduced in
transplanted intact rats compared with controls (Fig. 4.3; ?/-
0.001). However, serum testosterone was unaltered (controls 3.5 _+
0.2 ng/ml; transplanted 3.1 _+ 0.3 ng/ml; means +_ SEM).
Pituitary LHRH receptors were significantly lowered in
transplanted versus intact control rats (P^L.0.01; Fig. 4.3).
Castrated Rats: Serum PRL levels were increased in transplanted rats
(32 _+ 4 ng/ml controls; 121 _+ 12 ng/ml transplants means +_ SEM;
P 0.001). Castration resulted in the expected raised pituitary
content and serum LH and FSH levels compared with intact rats (Fig.
4.3; P 0.001). Serum testosterone v/as^LO.l ng/ml in castrate rats.
Castration resulted in a marked rise in pituitary LHRH receptors
compared with those of intact controls (P^- 0.001). The presence of
raised PRL in the transplanted rats had no significant effect on any of























































FIGURE 4.3 Effect of hyperprolactinaemia induced by pituitary
transplants (P) on pituitary LHRH receptors, pituitary content
and serum concentrations of LH and FSH in intact adult male
control rats (C), in rats given a transplant of 2 pituitary
glands 98 days previously (P) and left intact or castrated 49
days after receiving a pituitary transplant.
Data are Mean +_ S.E.M. (5 animals per group).
** P-<0.01; *** P -CO.001 compared to intact control value.
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TABLE 4.1
Pituitary LHP.H receptors, gonadotrophin content and serum PRL and
testosterone from glands transplanted under the kidney capsule
Control Castrate
LH (>jg/pit) 7 ± 1 30 + 14
FSH (jjg/pit) 13 + 1 7+2
Serum PRL ng/ml 107 + 13 121 + 12
Serum Testosterone ng/ml 3.1 + 0.3 ^0.1
LHRHflbound fmol/pit. 25 + 3.9 24+4.2
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Transplanted Pituitaries: Results obtained from analysis of the LHRH
receptor concentration and gonadotropin n content of the original
two anterior pituitaries recovered from the kidney capsule, are shown
in Table 4.1. Although the tissue had an atrophied appearance and
decreased gonadotropin n content it still possessed LHRH receptors.
In addition, there was no difference in receptor numbers from
transplants in intact versus castrate rats.
Discussion: Previous work has shown that transplantation of
pituitaries under the kidney capsule results in reduced serum and
pituitary content of gonadotroph!'ns, while leaving serum testosterone
levels unaffected (Bartke et al., 1977; McNeilly et al., 1978). It
is also known that, as in the lactating female, pituitary
responsiveness to LHRH is reduced during hyperprolactinaemia (e.g.
Winters A Loriaux, 1978). This decreased responsiveness may be due
to decreased LHRH receptors as indicated by the above data. Since
testosterone levels remained unchanged, the effects of
hyperprolactinaemia on receptors in intact males are presumably
mediated via PRL-induced changes alone. These data have been confirmed
by Marchetti et al., (1982) who showed that injection of PRL, or
raising endogenous levels by treatment of immature females for 14 days
with sulpuride, resulted in decreased pituitary LHRH receptor content.
These changes could be reversed by a dopaminergic agonist (Marchetti et
al_., 1982).
Short-term hyperprolactinaemia (3 weeks) had no effect on
pituitary LHRH receptors in intact rats (Clayton 8 Bailey, 1982).
However, prolonged hyperprolactinaemia clearly reduced receptor
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numbers (Fig. 4.3). The importance of distinguishing between acute
and chronic effects is further highlighted by the effect of
hyperprolactinaemia on the receptor response to castration. Whereas
the short-term exposure (7 days) to high PRL reduced the receptor
increase (Clayton & Bailey, 1982; Marchetti & Labrie, 1982), prolonged
hyperprolactinaemia had no effect (Fig. 4.3). This latter observation
correlates with the finding that the long-term gonadotroph!n response
to castration is unaffected by pituitary transplants (McNeilly et al.,
1980).
Since prolonged hyperprol actinaemia reduced LHRH receptors in
intact but not castrate rats (Fig. 4.3) it could be suggested that
the presence of testosterone is required for the long-term effects of
prolactin on receptor numbers. This conclusion is supported by the
observation that the decrease in post-ovariectomy response to
short-term hyperprolactinaemia was enhanced by oestradiol (Marchetti &
Labrie, 1982).
It is interesting to note that pituitary tissue transplanted
under the kidney capsule, and thus deprived of LHRH, still possessed
receptors, albeit at low levels indicating that exposure to the
endogenous ligand is not a prerequisite for receptor expression. In
addition, since transplant receptor numbers were not significantly
different in intact and castrate rats, it could be suggested that
steroid-mediated inhibition of receptor numbers does not occur in the
absence of endogenous LHRH.
Cone!usion: Hyperprolactinaemia was associated with a decrease in
pituitary LHRH receptors in intact rats, but not in castrate rats,
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indicating that gonadal steroids may play a contributory role in
receptor regulation under these conditions.
4.3.2.3 Inhibin and Opioids
Inhibin, a non-steroidal gonadal peptide is believed to regulate
FSH release from the pituitary by influencing the responsiveness of
the pituitary to LHRH (e.g. Bramble et al., 1975). That this may be
brought about by receptor changes was suggested by the demonstration
that daily subcutaneous injection of adult male rats with an inhibin
extract, resulted in decreased LHRH receptor numbers (Sheth et al.,
1982). However, the physiological relevance of this observation
remains to be determined.
Opioids block the gonadotrophs surge and ovulation in rats
(e.g. Pang et al., 1977; Koves et al., 1981). Morphine and naloxone
administration has been shown to result in changes in pituitary LHRH
receptor concentration (Barkan et al., 1983a) thus implicating a role
for endogenous opioids in the regulation of pituitary LHRH receptors.
Whether this effect is mediated by a direct action on the pituitary
or via the hypothalamus (Ching, 1983) is unknown.
4.3.3 LHRH receptor Autoregulation
4.3.3.1 Introduction
A number of receptor systems appear to be regulated by the
ligand itself - so termed autoregulation. This phenomenon was first
observed when it was noticed that binding of labelled insulin to
cultured lymphocytes decreased after exposure to high insulin levels
(Gavin et al., 1974). This effect has been termed "down-regulation"
and has been reported following exposure of tissues
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to high doses of other hormones e.g. LH (Conti et al., 1976; Sharpe,
1976), growth hormone (Lesniak & Roth, 1976), TRH (Hinkle & Tashjian,
1975) and EGF (Heldin et a!., 1979). However receptor autoregulation
is not invariably inhibitory. For example, administration of lower
doses of angiotensin II resulted in an increase in glomerula cell
receptors (Hauger et al., 1978; Aguileraet a]_., 1978) i.e., "up-
regulation".
A realization that LHRH autoregulation was likely to be involved
in the determination of LHRH receptor numbers came from the
observation that a number of endocrine states associated with changes
in pituitary LHRH receptors are also correlated with altered
endogenous LHRH release. Thus, immunoreactive hypothalamic LHRH
increases from birth to day 21 of life (Araki et al., 1975),
correlating with receptor changes (although whether this is released
LHRH or not is unclear). LHRH is thought to be reduced during the
post-partum period (Lu et al., 1976) and LH pulse frequency is
reduced during lactation and hyperprolactinaemia, suggesting
decreased LHRH release (Bohnet et al., 1975). Similarly, after
castration, hypothalamic LHRH stores are depleted (Gross, 1980) and
this process can be reversed by treatment with testosterone or
oestradiol benzoate (Gross, 1980). Depleted stores of LHRH implied
that portal blood LHRH levels were increased and several studies have
indicated that this is indeed the case after castration (e.g. Neill et
al., 1977; Sherwood et al., 1980).
Due to the difficulties in sampling hypophysial portal blood
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it has not been possible to correlate directly changes in LHRH
release with changes in receptor numbers. However, the fact that
steroids have been shown to influence LHRH release (e.g. Sarkar &
Fink, 1979; Fink, 1979; Gross, 1980) renders it possible that the
receptor changes discussed under "heterologous regulation" are in
fact mediated, not by direct effects of steroids LH or PRL on LHRH
receptors, but rather by altering LHRH release and subsequent
autoregulation.
LHRH autoregulation has the potential therefore to be the primary
mechanism responsible for changes in LHRH receptors. The following
experiments set out to investigate this possibility using techniques to
immunoneutral ize endogenous LHRH levels.
4.3.3.2 Active immunization against LHRH in the intact male
In order to assess the importance of LHRH in the regulation of
its receptors, endogenous LHRH was immunoneutralized by active
immunization.
Method: 10 adult (90 day old) male Sprague Oawley rats were
immunized, five against RSA and five against LHRH (see Chapter 2).
Rooster immunizations were given at 6 and 11 months using Freund's
incomplete adjuvant. One month after the final booster the animals
were killed and blood and pituitaries collected as previously
described.
Results: LHRH antibody titre varied from 1:4,000 - 1:25,000 and v/as
sufficient to reduce both serum levels and pituitary content of LH
and FSH in all rats (Fig. 4.4). Serum testosterone levels were non-
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FIGURE 4.4 Effect of active immunization against LHRH (H) or HSA (I I )on pituitary LHRH receptors, serum concentrations and
pituitary content of LH and FSH in adult male rats.
Data are Mean +_ S.E.M. (10 rats in control group, 5 LHRHimmunized).
** P -d 0.05; *** P^-0.001.
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significantly with LHRH agonist, so were unlikely to interfere with
the receptor binding assay.
Pituitary LHRH receptors were markedly reduced in LHRH-immunized
rats (P^O.OOl; Fig. 4.4) compared with intact controls.
Discussion: It can be assumed that active immunization against LHRH
results in virtually complete inactivation of endogenous LHRH. Since
receptor numbers were dramatically reduced after active immunization,
this data provides strong evidence that LHRH autoregulation is
involved in the maintenance of its receptors. In addition it is
interesting to note that receptor numbers were not abolished after
immunization, but reduced to 30% of normal.
4.3.3.3 Passive Immunization against LHRH
In order to assess the effects of short-term removal of endogenous
LHRH on receptor numbers, the receptor changes following passive
immunization were investigated. The LHRH antiserum used was raised in
a ewe (No. 94) by immunization against LHRH conjugated to human serum
albumin by carbodiimide. Specificity was directed towards the
C-terminal end of the LHRH molecule (Ellis et al., 1983).
Method: 88 adult male Sprague Dawley rats were injected intravenously
(under ether anaesthesia) with either 1 ml LHRH antiserum (No. 94) or
with control BSA antiserum. Groups of 16 rats, 8 treated and 8
control, were killed 1, 6 or 24 h after antiserum injection.
The remaining animals were killed (5 control, 5 treated) 3, 7,
14 or 21 days after antiserum injection to assess receptor recovery.
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HOURS AFTER LHRH ANTISERUM
FIGURE 4.5 Pituitary LHRH receptors, serum testosterone and LH
concentrations 1, 6 and 24 h after administration of either
LHRH antiserum (E22 ) or control serum (□) to adult male
rats.
Data are Mean +_ S.E.M. (8 animals per group).
* P<0.05; ** P < 0.01; *** P< 0.001 for LHRH antiserum
































































3 7 14 21
DAYS AFTER LHRH ANTISERUM
FIGURE 4.6 Pituitary LHRH receptors, serum testosterone and LH
concentrations 3, 7, 14 and 21 days after administration of
either LHRH antiserum (E2 ) or control serum (EH) to adult
male rats.
Data are Mean +_ S.E.M. (8 rats per group).
* P0.05; ** P<L0.01 for LHRH antiserum treated compared to
control values at each time point.
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as described previously.
Results: Results are presented in Figs. 4.5 and 4.6. LHRH antiserum
resulted in an immediate reduction in serum LH and testosterone
levels (P-iC 0.001 after 1 h). Serum testosterone remained suppressed
at 1, 3 and 14 days, returning to control values after 21 days.
Serum LH levels were suppressed throughout the 21 day period although
the low value on day 14 was not statistically significantly different
from controls.
Pituitary LHRH receptors were significantly reduced only 24 h
after antiserum injection (P<C0.05) but not after 1 or 6 h. Receptor
numbers had returned to control levels 3 days after treatment.
Discussion: Antiserum administration clearly resulted in immediate
immunoneutralization of endogenous LHRH as seen by the precipitous
and maintained decreases in serum LH and testosterone levels (Figs.
4.5 & 4.6). This phenomenon has been noted following LHRH antiserum
administration to rams (Lincoln & Fraser, 1979), ewes (Fraser &
McNeilly, 1983) and castrate rats (Ellis et al., 1983) and emphasises
the essential role of LHRH in the control of pituitary (and hence
gonadal) function.
Several interesting observations can be made from the receptor
data. Firstly, receptor changes are not correlated temporally with
those of pituitary function. Thus the LHRH receptor decrease occured
after the decrease in serum LH and testosterone (Fig. 4.5),
suggesting that a prolonged period of reduced LHRH is necessary
before receptor numbers are decreased. In addition, receptor
recovery preceded that of serum LH and testosterone (Fig. 4.6).
Secondly, the fact that receptor numbers are unchanged 1 h and 6 h
after antiserum injection, despite the obvious presence of high
antibody titre as seen by the fall in LH, suggests that the antiserum
does not interfere with the LHRH receptor assay. Thirdly, since
receptor recovery preceded that of pituitary gonadotrophin release, it
could be suggested that only small quantities of LHRH are required to
initiate and maintain LHRH receptors. Thus, as LHRH antibody titre
declines, sufficient LHRH is available to induce receptor
"upregulation" but not LH release.
Cone!usions:
1) Data from this and the previous experiment confirm that LHRH
receptors are under positive autoregulatory control.
2) Receptor autoregulation exhibits a different time course from LH
release and receptor number is therefore not invariably corre¬
lated with pituitary responsiveness in the intact animal.
3) Passive immunoneutralization of LHRH provides a sensitive method
for the investigation of receptor autoregulation in the intact
animal, and the antibody used is unlikely to interfere in the
receptor assay.
4.3.3.4 Autoregulation in the Male - General Discussion
In addition to the above data utilizing active and passive
immunoneutralization of LHRH, the concept of a positive
autoregul atory influence of LHRH on its receptors has been
corroborated by studies in castrate males. That the post-castration
increase in receptors is due to LHRH autoregulation, has been
convincingly demonstrated. Thus, administration of LHRH antiserum
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identical to that used in the present study, to acutely or
chronically castrated rats, abolishes both the post-
castration receptor increase and the elevated serum LH (Clayton et
al., 1982b), receptor levels being lowered to values below those
detected in intact control rats (Clayton et al., 1982b). Similarly,
prevention of LHRH interaction with its receptors by infusion of LHRH
antagonist also prevented or reduced the post-castration receptor
response (Clayton et al., 1982a) confirming that it is the specific
interaction of LHRH with its receptor, rather than receptor occupancy
per se, which is responsible for the observed changes.
Further confirmation of the role of LHRH "up-regulation" was
demonstrated by removal of endogenous LHRH via lesioning the medial
basal hypothalamus (MBH). This resulted in an abolition of the post-
castration receptor increase (Clayton et al., 1982a; Pieper et al.,
1982). Receptors could be elevated to post-castration levels by
administration of LHRH or LHRH agonist, to reverse the effects of MRH
lesions or antibody treatment (Pieper et al ♦, 1982; Clayton et al.,
1982a). It appears, therefore, likely that the raised LHRH receptors
following castration are due to raised endogenous LHRH which both
initiates and maintains the increase.
LHRH administration concurrently with castration resulted in a
small decrease in receptors seen on day 7 (Frager et al., 1981).
Although the significance of this observation was not noted, in
another study LHRH injections from day 1 - 11 of castration reduced
binding (Naess et al., 1981). It could be suggested therefore that
further increases of LHRH above the post-castration level can reach
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the threshold level required for down-regulation of LHRH receptors
(Naess et al., 1981).
In intact rats, the effects of exogenous administration of LHRH
on pituitary receptors are complex, depending on both the dose and
duration of exposure to LHRH. The majority of reports indicate that
acute exposure (4 - 11 days) to either LHRH (Naess et al., 1981) or
LHRH agonist (Marshall et al., 1980; Heber et al_., 1980; Frager et
a 1., 1981; Marchetti et al., 1982; Clayton, 1982) resulted in
increased receptor numbers, thus confirming the up-regulation seen
after LHRH replacement in lesioned or antibody-treated castrate rats
(Pieper et al., 1982; Clayton et al., 1982a). Attempts at achieving
down-regulation in the intact rat using high doses of LHRH or LHRH
agonist have either resulted in no change in receptor concentration
(e.g. Heber et al., 1982) or a decrease (Clayton, 1982). The duration
of exposure was also important; thus administration of 200 ng LHRH
agonist/day for 20 days increased receptors, but for 40 days or 60 days
had no effect (Heber et al., 1982).
It is interesting to note that depriving the pituitary
gonadotroph of endogenous LHRH stimulation either by MBH lesions,
LHRH immunization or pituitary transplantation under the kidney
capsule, did not result in total abolition of LHRH receptor
concentration. The continued expression of receptors, albeit at
reduced levels, in the absence of ligand, suggests that a basal or
pre-programmed receptor level exists which is independent of
autoregulation. This hypothesis has recently been corroborated by the
demonstration of specific LHRH receptors in the pituitary of the
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hypogonadal mouse (Young et al., 1983). Receptor numbers were
similar to those found in immunized or lesioned rats i.e. indicative
of an absence of LHP.H. A basal level of receptors therefore appears
to be present irrespective of pituitary exposure to LHRH. It could
be suggested either that heterologous ligands maintain these basal
receptor numbers or more likely, that they are independent of
regulation.
4.3.4 LHRH Receptor Regulation in the Male - Summary
The experimental results obtained from studies in the male are
summarized in Table 4.2. The results show:-
1) Active immunization against testosterone resulted in similar
changes to those seen following castration. LHRH receptors were
1a creased.
2) Hyperprolactinaemia was associated with a decrease in
receptors in intact rats, but not in castrate rats.
3) Chronic active immunization against LHRH markedly reduced
receptor concentrations.
4) Passive immunoneutralization against LHRH was associated with a
decrease in LHRH receptors.
Cone!usions
1) Gonadal steroids and PRL exert negative regulatory influences on
LHRH receptor numbers.
2) LHRH autoregulation is primarily up-regulation. Receptor levels




Summary of data obtained from receptor studies in male rats.
Arrows indicate the influence of the treatment regime on a number of
parameters pertinant to receptor regulation, showing the direction of












against testosterone ? 4 4 4 44
Castration ? 4 44 44 Non
detectable
Castration + hyper PRL ? + 44 44 Non
detectable
Intact + hyper PRL ? 4 4 4 No change
Active Immunization
against LHRH
4 4 44 44 44
Passive Immunization
against LHRH 4 4 4 4
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4.4 REGULATION OF LHRH RECEPTORS IN THE FEMALE
4.4.1 Introduction, Aims, Models
Introduction: Pituitary LHRH receptors and pituitary responsiveness
to LHRH vary during the oestrous cycle (4.2.2). From the results of
studies in the male it was evident that both heterologous factors
(e.g. gonadal steroids) and LHRH itself were capable of regulating
LHRH receptor concentration. In contrast, chronic exposure to LHRH
agonist was known to result in marked antiferti1ity effects (Chapter
1.4.2) and this had been suggested to be due, in part, to
down-regulation of pituitary LHRH receptors (Chapter 5.1).
Aims:
1) To assess whether antiferti1ity effects induced by exposure to
extremes of LHRH could be explained by decreased LHRH receptor
concentrations.
2) To assess the relative importance of gonadal steroids, LH and
LHRH in controlling receptor concentrations in the cycling
female.
3) In particular to assess the role of receptor autoregulation
during the oestrous cycle.
Experimental models: Pituitary LHRH receptor concentrations were
assessed following disruption of the hypothalamic-pituitary-gonadal
axis by the following procedures:-
i) Chronic hyperstimulation with LHRH agonist or chronic hypo-
stimulation following LHRH antiserum treatment (4.4.2).
ii) Chronic neutralization of LH or LHRH by active immunization
(4.4.3).
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iii) Passive immunoneutral ization of LH or LHRH at specific times
during the oestrous cycle (4.4.4).
4.4.2 Effect of extremes of exposure to LHRH in the intact adult
female rat
Introduction: In order to assess the effects of extremes of exposure
to LHRH on the pituitary-ovarian axis, the effects of
hyperstimulation of pituitary function via daily injections of
various doses of LHRH agonist or hypostimulation following passive
immunoneutralization of endogenous LHRH were assessed. It was hoped
that analysis of pituitary LHRH receptors would reveal whether the
expected antiferti1ity effects produced by these means were due to
decreased receptor numbers.
Method: Regularly cycling adult female Sprague Dawley rats (60-80
days old) were used and daily vaginal smears taken to assess vaginal
cytology both before and during treatment.
Animals were divided into 6 groups of 8. Treatment commenced at
random stages of the cycle. Rats in groups 1-3 were injected
subcutaneously at 09.00 h daily for 3 weeks with 50, 500 or 5000 ng
LHRH agonist dissolved in 1% gelatin and 0.9% (w/v) NaCl. Rats in
Group 4 were injected with 0.5 ml of antiserum to LHRH (No. 94) once
every 3 days. The first antiserum injection was given intravenously
and the remainder subcutaneously. Control rats received either
vehicle alone or antiserum to human serum albumin (HSA) and were










































































































































































FIGURE 4.7 Effect of daily injections of 50, 500 or 5,000 ng LHRH agonist
(H) or 3 times weekly injections of LHRH antibodies (E3 ) on
pituitary LHRH receptors. Control animals received vehicle
alone (□ ) and were killed on the first day of dioestrus
(Dj) or pro-oestrus (P).
Values are Mean _+ S.E.M. (8 animals per group)
* P<C 0.05 compared to Dj control value.
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(Group 5). Since no difference was found between HSA and vehicle
treated rats, the results were pooled.
24 h after the final injection (or on the day of pro-oestrus or
dioestrus for controls in Groups 5 & 6), rats were anaesthetized with
CO2 generated from solid CO2. Blood was collected by
decapitation and after centrifugation the serum was stored at -20°C,
prior to hormone assay. The anterior pituitary was rapidly removed
and used immediately for the LHRH receptor assay (see Chapter 3.1.3).
The data are expressed as mean +_ SEM and values were compared to
control dioestrous values (Group 6).
Results: Changes in ovarian histology and receptors are presented in
Chapter 5.
LHRH Antiserum Treatment: Hypostimulation of the pituitary
following immunoneutralization of endogenous LHRH with a specific
LHRH antiserum resulted in significantly decreased serum LH and
progesterone concentrations (Table 4.3). Ovarian weight was reduced
(Table 4.3). Oestrous cycles, as assessed by vaginal cytology
ceased, as evidenced by a constant dioestrous-type vaginal smear.
Pituitary LHRH receptors were not statistically different from those
of dioestrous control rats (Fig. 4.7).
LHRH agonist treatment: Hyperstimulation of the pituitary using
daily treatment with 50, 500 or 5000 ng LHRH agonist, resulted in
decreased uterine weight and serum oestradiol (Groups 2 and 3).
Serum progesterone was reduced in all groups. Ovarian weight was
significantly increased in Groups 1 and 2. Vaginal cytology revealed
a constant dioestrous pattern indicative of impaired ovarian
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function.
Serum LH was unaltered although serum FSH levels were increased
in all treated groups.
Pituitary LHRH receptor concentrations were not significantly
different from dioestrous control values (Fig. 4.7).
Piscussion: Hyperstimulation of the pituitary with daily injections
of LHRH agonist led to a cessation of normal oestrous cycles, as
shown by constant dioestrous smears and decreased serum progesterone
and oestradiol levels indicative of impaired ovarian function. This
agrees with the findings of Johnson et al_., (1976a); Cusan et al_.,
(1979) and Maynard & Nicholson, (1979) and provides another example
of the paradoxical antiferti1ity effects seen after prolonged
administration of LHRH agonist, as discussed in Chapter 1. Receptor
changes following LHRH administration as studied in the male (see
4.3.3) have shown that chronic administration of LHRH does not
invariably result in decreased receptor numbers. This indicates that
the observed antiferti1ity effects (Chapter 1) cannot be explained
entirely by a down-regulation of pituitary LHRH receptors under these
conditions. Similarly, in the female, decreased pituitary-ovarian
function occurred in the absence of receptor changes (Fig. 4.7).
Marchetti et al_., (1982) found that injection of 200 ng LHRH
agonist/day for 2 weeks also failed to alter receptor numbers
significantly from those found in intact female controls. The data
presented confirms and extends this finding by showing that chronic
treatment of intact female rats with a range of doses of LHRH agonist
(50, 500 or 5000 ng/day) resulted in pituitary receptor
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levels within the range for the cyclic animal. It is unlikely
therefore that pituitary LHRH receptor down-reguation is a primary
mechanism involved in the antiferti1ity effects seen in either male
or female animals after repeated daily injections of LHRH agonist.
Although basal LH levels v/ere unchanged by LHRH agonist
administration (see Table 4.3), each injection would be followed by a
huge rise in serum LH (Kledzik et al ., 1978; Cusan et al ., 1979).
Thus the possibility of gonadal desensitization following excess
gonadotrophin stimulation (Conti et al ., 1976) cannot be excluded.
Neither can direct ovarian actions of LHRH agonist.
Immunoneutralization of LHRH also led to cessation of oestrous
cycles and impaired ovarian function similar to that seen after
active immunization against LHRH (Fraser ft Baker, 1978). Despite this,
pituitary LHRH receptors were within the range found in control cycling
animals at dioestrus (Fig. 4.7). Since passive immunization of intact
males with the same antiserum resulted in a 25-35% reduction in LHRH
receptors (see 4.3.3.3) it was surprising that no such effect was seen
in the intact female. However, it must be remembered that receptor
numbers vary during the oestrous cycle and these cyclic changes
presumably do not occur under the treatment regime. Thus it could be
suggested that after 3 weeks of antibody treatment the presence of
ovarian steroids, albeit at altered levels, is sufficient to maintain
receptor levels at the basal cyclic level.
Alternatively, it is possible that prolonged administration of
LHRH antiserum resulted in the development of antibodies to the
injected antiserum and thus complete immunoneutral ization of LHRH
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cannot be assumed.
It is also possible, but unlikely, that a fundamental difference
exists between males and females in the importance of pituitary LHP.H
receptor autoregulation in the intact animal.
Conclusions:
1) Prolonged daily hyperstimulation of the pituitary with LHRH
agonist disrupted oestrous cycles but did not result in altered
pituitary LHRH receptor concentrations, indicating an absence of
pituitary receptor down-regulation.
2) Hypostimul ation also failed to alter pituitary LHRH receptors
from the range seen in the cycling rat.
3) Therefore, either the role of autoregulation is secondary to the
influence of circulating hormones in the intact animal, or the
regime used was insufficient to neutralize all endogenous LHRH.
4.4.3 Active immunization against LH and LHRH
Introduction: In order to assess the relative contribution of LH,
steroids and LHRH in the regulation of pituitary LHRH receptors in
the female, the effects of active immunization against LH and LHRH
were compared.
Method: 31 regularly cycling adult female Sprague Dawley rats
were immunized as described in Chapter 2.6. 14 control rats were
immunized against BSA, 6 rats against LH and 11 against LHRH. Three
months after the initial injections, rats were boosted using Freund's
incomplete adjuvant, then killed 3 weeks later, blood and pituitaries
being collected as described previously. Ovaries were also removed
















































































FIGURE 4.8 Effect of active immunization of adult female rats against LH
(BI3) or LHRH (M) on pituitary LHRH receptors, uterine and
ovarian weight and hypothalamic LHRH content. Control animals
were immunized against BSA and killed either at 10.00 h
dioestrus (D) or 12.00 h pro-oestrus (P).
Data represents Mean +_ S.E.M. (7 in each of control groups, 11
LHRH immunized and 6 LH immunized).
* P < 0.05; *** P <.0.001 compared to D control value.
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Resul ts: Out of 14 control rats, 2 were spontaneously acyclic and
2 showed cycles of abnormal length so the tissues were not included in
the receptor assays. These results are unlikely to be due to control
immunization procedure since a group of 12 untreated rats of similar
age (200 days old) showed similar characteristies. The remaining
control rats exhibited regular 4 day cycles and were killed either at
10.00 h dioestrus or at noon pro-oestrus.
Although LH-j^titres were not measured, they were clearly
sufficient to abolish ovarian function in all animals, as evidenced
both by cessation of oestrous cycles, and dramatically decreased
ovarian uterine weight as previously described by Lawrence & Ichikawa
(1968). Pituitary LHRH receptors were significantly elevated in the
LH-immunized rats, compared with dioestrous control levels, to levels
comparable to those found at pro-oestrus in the cycling animal (Fig.
4.8).
LHRH antibody titres ranged from 1:900-1:13,000 and all rats
showed characteristic changes associated with immunoneutralization of
LHRH, namely decreased uterine weight, cessation of cyclicity (as
assessed by vaginal smears) and decreased ovarian weight (Fraser &
Raker, 1978). These changes were similar to those seen after LH
immunization. However, in marked contrast to LH, immunization of
LHRH resulted in dramatic reduction in the number of pituitary LHRH
receptors (P^LO.001) and hypothalamic content of LHRH (Fig. 4.8).
Piscussion: The ability of chronic immunoneutralization of LHRH to
reduce pituitary LHRH receptors in the intact female indicates that
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as in the male, autoregulation is involved in the maintenance of
pituitary LHRH receptors.
The receptor changes following active immunization against LH
v/ere similar to those seen after ovariectomy (see 4.4.4) and indicate
that the removal of gonadal steroids raises receptor levels to those
found in pro-oestrous rats.
Cone Iusions:
1) Gonadal steroids exert a negative influence on pituitary LHRH
receptors.
2) LHRH receptors are positively autoregu I ated in the intact
animaI.
4.4.4 Passive Immunization of LHRH in ovariectomized rats
Introduction: Lxtensive studies in the male had indicated that the
post-castration LHRH receptor increase was due to LHRH autoregulation
(discussed in 4.3.3.4). In order to assess the efficacy of the
LHRH antiserum in females, and to determine the role of
autoregulation in post-ovariectomy receptor changes, the same
antiserum which had successfully immunoneutralized endogenous LHRH in
the male (4.3.3.3), was administered to female rats 7 days after
ovariectomy.
Method: 12 adult female rats, at random stages of the oestrous
cycle v/ere ovariectomized under ether anaesthesia. After seven days
the animals v/ere injected intravenously under ether anaesthesia, with
either 0.5 ml LHRH antiserum (94) or HSA antiserum. 21 h later blood
and anterior pituitary glands were collected as described
previously.
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FIGURE 4.9 Effect of administration of LHRH antiserum to adult female
rats ovariectomized 7 days previously, on pituitary LHRH
receptors and serum LH measured 21 hours later.
Data are Mean + S.E.M. (6 animals per group).
* P < 0.05.
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Results: Ovariectomy resulted in elevated serum LH levels as measured
8 days later and these levels were reduced (P-<0.05) by treatment with
LHRH antiserum 21 h previously (Fig. 4.9). Pituitary LHRH receptors
were raised to pro-oestrous levels in the control ovariectomized rats
while after LHRH antibody treatment, receptor numbers fell (P-C0.05)
to the range found for oestrous rats (Fig. 4.9).
Discussion: Ihe ability of specific immunoneutralization of endogenous
LHRH to reduce the post-ovariectomy rise in LHRH receptors emphasises
the importance of endogenous LHRH in maintaining LHRH receptors after
castration. This has also been found to be the case in males (e.g.,
Clayton, 1982).
4.4.5 The effects of passive immunoneutral ization of LHRH or LH on
Pituitary LHRH receptors during the rat oestrous cycle.
Introduction: Pituitary LHRH receptor numbers vary during the
oestrous cycle of the rat and hamster with a slow maintained increase
during dioestrus day one, reaching maximal levels between dioestrus day
2 and the morning of pro-oestrus, after which numbers fall to a nadir
at oestrus (e.g. Adams ft Spies, 1981a; Clayton et a I ., 1980; Savoy-
Moore et_aj_., 1980). The increase in receptors has been suggested to
be influenced either by ovarian steroids and/or gonadotrophins, or an
autoreguIatory action of LHRH (Savoy-Moore et a I ., 1980; Clayton,
1982). The reasons for the fall in LHRH receptors are largely unknown,
but could be due to LHRH down-regulation similar to that described for
LH (Conti et al., 19/6), since portal blood levels of
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LHRH are raised on the afternoon of pro-oestrus (Sarkar et al ., 1976;
Levine ft Ramirez, 1982). Alternatively or additionally the changing
steroid environment could be involved.
One way to investigate the factors stimulating these changes
within the "LHRH-LHRH receptor-LH-ovarian steroid axis' is to
specifically neutralize either LHRH or LH by antisera. Injection of
antibodies to LHRH on the first day of dioestrus prevents follicular
development and oestrogen secretion, while administration at noon on
pro-oestrus prevents the LH surge and ovulation (Fraser ft Gunn, 1973;
Koch et a I., 19/3; de la Cruz et a I., 19/6). Injection of LH
antibodies at these times has similar effects on ovarian function,
but leaves LHRH free to act on its pituitary receptors (Schwartz ft
Ely, 1970; Ely ft Schwartz, 1971).
Materials and Methods: Adult female Sprague Dawley rats (60-80 days
old) housed under conventional conditions with lights on between
05.00 h and 19.00 h and with regular 4 day oestrous cycles, were used
in the study.
Anti sera: Ihe LHRH antiserum (No. 94) had been used previously in
males (4.3.3.3) and females (4.4.2). Preliminary results showed that
the minimum effective dose of the LHRH antiserum required to block
ovulation in 5 out of 5 rats when administered intravenously at 12.00
h pro-oestrus, was 100 ^1. A dose of 0.5 ml was used in the main
study.
The LH antiserum was raised against ovine LH (NIAMDD-oLH-23) in
a New Zealand White Rabbit (Sharpe ft Fraser, 1983). Antiserum
obtained from one animal (R28) after the first booster immunization,
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was used in the present study. Titration curves prepared by
incubating dilutions of the antiserum under standard radioimmunoassay
conditions showed that the titres of the antiserum, expressed as the
final dilution binding 33% of 125j _0LH or 125j_rLH, were
1:1,350,000 and 1:195,000 respectively. The antiserum also bound
125j_rpsH, but at a much lower titre of 1:9,600. Initial studies
showed 250 ^il of this antiserum blocked ovulation in 5 out of 5 rats
when administered intravenously at 12.00 h pro-oestrous.
Administration of antisera at 11.00 h Dioestrus: To examine the
effects of neutralization of LHRH or LH on the rise in pituitary LHRH
receptor numbers between the first day of dioestrus and noon
pro-oestrus, 3 groups of 5 rats were injected intravenously via the
tail vein (under light ether anaesthesia) at 11.00 h dioestrus one,
with either 0.5 ml LHRH antiserum, 1 ml LH antiserum or 1 ml
antiserum to human serum albumin (HSA). 5 untreated control rats
were killed with CO2 generated from dry ice at 11.00 h dioestrus
one. The antibody treated rats were killed at 12.00 h pro-oestrus,
with blood and serum collected as described previously. The uterus
from each animal was weighed and checked for distension.
Administration of antisera at 12.00 h Pro-oestrus: lo examine the
effects of immunoneutraI ization of LH or LHRH on the decrease in
pituitary LHRH receptors between 12.00 h pro-oestrus and 09.00 h
oestrus, 2 groups of 10 rats were injected at 12.00 h pro-oestrus
with either 0.5 ml LHRH antiserum, or 0.5 ml HSA antiserum. 5
untreated control rats were killed at 12.00 h pro-oestrus. 5 rats
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from each group were killed at 17.00 h pro-oestrus. The remaining
animals were bled from the tail vein at 17.00 h pro-oestrus (under
light ether anaesthesia) and killed at 09.00 h oestrus. 5 rats were
injected with 1 ml LH antiserum at 12.00 h pro-oestrus and killed at
09.00 h oestrus. Blood, pituitaries and right ovaries were collected
as described previously. Oviducts were removed from animals killed
at oestrus and examined for ova.
ResuIts: (Data on ovarian receptors is presented in Chapter 5).
Immunoneutralization of LH or LHRH at 11.00 h dioestrus one
I he effectiveness of the antisera to LHRH or LH in blocking
follicular steroidogenesis was demonstrated by the fact that the
increase in uterine weight (P 0.001) between dioestrus and
pro-oestrus observed in control animals, was completely prevented
(P^L. 0.001) in the rats receiving LHRH or LH antibodies (Fig. 4.10).
While all the control animals showed evidence of uterine distension,
this was absent in all the treated rats.
Control animals showed the expected increase in pituitary LHRH
receptors between 11.00 h dioestrus one and 12.00 h pro-oestrus
(P -==4.0.001; Fig. 4.10). Passive immunoneutral ization of LHRH
prevented this receptor increase (P .^L. 0.001; Fig. 4.10) whereas
administration of LH antiserum had no effect (Fig. 4.10).
Immunoneutralization of LH or LHRH at 12.00 h pro-oestrus
The effectiveness of passive immunization of LHRH or LH at
12.00 h pro-oestrus was indicated by the abolition of ovulation in
animals killed at 09.00 h oestrus. Control animals shed an average





FIGURE 4.10 Effect of administration of antiserum to LH (EH1), LHRH (■§)
or control serum (t l) at 11.00 h dioestrus on pituitary LHRH
receptors and uterine weight measured at 12.00 h pro-oestrus.
Data are Mean _+ S.E.M. (5 animals per group).












FIGURE 4.11 Effect of administration of antiserum to LH (EH), LHRH (
or USA (□ ) at 12.00 h pro-oestrus, on pituitary LHRH
receptors measured at 17.00 h pro-oestrus and 09.00 h
oestrus.
Data are Mean +_ S.E.M. (5 animals per group).
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treated animals had no ova present. Passive immunization of LHRH
also abolished the LH surge, reducing serum LH levels from 25(H60
ng/ml (control) to 36_+3 ng/ml (antiserum treated) at 17.00 h
pro-oestrus (P^0.05).
Pituitary receptors declined from 12.00 h pro-oestrus to 09.00 h
oestrus in control animals (P^C 0.001; Fig. 4.11). Administration of
LHRH or LH antiserum at 12.00 h pro-oestrus did not alter the
receptor numbers (Fig. 4.11); neither were receptor numbers altered
at 17.00 h pro-oestrus in control or LHRH antiserum treated animals.
Pi scussion: I he neutralization of LHRH or LH by antibodies from the
first day of dioestrus had similar effects, both treatments blocking
follicular oestrogen secretion as indicated by the absence of increased
uterine weight on the morning of pro-oestrus. However, these
treatments had markedly different effects on the rise in the number of
pituitary LHRH receptors which occurs during this period (Park et al .,
1976; Clayton et a I., 1980; Savoy-Moore et a I♦, 1980; Marian et al .,
1981; Reeves et a I., 1982). While the LH antiserum failed to effect
this change, treatment with LHRH antiserum completely abolished the
rise. Since the essential difference betv/een the inhibitory treatments
on the 'LHRH-LHRH receptor-LH- ovarian steroid axis' is the removal of
the LHRH by the LHRH antibodies, these results suggest that the primary
driving force for the rise in pituitary LHRH receptors at pro-oestrus
is LHRH itself.
Pituitary receptors showed a marked fall from high levels at
12.00 h pro-oestrus to low levels at 09.00 h oestrus, a finding in
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agreement with that of others (Park et al ., 1976; Savoy-Moore et al.,
1980; CI ayton et al ., 1980). Since LHRH levels in hypophyseal portal
blood are highest during the afternoon of pro-oestrus (Sarkar et al ♦,
1976; Levine & Ramirez, 1982) it is possible that LHRH itself acts as
the stimulus for its own receptor decline. Immunoneutralization of
LHRH at 12.00 h pro-oestrus resulted in abolition of the LH surge and
ovulation. Despite this, the number of pituitary LHRH receptors was
unaltered at 17.00 h pro-oestrus and the fall to 09.00 h oestrous
levels was not prevented. Since LHRH antibodies presumably prevent
LHRH reaching its pituitary receptor, the inability of
immunoneutral ization of LHRH to influence the receptor decline
indicates that the change in the number of pituitary receptors
between pro-oestrus and oestrus is independent of LHRH.
Immunoneutralization of LH similarly resulted in abolition of
ovulation and also failed to influence the receptor decline. The low
receptor numbers at 09.00 h oestrus are therefore likely to be due to
changes occurring between 12.00 h pro-oestrus and 09.00 h oestrus,
which are independent of changes in the secretion of LHRH, LH or
ovarian steroids during this period. It has been suggested that the
low receptor numbers at oestrus are due to occupation by endogenous
ligand and therefore do not represent a true fall (Smith-White &
Ojeda, 1983). However, this is unlikely to be the case due
to the rapid rate of dissociation of LHRH from its hormone receptor
complex under the conditions of the assay (Clayton & Catt, 1981b).
Detailed time course studies of receptor changes between
pro-oestrus and oestrus have indicated that 2 phases may be involved;
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an initial acute fall which is transitory, followed by a more gradual
decrease to nadir levels (Savoy-Moore et al., 1980; Adams ft Spies,
1981a). The acute fall was abolished by (pentobarbitone given at
12.00 h pro-oestrus (Savoy-Moore et al ., 1981; Adams ft Spies, 1981b)
and in the hamster could be restored by LHRH administration (Adams ft
Spies, 1981b). A similar acute fall was observed in the
ovariectomized oestrogen-treated rat which was also pentobarbitone
sensitive (Barkan et a I., 1983b). Although this acute transitory
fall appears to be LHRH dependent, several problems exist concerning
interpretation of its relevance. Firstly, it appears to occur prior to
the LH surge (Savoy-Moore et al ., 1981; Barkan et al., 1983b) and
secondly, it may be modulated by endogenous opioids (Barkan et al.,
1983a) by a mechanism independent of endogenous LHRH, since reduced
portal blood LHRH was not always associated with the impaired LH surge
following treatment with naloxone or morphine (Ching, 1983). In
addition it may represent an apparent loss of receptors only, due to
receptor occupancy (Smith-White ft Ojeda, 1983). In this study we
investigated the overall decrease in receptors which occurred between
pro-oestrus and oestrus and which seemed to be unaffected by
pentobarbitone (Savoy-Moore et al ., 1981) and was unlikely to be due
to receptor occupancy (Smith-White ft Ojeda, 1983).
Since pentobarbitone also influences the release of other
hormones it was important to establish whether the overall fall in
receptors wou1d be affected by specific neutralization of LHRH. Our
data extends those obtained using (pentobarbitone and indicates that
the fall in receptors is likely to be independent of LH, LHRH and
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ovarian steroids and is therefore probably under the control of other
factors of hypothalamic or ovarian origin. Alternatively, the return
of receptors to basal levels may be a pre-programmed response to
hormonal changes which occurred earlier in the cycle.
In addition, it could be postulated that since specific removal of
LHRH has been shown to result in decreased LHRH receptors (e.g., see
4.3.3.3 and 4.4.3), the decrease in LHRH receptors at pro-oestrus is
due to a removal of endogenous LHRH support, rather than
down-regulation following high LHRH stimulation. Thus portal blood
LHRH concentrations are known to be maximal coincident with the LH
surge, falling to nadir levels on the evening of pro-oestrus (Sarkar et
al., 1976; Levine & Ramirez, 1982). In conclusion, it appears that:-
(1) LHRH autoregulation alone is responsible for the increase in
pituitary LHRH receptors between dioestrus one and noon
pro-oestrus, but that
(2) the fall in receptors from pro-oestrus to oestrus is independent
of LHRH, LH and ovarian steroids. Whether the fall is regulated
by a pre-programmed mechanism, or by other factors such as
endogenous opioids, remains to be determined.
4.4.6 LHRH Receptor Regulation in the Female - Summary
I he experimental results obtained from the studies described in
the female are summarized in Table 4.4.
The results show:-
(1) Chronic hyperstimulation of the pituitary with LHRH agonist
failed to down-regulate pituitary LHRH receptors.
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TABLE 4.4
Summary of data obtained from studies on pituitary LHRH receptor regulation
in the female.
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(2) Active immunization against LH resulted in increased receptor
concentrations.
(3) Active immunization against LHRH resulted in decreased receptor
concentrations.
(4) Passive immunization against LHRH decreased the high post-
ovariectomy receptor numbers.
(5) Passive immunization against LH had no effect on pituitary
receptor numbers during the oestrous cycle.
(6) Passive immunization of LHRH in intact female rats at dioestrus
prevented the increase in receptors at pro-oestrus, but
administration at noon pro-oestrus did not prevent the fall in
receptor numbers at oestrus.
Conclusions:
(1) Pituitary LHPH receptor down-regulation is unlikely to be the
sole explanation for the antifertility effects of LHRH agonist.
(2) Pituitary LHRH receptors are primarily under positive auto-
regulatory control, numbers reflecting known or assumed changes
in endogenous LHRH release.
(3) The fall in receptor numbers between pro-oestrus and oestrus is
unlikely to be due to LHRH receptor down-regulation and may be
caused by removal of positive autoregulatory influence of LHRH
i.e. decreased LHRH release.
(4) Positive autoregulatory control of LHRH receptors is physio¬
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5.1 INTRODUCTION AND AIMS
From the data discussed in the previous chapter it is evident
that pituitary LHRH receptors are regulated by both heterologous
factors, such as prolactin and steroids, and by LHRH itself. Since
ovarian LHRH receptors have been shown to have identical
characteristics of affinity and specificity to those of the pituitary
(Chapter 3) it seemed reasonable to expect that similar regulatory
processes could be applied.
The experiments detailed in this chapter therefore set out to
determine whether ovarian LHRH receptor concentrations, measured in
whole ovarian homogenates (as described in Chapter 3) varied under
conditions known to produce marked alterations in ovarian structure
and function, namely:-
(a) Exposure to constant light
(b) Active immunization against LH or LHRH
(c) Chronic hyperstimulation with LHRH agonist or
hypostimulation following prolonged passive
immunoneutralization of LHRH
(d) Short term passive immunization against LH or LHRH.
Experimental details, together with serum analyses and pituitary
LHRH receptors, are presented in Chapter 4; only the ovarian
receptors are discussed in this chapter. For each experiment the
ovaries were rapidly removed and either stored at -40°C prior to
assay of LHRH receptors or taken for histology. No differences were
found between right and left ovaries which were taken at random for
receptor assay or histology.
122
5.2 OVARIAN LHRH RECEPTORS - REVIEW
Gonadal LHRH receptor concentrations show marked changes during
the period of sexual maturation in both male and female rats, with
receptor concentrations being highest in immature rats (Harwood _et
al., 1980b). Receptor levels were low at day 5 of age and rose to
maximal at day 20-25 (Dalkin et al ., 1981; Smith-White A Ojeda, 1981)
before declining to adult levels by day 40-80 of age (Dalkin et al .,
1981). This prepubertal decline in LHP.H receptor concentrations
occurred during the days preceeding the first pre-ovulatory LH surge
(Smith-White & Ojeda, 1981). These receptor changes during sexual
maturation bear considerable resemblance to those reported for the
pituitary (Chapter 4.2.1). In both cases, expression of receptor
numbers per gland shows gradual increase with increasing age and
tissue weight (Dalkin et al., 1981).
In contrast to the pituitary, total ovarian LHRH receptor
concentrations do not alter during adulthood in female rats, no
evidence being available for cyclic changes during the oestrous cycle
(Dalkin et al ., 1981; Pieper et al., 1981; Reeves et al., 1982).
However ovarian LHRH receptor concentrations were found to decrease
in the third week of pregnancy and in the first week of lactation
(Reeves et al ., 1982).
As with pituitary LHRH binding, there was no evidence to suggest
an alteration in ovarian LHRH receptor affinity (Dalkin et al., 1981;
Reeves et a I ., 1982), thus validating the use of saturation analysis
for receptor measurement (Chapter 3) in the following studies.
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5.3 OVARIAN LHRH RECEPTORS AND MORPHOLOGY IN RATS EXPOSED TO CONSTANT
LIGHT
5.3.1 Method
Ovarian LHRH receptors were assessed in individual ovaries (as
described in Chapter 3) taken from adult female rats kept under
(ttc -
conditions of constant light jjfor 14 weeks and compared with those of
10 normal adult rats of the same age killed at dioestrus or
pro-oestrus (details given in 4.2.5).
5.3.2 Results
Vaginal smears revealed a predominance of cornified cells
typical of a persistent oestrous state induced by exposure to
constant light. Ovarian histology indicated a marked absence of
active luteal tissue and the ovaries shov/ed the typical
polyfollicular appearance indicative of impaired ovarian function
(Plate 5.1 and see also Lawton & Schwartz, 1967; Reiter A Klein,
1971). Despite these changes in ovarian morphology, serum LH and
oestradiol concentrations have been reported as being within the
normal cyclic range in rats exposed to constant light (Naftolin _et
al., 1972; Brown-Grant et al ., 1973).
Ovarian LHRH receptor concentrations were significantly higher
than dioestrous control values (P-C. 0.001; Fig. 5.1). In addition,
no difference was observed in receptor concentrations (or numbers per
gland) betv/een dioestrous and pro-oestrous control ovaries.
Ovarian weight was decreased by treatment (control ovaries
combined weight 80_+7 mg: constant light ovaries 41+4 mg; P 0.001;
mean +_ S.E.M.). Expression of the receptor data as fm LHRH agonist
bound/ovary abolished the increase seen after exposure to constant
1ight (Fig. 5.1).
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PLATE 5.1 Histological section through rat ovary from a rat kept under





























FIGURE 5.1 Ovarian LHRH receptors measured in control rats (□) at
10.00 h dioestrus (D) or 12.00 h pro-oestrus (P) and in rats
exposed to constant light (ED).
Data are expressed as fm bound per mg ovarian protein (left
panel) and as fm bound per ovary (right panel) and represent
Mean _+ S.E.M. (10 constant light rats and 5 rats in each
control group).
*** P<L 0.001 for constant light compared to control D value.
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5.3.3 Piscussion
In contrast to the pituitary, ovarian LHRH receptors from
control adult cyclic rats were unchanged at dioestrus and
pro-oestrus, indicating an absence of cyclic variation of receptor
concentrations in the whole rat ovary (see also Pal kin et al., 1981;
Reeves et al ., 1982).
Although pituitary LHRH receptors were within the normal cyclic
range after exposure to constant light (see 4.2.5), ovarian receptor
concentrations were raised. This may be a reflection of the reported
higher concentration of LHRH receptors in follicular compared with
luteal tissue (Pieper et al., 1981).
It is evident from the data presented that ovarian and pituitary
LHRH receptors are likely to be independently regulated.
5.4 OVARIAN LHRH RECEPTORS ANP MORPHOLOGY FOLLOWING CHRONIC
TREATMENT WITH LHRH AGONIST OR LHRH ANTISERUM
5.4.1 Method
Adult female rats were treated daily for 3 weeks with 50, 500 or
5,000 ng LHRH agonist (Group 1-3) or LHRH antiserum No. 94 (Group 4)
as described previously (4.4.2). Ovaries were removed immediately
after cessation of treatment and either taken for LHRH binding assay
or placed in Bouin's solution for fixation and histology. This
experiment was performed in collaboration with Or. R. Gosden.
5.4.2 Results
The effects of hypo or hyperstimulation with LHRH on serum
gonadotrophins and steroids, on ovarian and uterine weight and on
pituitary LHRH receptors are discussed in 4.4.2.
LHRH agonist treatment: Long-term treatment with LHRH agonist
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resulted in cessation of oestrous cycles (as evidenced by constant
dioestrous type vaginal smears), increased ovarian weight, decreased
uterine weight and serum oestradiol (Table 4.J). In addition
dramatic alterations in ovarian morphology were evident, ovaries
having a predominance of luteal tissue (Plates 5.2 Si 5.3).
Assessment of the contribution of follicles, corpora lutea and stroma
to the overall mass of the ovaries showed the greatest degree of
contrast between the 5,000 ng/day group (Group 3) and the controls at
dioestrus and pro-oestrus (Groups 6 and 5). Growing follicles (from
unilaminar to Graafian sizes) were notably deficient in Group 3 rats
and in one animal were virtually absent. These types were also less
abundant in the treated animals in Groups 1 and 2, although to a
smaller degree. The numbers of primordial (non-growing) follicles
were counted in one approximately equatorial section of each ovary
but were unaffected by the treatments (range of means 11-15 in Groups
1, 2 and 3). Small and medium-si zed follicles appeared to be growing
normally whereas Graafian follicles were frequently seen to be
undergoing premature 1uteinization without releasing the oocyte
(Plate 5.3). These oocytes had not resumed meiosis, neither was
there any mucification of the adjacent cumulus cells, suggesting that
the follicles had not been exposed to a normal ovulatory stimulus
despite the 1uteinization of the granulosa cells. Ovaries of rats in
groups 1-3 contained many lutein bodies some of which contained a
structure which may have been the remnant of an oocyte that had
undergone cytoplasmic cleavage (Plate 5.3). These bodies differed
therefore from the corpora lutea of the control ovaries, although
they were similar in size and in cellular morphology and
eosinophilia.
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PLATE 5.2 Histological section through rat ovaries from normal
dioestrous rats (A) or rats treated with LHRH antiserum (B). X
50.
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PLATE 5.3 Histological section through rat ovaries from LHRH agonist
treated rat showing predominance of luteal tissue (A) X 50 and
a trapped oocyte undergoing cleavage (B) X 320.
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FIGURE 5.2 Effect of daily injections of 50, 500 or 5,000 ng
LHRH agonist (W ) or 3 times weekly injections of LHRH
antibodies (E3) on ovarian LHRH receptors. Control animals
received vehicle alone (□) and receptors were determined on
the first day of dioestrus (Di) or on pro-oestrus (P).
Values are Mean + S.E.M. with 8 animals per group.
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Ovarian LHRH receptor concentrations were not significantly
different either between pro-oestrous and dioestrous control levels
or after LHRH agonist treatment (Fig. 5.2). Results were not altered
by expression of results as fm/ovary.
LHRH antiserum treatment: ImmunoneutraIization of LHRH also led to
cessation of oestrous cycles, as evidenced by constant dioestrous
type smears, decreased ovarian weight and serum oestradiol, as well
as marked changes in ovarian morphology consistent with an impared
ovulatory Lll surge. There was no evidence of inhibition of
follicular growth in antibody treated rats. Half the animals had no
corpora lutea and contained large Graafian follicles with an
abnormally enlarged antrum (i.e. cystic follicles). Ovarian LHRH
receptors were not significantly different from control dioestrous
values in treated animals (Fig. 5.2).
5.4.3 Piscussion
Both LHRH agonist and LHRH antibody treatment resulted in marked
but opposite changes in ovarian morphology. The former was
associated with a predominance of luteal tissue (see also Sandow,
1982) and an inhibition of follicular growth (or an induction of
atresia); the latter was consistent with impaired LH surges and
resultant over mature and atretic follicles. Also present were
cystic follicles similar to those seen in rats in persistent oestrus
or when ovulation has been blocked by pentobarbitone (Everett &
Sawyer, 1950; Braw and Tsafriri, 1980), or after active immunization
against LHRH (Fraser & Baker, 1978). The contribution of possible
direct inhibitory effects of LHRH agonist on follicular development
is unknown.
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The absence of an associated progesterone rise despite abundant
luteal tissue in the LHRH agonist treated groups is interesting.
This could be due to desensitization of the ovary after excess
gonadotroph!n stimulation (e.g. Conti et al ., 1976) and/or direct
inhibitory effects of LHRH (e.g. Clayton et al ., 1979a). Since
cystic follicles are usually associated with increased progesterone
(Braw & Tsafriri, 1980) these structures may contribute to the serum
progesterone concentrations after antibody treatment.
The absence of changes in ovarian LHRH receptor concentrations
despite such marked changes in morphology and extremes of
gonadotroph!n exposure induced by LHRH agonist and antibody
treatment, is surprising. This is likely to be due to the
observation that LHRH binds to most cell types within the ovary (see
autoradiographic data in Chapter 3) and would therefore be unlikely
to be affected by changes in relative abundance of specific tissue
types. Moreover, Pieper et al ., (1981) reported that thrice daily
injections of 6 jjg LHRH to intact females failed to alter the number
of ovarian receptors, a finding consistent with the above
observations using LHRH agonist.
However, ovarian LHRH receptors have been reported to increase 6
and 24 hrs after a single injection of 10 jjg LHRH, to PMSG-hCG primed
immature rats (Harwood et al., 1980b) and 3 times daily injections of
LHRH to rats with predominantly follicular or luteal tissue results
in increased receptors (Pieper et al ., 1981). This indicates that
the effects of exogenously administered LHRH may depend on the
predominant tissue present at the onset of treatment.
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5.5 OVARIAN LHRH RECEPTORS AMD MORPHOLOGY IN RATS ACTIVELY IMMUNIZED
AGAINST LH OR LHRH
5.5.1 Method
Individual ovarian receptors were assessed in one ovary from
each of 6 rats immunized against LH and 11 rats immunized against
LHRH. Of 10 control rats immunized against HSA, 5 were killed at
10.00 h dioestrus and 5 at 12.00 h pro-oestrus, (see Chapter 4.4.3
for details). The remaining ovary in each case was taken for
histology.
5.5.2 Results
Similar morphological changes were observed in ovaries of rats
immunized against LH and LHRH, indicating inhibition of ovulation but
not follicular development. Thus the ovaries were characterized by
predominance of follicular tissue with an absence of luteal tissue
(Plate 5.4). Interestingly, ovaries from 2 of the spontaneously
non-cyclic control animals (which were excluded from the
study - see Chapter 4.4.3) showed morphological characteristics
similar to those seen in ovaries from rats exposed to constant light
previously discussed in section 5.3. In addition the ovarian
receptor concentrations were high (28 and 32 fm/mg protein) compared
with the normal dioestrous control value (16_+3 fm/mg protein).
Impairment of ovarian function was also indicated by a marked
decrease in uterine and ovarian weight and constant dioestrous smear
pattern.
Ovarian LHRH receptor concentrations were significantly greater
than controls in both immunized groups (P^ 0.001). If the data was
expressed as fm bound/ovary however, no significant difference was
134
PLATE 5.4 Histological section through rat ovaries from rats immunized


































FIGURE 5.3 Ovarian LHRH receptors measured in control rats (Q ) at
10.00 h dioestrus (D) or 12.00 h pro-oestrus (P) and in rats
actively immunized against LH (El) or LHRH (W).
Data are expressed as fm bound per mg ovarian protein and as
fm bound per ovary, and represent Mean +_ S.E.M. (7 rats in
each control group, 11 and 6 in the LHRH and LH immunized
groups respectively).
*** P <. 0.001; ** P<i0.01; * P<.0.05 for immunized compared
to control D value.
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seen with LH immunization whereas immunization of LHRH resulted in a
significant (P*C0.001) decrease in receptor numbers (Fig. 5.3).
This data contrasts with that of the pituitary where active
immunization against LH increased receptor numbers, whereas
immunization against LHRH, reduced receptor concentrations (Chapter
4.4.3).
5.5.3 Piscussion
Ovarian LHRH receptor concentrations were markedly increased
subsequent to active immunization against LH. This suggests that LH,
and perhaps steroids, are negative regulators of receptor
concentrations. Decreased receptor concentrations have been reported
following treatment of immature rats with gonadotroph!'ns (PMSG and
hCG) (Harwood et al ♦, 1980b), or following sequential treatment of
immature hypophysectomized rats with FSH, LH and RRL (Jones et al .,
1980).
The marked increase in receptor concentration following active
immunization against LHRH is interesting, the reverse pattern being
true for the pituitary (see Chapter 4.4.3). It could be suggested
that either an intragonadal LHRH-like factor is immunoneutralized by
the antisera, thus removing a negative regulator, or that the effects
are due to a concurrent reduction in LH in LHRH-immunized rats. The
latter explanation seems more probable, since it is unlikely that all
immunized rats would develop antibodies cross reacting with a
putative LHRH-like factor, in response to immunization against LHRH.
It is interesting to speculate on the significance of negative
regulation of ovarian LHRH receptors by gonadotrophs. Since LHRH
inhibited LH and FSH induced steroidogenesis (see Chapter 1) the
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decrease in LHP.H receptors with increased LH would enable full
expression of gonadotropin'n induced steroidogenesis. However, as
will be discussed in Chapter 7, it appears that the short term
effects of LHRH on basal events in follicular tissue are stimulatory.
In this case in the presence of low LH, LHRH receptors would increase
and thus ensure continuation of basal steroidogenesis.
Since follicular tissue has been reported to contain higher
concentrations of LHRH receptors than luteal tissue (Pieper et al .,
1981) it is interesting that the three treatment regimes reported to
be associated with high ovarian receptor concentrations (namely,
exposure to constant light or active immunization against LH or LHRH)
are also associated with similar changes in ovarian morphology.
Increased ovarian LHRH receptor concentrations were therefore
correlated with the predominance of follicular tissue with a marked
absence of luteal tissue.
5.6 OVARIAN LHRH RECEPTORS IN CYCLIC RATS PASSIVELY IMMUNIZED AGAINST
LH OR LHRH
5.6.1 Method
Ovarian LHRH receptors were assessed in individual ovaries taken
from rats killed at 12.00 h pro-oestrus (having been passively
immunized against LH, LHRH or RSA at 10.00 h dioestrus day one) and
from rats killed at 09.00 h oestrus (having been passively immunized
against LH, LHRH or BSA at 12.00 h pro-oestrus - see Chapter 4.4.5
for further details).
5.6.2 Results
Passive immunization against LH or LHRH disrupted ovarian
function as evidenced by presence of dioestrous type smears on
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TABLE 5.1
Ovarian LHRH receptors (fm LHRH agonist bound/mg ovarian protein) at
11.00 h dioestrus (A) and 12.00 h pro-oestrus (B) and after passive
immunization at 11.00 h dioestrus (A) and 12.00 h pro-oestrus (B)
with LH or LHRH antisera.









Dioestrus 21 + 2
12.00 h
Pro-oestrus 24 + 4 21 + 3 25 + 4
(B)
12.00 h
Pro-oestrus 25 + 3
09.00 h
Oestrus 29 + 3 24 + 2 33 + 4
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the expected day of pro-oestrus in rats immunized on dioestrus one,
and a failure of ovulation in rats immunized on pro-oestrus. Ovarian
LHRH receptor concentrations were not significantly different either
between control rats at dioestrus, pro-oestrus and oestrus or between
control and treated rats at any time (Table 5.1). No difference was
detected if results were expressed as fm LHRH bound per ovary.
5.6.3 Piscussion
Short-term passive immunoneutralization of LH or LHRH failed to
alter ovarian LHRH receptor concentrations despite both treatments
abolishing ovulation and reproductive function. This contrasts with
data on pituitary LHRH receptors presented in Chapter 4.4.5 showing
decreased receptors, after LHRH immunoneutral ization, at
pro-oestrus.
The data suggest that LH, steroids and LHRH are not involved in
the short-term regulation of ovarian LHRH receptors. This is in
contrast to the situation in the male, where passive immunization
against LH resulted in increased testicular LHRH receptors (Sharpe Si
a
Fraser, 1983). Since prolonged deprivation of LH or gor^dotrophin
stimulus by active immunization against LH or LHRH resulted in
increased ovarian LHRH receptor concentrations (see 5.5), whereas
short-term immunoneutralization had no effect, it is likely that
gonadotroph!"ns are involved in regulating the long-term, but not
short-term, ovarian LHRH receptor concentration.
5.7 CONCLUSIONS
The experiments described in Sections 5.3 - 5.6 are summarised
in Table 5.2 and are consistent with the following conclusions



















































































































(a) Ovarian and pituitary LHRH receptors are not concomitantly
control 1ed.
(b) Hyperstimulation with LHRH agonist had no effect on ovarian LHRH
receptor concentrations.
(c) Gonadotropin'ns are likely to be involved in the long-term, but
not the short-term regulation of ovarian LHRH receptor
concentrations.
5.8 GENERAL DISCUSSION
The above conclusions were based on data obtained from analyses
of LHRH receptor concentrations in total ovarian homogenates. There
are several problems with this model, which are revealed by a
consideration of the nature and characteristics of ovarian LHRH
binding. Firstly, binding sites for LHRH are present in most cell
types within the ovary (e.g. granulosa, theca and luteal tissue).
Binding is diffuse, not localized on specific clusters of cells as in
the pituitary (see autoradiographic data in Chapter 3). Therefore
analysis of total receptor concentration does not enable differences
in receptor numbers between compartments to be determined. Secondly,
the complexity of LHRH action on ovarian tissue (see Chapters 1 and
7) means that there are no well-defined data available on sensitivity
of the different cell types to LHRH, so the physiological
significance of changes in receptor concentrations remains unsolved.
Finally the identity, source and pattern of secretion of the putative
endogenous ovarian LHRH-like ligand is unknown. This contrasts with
the pituitary where detailed evidence is available as to the
sensitivity and pattern of secretion of LHRH (see Chapter 4).
LHRH receptor concentrations are likely to be regulated within
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different ovarian compartments. Separate analyses of receptor
concentrations revealed higher levels in granulosa cells than in
luteal and residual ovarian tissue (Pieper et al., 1981). Studies
utilizing isolated granulosa cells in vitro have shown that receptors
are biphasically regulated by LHRH agonist, being increased in the
presence of low doses and decreased in the presence of higher levels
(Ranta et al ♦, 1982). In addition granulosa cells cultured in the
absence of FSH showed decreased receptor numbers (Ranta et al ., 1982).
Confirmation that granulosa cell LHRH receptors are indeed regulated
in vivo has come from data on cells isolated from pre-pubertal rats.
The loss of binding prior to the first LH surge (Smith-White ft Ojeda,
1981) was reflected by loss of granulosa cell, but not residual
thecal/interstitial cell, LHRH receptors (Smith-White ft Ojeda, 1983).
Studies in the male are simplified by the fact that only one
cell type within the testis, namely the Leydig cells, possesses LHRH
receptors and essentially one biological response, namely
testosterone production, is influenced by LHRH (see Sharpe et al .,
1982a for review). In the male, hypophysectomy resulted in increased
testicular LHRH receptors (Bourne et al ., 1980) and exogenous
administration of LHRH further enhanced binding capacity (Bourne et
al., 1980). However in the female neither hypophysectomy nor
subsequent LHRH administration had any effect on ovarian receptors
(Pieper et al ., 1981). Testicular LHRH receptors were increased
after injection of LHRH to intact rats and this increase was
associated with an enhanced response to LHRH (Bourne et al ., 1980).
In contrast, treatment with LHRH agonist was reported to decrease
testicular LHRH receptors (Sharpe ft Fraser, 1980a).
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Heterologous regulation of testicular LHRH receptors by LH has
been suggested by the observations that hypophysectomy (Bourne _et
al., 1980) or passive immunization against LH (Sharpe & Fraser, 1983)
increases both Leydig cell LHRH receptors and increases Leydig cell
reponsiveness to LHRH (Sharpe & Fraser, 1983). *
Thus, testicular LHRH receptors, and to a limited extent
isolated granulosa cells, appear to be regulated in a manner
analogous to that of pituitary LHRH receptors, showing evidence for
both heterologous regulation by LH and homologous regulation by LHRH.
However, the regulation of ovarian receptors in other ovarian
compartments remains largely unsolved. Perhaps follicles are only
affected by LHRH as they pass through a certain stage of development
and after active immunization the effects of prolonged deprivation of
LH are revealed. Elucidation of the significance of ovarian LHRH
receptor changes and ovarian responsiveness to LHRH must await
detailed studies of receptor concentrations and steroidogenic effects
within specific ovarian compartments.
Ovarian LHRH receptors have been reported to decrease 24hr after
administration of hCG suggesting that hCG is capable of exerting a
short-term effect on ovarian LHRH receptor numbers (Harwood et al. 1980b).
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6.1 INTRODUCTION
Direct gonadal actions of LHRH have been demonstrated in a variety of
species e.g. rat (see Chapter 7; e.g. Clayton et al ♦, 1979a), pig
(Massicotte et al ., 1980), rabbit (Koos et al ., 1982), cow (Milvae &
Hansel, 1980) and chicken (Hertelendy et al., 1982). These
extra-pituitary actions are likely to be mediated via specific LHRH
receptors present on ovarian and testicular tissue (Chapter 3; Sharpe,
1982; Ranta et al ., 1982). However, the relevance of these observations
to the human remains uncertain. Since LHRH and its analogues are used
clinically to modify reproductive function (see Chapter 1) it is clearly
of primary importance to determine whether LHRH is capable of acting at
sites other than the pituitary in the human.
6.2 SOURCE OF TISSUE
Human luteal tissue was obtained from women undergoing laparotomy
during the luteal phase of the cycle and human postmenopausal tissue was
obtained from women undergoing hysterectomy (the informed consent of the
patient was obtained for this procedure). The tissue was provided by Dr.
R.W. Shaw and Prof. D.T. Baird from the Royal Infirmary, Edinburgh.
The tissue was transported immediately after removal from the patient
to the laboratory where it was either stored at -70°C or -40"C, or used
directly for the binding assay.
Hormones: LHRH agonist^ ) Kindly provided by
(D-Ser but® des Glyl^ LHRH ethylamide) ) Dr. J. Sandow
N
TRH ) (Hoechst, U.K.)
Somatostatin )
LHRH agonist2 (6-D-2-naphthyl-al anine-LHRH), D-Nal (2)®
LHRH was provided by Dr. B. Vickery (Syntex)
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Oxytocin was a gift from Sandoz labs.
6.3 ASSESSMENT OF LHRH AGONIST BINDING
Ovarian tissue was homogenized in 10 mM Tris HC1 (0.3 M sucrose, 1 mM
EDTA pH 7.4) using either a Polytjpn homogenizer or a glass pestle hand
homogenizer. Aliquots of homogenate were then used for the binding assay.
Incubations were carried out in duplicate or triplicate in the presence of
125i_[_E!RH agonist (100,000 - 120,000 cpm) and non-specific binding
(NSB) was determined in the presence of 10-5 ^ unlabelled hormone.
These studies were performed in collaboration with Or. T.A. Bramley.
6.4 TIME COURSE OF LHRH AGONIST BINDING
Initial studies were performed utilizing the methods described for
analysis of rat LHRH receptors (Chapter 3). The incubation was set up as
described above for various times on ice, with separation of free from
bound being achieved by filtration under vacuum through Whatman OF/C glass
fibre filters, pre-soaked in 2% BSA, followed by washing with 3 x 2 ml
PBS. The results obtained for luteal tissue and post-menopausal ovarian
tissue are shown in Fig. 6.1. Luteal tissue specifically bound
125i_|_hrh agonist (4.5% of total counts added) whereas no binding
could be detected to post-menopausal ovarian tissue. Maximum binding to
luteal tissue was obtained after 120' incubation at 0-4°C.
In a separate study luteal homogenates were incubated for different
times and temperatures to confirm the point of maximum binding (Fig. 6.2).
Again binding was shown to be time and temperature dependent with rapid
binding following by a sharp decline at 37"C (presumably due to rapid
ligand and/or receptor degradation at this temperature) and a slower rise
to maximum levels at 20° and 0-4uC. Binding assays were therefore








































FIGURE 6.1 Specific binding of 125x_LHRH agonist (LHRH/\) to human
corpus luteum tissue and to human postmenopausal ovarian
tissue. Each point represents mean of duplicate estimations,































































































6.5 SEPARATION OF FREE FROM BOUNP
Several methods of separating free from bound hormone were examined
either based on filtration using various Millipore filters or polyethylene
glycol (PEG) precipitation (as described in Chapter 3). A number of
MiHi pore filters were tested. Duropore disc filters composed of a
polymer of polyvinylidine fluoride (PVF) with pore sizes 0.22 y (GVWP) or
0.45 (HVLP), mixed ester filters composed of cellulose acetate (CA) and
cellulose nitrate (CN) with pore size 0.45 jj (HAWP), celotate filters
composed of pure inert CA and pore size 0.5 y (EHWP) and finally a bonded
acylate pre-filter (GF). All filters were pre-soaked in 2% BSA to
minimize non specific adsorption of tracer.
Specific binding of LHRH agonist to human luteal tissue could only be
detected by EHWP, GVWP, Whatman GF/C filter and PEG precipitation (Fig.
6.3), the latter method giving the greatest degree of recovery of bound
hormone.
The binding assay was therefore routinely terminated by chilling the
tubes on ice before the addition of 0.5 ml 0.5% bovine immunoglobulin and
1 ml 25% PEG followed by thorough vortexing and centrifugation at 2000 rpm
for 15 minutes at 4UC. Radioactivity retained in the pellet was then
measured in a gamma counter.
During the course of these studies a report was published failing to
demonstrate the presence of specific binding of 125j_lhRH agonist to
human luteal tissue (Clayton & Huhtaniemi, 1982). Using this method,
namely incubation in the presence of 10,000 cpm 1-LHRH agonist and
an MSB of 10~8 M LHRH agonist with separation by Whatman GF/C filters,








































































































































6.6 SPECIFICITY OF BINDING
The specificity and affinity of the binding sites for LHRH v/ere
examined by testing the ability of unlabel led hormones to compete for
binding of the iodinated agonist (Fig. 6.4). The apparent affinity
constants (Ka) calculated from the displacement curves with LHRH agonist
as tracer, were found to be 3 x 10? M~1 in 3 separate experiments
using different corpus luteum homogenates (Fig. 6.4). This value was also
obtained for a second LHRH agonist ((D-Mal (2)6) LHRH). Native LHRH
gave an apparent Ka of 106 indicating a slightly lower affinity
of the binding site for LHRH. Rinding was specific for LHRH and LHRH
agonists, neither oxytocin, somatostatin nor TRH competing for binding at
concentrations up to 10,000 ng.
6.7 DISCUSSION AND CONCLUSIONS
These results demonstrate that binding sites for LHRH are present on
human luteal tissue and that these sites are specific for LHRH and related
peptides. The studies indicated that for native LHRH, the apparent
affinity of binding to the human corpus luteum was similar to the value
reported for binding to the rat pituitary (Clayton et al ., 1979b) and
gonadal tissue (Clayton & Catt, 1981b; Chapter 3). In marked contrast,
human ovarian binding sites had similar affinities for the two agonists
and for native LHRH, indicating a clear species difference.
These findings are in contrast to a recent report in which LHRH
binding to human luteal tissue was not detectable (Clayton & Huhtaniemi,
1982). The reasons for this discrepancy became clear from the data
presented here on the nature of the binding site. In order to detect the
presence of a relatively low affinity receptor, it is necessary to use
both a sufficiently high concentration of radiolabel1ed ligand and a
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sufficiently high concentration of unlabel led hormone (10*5-10~6 M)
to assess non-specific binding. Using the method of Clayton and Huhtaniemi
(1982) with a lower concentration of both unlabelled (10~8m) and
labelled (10-50,000 cpm) ligand, no binding was detected to a homogenate of
human luteal tissue. The same tissue in the assay described, specifically
bound 37.5 pg LHRH agonist/jjg DNA.
Several possible explanations for the low apparent affinity of LHRH
binding to the human corpus luteum can be suggested. Firstly, the
apparent Ka (3 x 107p|-l) may represent the true affinity of the
binding site, in which case its physiological significance remains
uncertain due to the relatively high concentrations which would be
necessary to activate the receptor. Secondly, the true affinity of the
receptor may be greater than lO^M"!, but the agonist and native
hormone may be degraded to a similar extent (as suggested for human
placental tissue (Currie et al ., 1981)) giving rise to apparent low-
affinity binding. Thirdly, the putative intragonadal factor(s)
interacting with such a binding site in vivo are unlikely to be identical
to hypothalamic LHRH or its agonist. Indeed, LHRH-like molecules detected
in rat testicular tissue have been shown to be non-identical to LHRH
(Dutlow Fi Millar, 1981; Sharpe et al., 1981). Thus the physiological
ligand for such receptors may well have a greater affinity than either
LHRH or LHRH agonist. In addition there is no data available on the
affinity of the human pituitary LHRH receptor (and indeed the levels of
specific binding reported were extremely low in comparison to rat tissue
(0.9 - 2.3% of total counts specifically bound for human pituitaries,
compared with 16-26% for rat - see Clayton & Huhtaniemi 1982). It is also
possible, but unlikely, that human pituitary LHRH receptors have different
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affinities from those of rat.
In a similar study, but utilizing ovarian tissue from rhesus monkeys,
no specific binding of LHRH agonist was detected (Asch et al ., 1981).
However, although a high NSB (10"4M) was utilized, the total number of
counts added was low (10,000 cpm). It would be of interest to repeat such
studies using a greater quantity of 125j_LHRH agonist.
The possibility that human ovarian binding sites might mediate direct
effects of LHRH has been suggested by the observation that isolated human
granulosa cells, when incubated for prolonged periods (96 h) with LHRH
agonist, showed a 65% reduction in basal progesterone production (Tureck
et al ., 1982). However, a similar study failed to show any effect of
native LHRH on basal or FSH-induced steroidogenesis in isolated human
granulosa cells (Casper et al., 1982). Neither was any effect seen on
progesterone production from human (Tan & Biggs, 1983) or rhesus monkey
(Asjh et al ., 1980) luteal cell progesterone production, although a recent
report implicated a direct effect of LHRH on progesterone production from
cultured monkey granulosa cells (Knecht et al., 1983).
The possibility of direct testicular effects of LHRH has not been
examined in the human. LHRH suppression of basal testosterone from an
isolated Sertoli-Leydig cell tumour has been reported (Lamberts et al .,
1982). Thus LHRH may well bind to human testicular tissue. Preliminary
data suggests that isolated human Leydig cells are capable of specific
binding of 125j_lhrh agonist with similar displacement characteristics
to those shown for human luteal tissue (Sharpe - personal communication).
Extra hypothalamic LHRH-like material has been detected in the human
in carcinoid tumours (Wahlstrom & Seppala, 1981), milk (Amarant et al .,
1982), peritoneal fluid (Demoulin et al ., 1981) and placenta (Khodr &
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Siler-Khodr, 1978b & 1980; Seppala et al ., 1980). However, as will be
discussed in Chapter 8, the detection of such material is subject to many
pitfalls. The physiological significance, if any, of both human LHRH-like
molecules and LHRH binding sites in the endogenous control of ovarian
function, remains to be determined. It seems likely that the discovery of
these binding sites owes a great deal to serendipity and that the true
ligand has a higher affinity for the binding sites. .
However, since human luteal binding sites have such a low affinity
for LHRH and LHRH agonist, it is highly unlikely that even large
clinically administered doses would induce circulating concentrations high
enough to interact with the binding sites. Thus circulating
concentrations greater than 0.3 pg/ml of LHRH agonist or 1 ^ig/ml for LHRH
would need to be achieved to reach the Ka for the binding site, requiring
i/v administered doses in excess of 1.4 mg LHRH agonist or 45 mg LHRH.
Thus, from a clinical point of view, small doses administered over
prolonged periods of time are unlikely to interact with these binding
sites whereas huge doses administered at specific times may activate
ovarian binding sites. It seems likely therefore, that the antiferti1ity
effects of LHRH agonists in the human discussed in Chapter 1 are mediated
through changes in pituitary gonadotrophin release rather than direct
gonadal effects.
With new techniques available for the isolation of rat pituitary and
ovarian LHRH receptors (see Chapter 3) it is hoped that the application of
this technology to human luteal tissue will resolve whether the binding
demonstrated is physiologically relevant or represents binding to a low-
affinity protein such as a protease.
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CONCLUSIONS
1. The human corpus luteum possesses binding sites for LHRH and LHRH
agonist.
2. These binding sites are absent from human post-menopausal ovarian
tissue.
3. The binding sites are specific for LHRH and LHRH agonist but have a
low affinity for LHRH agonist.
4. The nature of the binding site (receptor for endogenous ligand or
enzyme) is unknown.
5. Circulating levels of LHRH or LHRH agonist induced by exogenous
administration for clinical purposes are unlikely to be high enough
to interact with such sites in vivo.
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7.1 INTRODUCTION AND AIMS
The concept of direct ovarian actions of LHRH and LHRH agonist is now
widely acknowledged for the rat, in the light of specific high affinity
ovarian LHRH receptors (discussed in Chapters 3 & 4) together with direct
effects on several parameters of ovarian function (discussed in Chapter
1.4.2.1). The direct actions reported appear to be predominantly
inhibitory in nature, reducing gonadotrophin-induced events (see Chapter
1). However, several factors were noted from these studies. Firstly, the
majority of results had been obtained utilizing prolonged incubation
conditions ( >• 48 hrs) and were concerned with gonadotrophin-induced
events (see Hsueh & Jones, 1981 for review). Moreover few reports
included data on 'control' incubations with LHRH effects on basal
e
steroidogenesis (e.g. Hsueh & Erickson, 1979a). It was possible therefore
that, as in the pituitary, the physiological response to short-term
exposure to LHRH might be stimulatory, particularly to basal events.
Secondly the studies were largely confined to a consideration of
granulosa cell function (as reflected by oestrogen and progesterone
production) with only one report indicating a possible thecal/intersitital
action (Magoffin et al., 1981). Thus an inhibition of androsterone
production was noted after 4 day culture of collagtnase-dispersed cells
from immature rat ovaries (Magoffin et al ., 1981). Although androgen
release was measured, its source (i.e. thecal or interstitial cell) was
not determined.
Since thecal androgen provides substrate and regulatory steroids
essential for granulosa cell function (Leung & Armstrong, 1980; Hillensjo,
1981 for reviews) any actions of LHRH on thecal cells would clearly be of
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primary importance in the regulation of follicular function. A model
system was therefore sought which would enable assessment of thecal and
granulosa cell function.
Isolated rat follicles:
Individual follicles can be isolated from rat ovaries and have been
utilized to study, in vitro, the factors influencing follicular function.
The first studies reported utilized Graafian follicles isolated from
pro-oestrous rats (e.g. Tsafriri et al ., 1972; Tsafriri et al ., 1973;
Lindner et al♦, 1974). However, the use of follicles isolated from
immature rats treated with pregnant mare's serum gonadotrophin (PMSG) to
induce follicular development had the advantage of convenience and the
production of a single crop of follicles of known age. Initial in vitro
studies, examining LH responsiveness and oocyte maturation, indicated that
follicles isolated from pro-oestrous rats or from rats killed 48 hrs after
PMSG treatment, had esentially the same steroidogenic capacities
(Hi 11ensjo et al ., 1976). A dose of 4 international units (IU) PMSG was
found to induce adequate follicular development of 10-12 follicles (after
48 h), oestrogen production, an LH surge and progesterone increase after
54 h, and a normal quota of ova 72 h later (e.g. Guillet & Rennels, 1964;
Armstrong et al ., 1969; Armstrong et al ., 1976). Since this regime of
PMSG treatment thus mimicked events of the oestrous cycle and had been
utilized by a number of groups (e.g. Fortune A Armstrong, 1977 A 1978) it
was adopted for the studies described in this Chapter.
AIMS
The following studies utilized isolated rat preovulatory follicles to
examine:-
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(1) The nature of the short-term effects of LHRH and LHRH agonist on
basal steroidogenesis.
(2) The specificity, dose dependence and time course of such effects.
(3) Whether LHRH directly influences thecal function.
(4) The nature of short-term effects of LHRH agonist on gonadotropin'n-
stimulated events.
(5) The effects of LHRH agonist on prostaglandin- and dibutyryl cyclic
AMP (db cAMP)-stimulated steroidogenesis.
(6) The effects of indomethacin and aspirin on LHRH agonist actions.
(7) Whether follicles from different stages of development respond to
LHRH agonist.
7.2 MATERIALS AND METHODS
The following procedures were routinely adopted for the experiments
described in this Chapter.
Animals: Immature female Sprague Dawley rats from the laboratory colony,
housed under standard conditions (with lights on between 05.00 h - 19.00 h
and access to food and water ad libitum), were injected subcutaneously
(s.c.) with 4 IU PMSG between 8.30 - 10 a.m. on days 26 - 30 of age. 48 h
after injection the animals were killed with dry ice CO2 and the
ovaries, trimmed of fat and oviduct tissue, removed to incubation medium.
Chemicals and Hormones:-
Incubation Medium (M199):-
Medium 199 containing 20 mM Hepes (Plow Labs) to which was added :-
2 mM Glutamine (Sigma)
0.35 g/1 sodium bicarbonate
100 IU Penicillin ) Difco Labs, Detroit
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LHRH agonist (D-Ser (Bu^)® des GlylO
LHRH ethyl amide)
Thyrotropin releasing hormone (TRH)
Growth hormone inhibiting hormone (GHIH)
LHRH




Human Chorionic gonadotrophs (hCG) Chorulon, Intervet, Cambridge
Dibutyryl cyclic AMP (db cAMP))








*Prostaglandin E2 (PGE2) )
*Were added to the incubation medium in ethanol. In each case an equal
volume of ethanol alone was added to control wells. No deleterious effect
was seen on follicular steroidogenesis provided the ethanol concentration
was 2%.
Isolation of follicles:- The largest follicles (5-6 per ovary 0.9 - 1.3
mm diameter) from each ovary were dissected out and trimmed of surrounding
interstitial tissue under a stereomicroscope using fine dissecting
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PLATE 7.1 Histological section through a single follicle isolated from
the ovary of an immature rat 48 h after treatment with PMSG. X
50.
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forceps (Plate 7.1). Follicles from each animal were pooled and 1-2
follicles from each animal were placed in each of the treatment groups.
Each group contained 10 follicles which were incubated individually in
Linbro multiwell plates in a final incubation volume of 0.5 ml.
Incubations were carried out for various times in a modular incubation
chamber gassed with 95% 02/5% CO2 at 37°C.
Steroid assays:- Steroids were assayed in duplicate from unextracted
culture medium as described in Chapter 2, and the results expressed as pg
or ng per follicle i.e. per 0.5 ml incubation medium.
Analysis of data:- Data presented represent mean +_ S.E.M. of steroid
values from 10 individually incubated follicles. Each figure shows the
results from one representative experiment, each experiment having been
repeated at least once.
Statistical analysis was assessed by Student's t test and/or analysis
of variance.
7.3 DIRECT EFFECTS OF LHRH AND LHRH AGONIST ON BASAL STEROIDOGENESIS
7.3.1 Effect of LHRH Agonist on basal steroid release
Method:- Three groups of 20 follicles were incubated with or without
10~8 M LHRH agonist for 3 h, 6 h or 18 h, after which the medium was
removed and stored at -20°C for steroid assay.
Results:- LHRH agonist caused significant increases (P-^L 0.001) in
both androstenedione and testosterone release at 3 h, 6 h and 18 h
(Fig. 7.1). Progesterone levels were non-detectable (^50 pg/follicle)
at 3 h and 6 h but a small but significant (P^C. 0.02) increase in
progesterone was seen at 18 h (Control 332 51 pg/follicle; LHRH agonist


















































FIGURE 7.1 Androstenedione, testosterone and oestradiol release from
isolated rat follicles incubated with (■ ) or without (□ )
ICT^m LHRH agonist for periods of 3, 6 or 18 h.
Data shown are Mean _+ S.E.M. (10 follicles per group).
* P 0.001 for treated compared to control values at each
time period.
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unaffected by LHRH treatment at any time.
7.3.2 Release versus production of steroids
MethodIn order to investigate whether accumulation of steroids
into the medium was the result of leakage of preformed steroids or due to
net production i.e. de novo synthesis and release, 20 follicles were
incubated, 10 with and 10 without lO'^M LHRH agonist, for 6 h. After
incubation the follicles were removed and their steroid content assessed
by ethanol extraction. To assess tissue content prior to incubation 10
unincubated follicles were also subjected to ethanol extraction. After
individual homogenization of follicles in 1 ml ethanol in a glass 1 ml
homogenizer, the homogenate was left overnight at 4°C prior to drying the
supernatant under nitrogen and reconstituting the residue in PGBS for the
estimation of total tissue steroid content.
Results:- Follicular content of testosterone and oestradiol was low
and unchanged by incubation in control medium. Tissue progesterone
content was non-detectable ( 50 pg/follicle) prior to incubation and
just detectable (70 pg/follicle) after control incubation. Incubation
with 10"8m LHRH agonist resulted in a significant increase in .both
tissue content and released steroid for testosterone (P 0.001) and
progesterone (P-^0.01) but had no effect on oestradiol (Fig. 7.2). Since
LHRH agonist treatment resulted in steroid levels greater than those found
in pre-incubated tissue (P ^L. 0.001 for testosterone, oestradiol and
progesterone) it is clear that net production of steroids occurred during
the incubation.
It is interesting that in control incubations the released steroid

















































FIGURE 7.2 Testosterone, oestradiol and progesterone levels after
incubation for 0 h or 6 h with (■§ ) or without (□ )
10~8m LHRH agonist in ethanol extracted follicles (F),
medium alone (M) or after freezing and thawing of both medium
and follicles (M + F).
Data shown are Mean _+ S.E.M. (10 follicles per group).
** P0.01; *** P 0.001 for treated compared to control
values in each pair of columns.
165
basis of passive release of preformed steroid indicating that de novo
steroid synthesis had occurred in control follicles.
7.3.3 Freezing and thawing as a measure of tissue steroid content
Method:- Since freezing and thawing of follicles has been shown to
result in the release of 98% of the tissue content of oestrogens
(Carson et al ., 1981) it was decided to compare the steroid content of
medium after freezing and thawing of medium plus follicle, with that
estimated from separate analyses of follicle and medium content. Twenty
follicles were incubated for 6 h in the presence or absence of 10-8m
LHRH agonist (10 follicles per group) and the incubation terminated by
freezing the incubation tray (medium + follicle) at -20°C prior to assay.
Results:- Freezing and thawing of medium plus follicle resulted in
the liberation of the majority of tissue steroid content (Fig. 7.2; see
Carson et al ., 1981). No significant differences were found between the
expected value for medium plus tissue content calculated after separate
analysis, and that obtained after assay subsequent to freezing and thawing
(values for estimated recovery of tissue content ranged from 78-100%).
The results obtained after freezing and thawing thus gave essentially the
same results as those estimated from separate analyses of medium and
steroid content, namely net stimulation of androgen and progesterone
production by LHRH agonist. Since oestradiol was unchanged, it was
unlikely that the variability in oestradiol seen in subsequent experiments
was due to insufficient release of tissue content. For convenience all
subsequent experiments were therefore terminated by freezing the follicle
and medium. The medium content of steroids was then considered to




Method:- In order to assess the dose-dependence of LHRH agonist
stimulation 8 groups of 10 follicles were incubated with medium alone or
with various doses of LHRH agonist for 18 h.
ResultsLHRH agonist stimulated production of androstenedione,
testosterone and progesterone in a dose-dependent manner. The minimal
stimulatory dose [V 0.001) was 5 x 10-10m (Fig. 7.3). Oestradiol
production was variable and, although no dose dependent changes were seen,
levels increased significantly over control values in the presence of
5 x 10"10m LHRH agonist. Concentrations ranged from 6 _+ 1 ng/follicle
(control) to 7.5 +_ 0.3 - 10.5 _+ 1.5 ng/foll icle (treated), mean +_ SEM.
7.3.4.2 LHRH
Method:- Six groups of 10 follicles were incubated with medium alone
or in the presence of various doses of LHRH for 18 h.
Results:- LHRH stimulated androgen and progesterone production in a
dose-dependent manner with doses greater than 10"^M (Fig. 7.4).
Oestradiol levels ranged from 1.5 _+ 0.9 ng/follicle (control) to
2.1 _+ 1.2 ng/fol 1 icle (treated), mean +_ SEM.
7.3.5 Time course of stimulatory action
Method:- Three groups of 10 follicles were incubated for 20 h with
10"8m LHRH agonist, lO'^M LHRH or medium alone for 20 h. Medium
was replaced \ , , containing the same hormonal additions after 2,
4, 6, 8 and 20 hrs.
Results:- The results were either expressed as cumulative steroid
release (Fig. 7.5) or as steroid released during each incubation period
167
10-1
—t I I I I
„ -11 -10 -9 -8
0 10 10 10 10




FIGURE 7.3 Dose-dependent stimulation of androstenedione (•—•),
testosterone (a—a) and progesterone (o—o) production from
follicles incubated with various concentrations of LHRH for
18 h.
Data are Mean +_ S.E.M. (10 follicles per group).
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FIGURE 7.4 Dose dependent stimulation of androstenedione (•—#),
testosterone (a—&) and progesterone (o—o) production from
follicles incubated with various concentrations of LHRH for
18 h.
Data are Mean _+ S.E.M. (10 follicles per group).
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Time course of androstenedione, progesterone and oestradiol
release from follicles incubated with 10"^M LHRH agonist
(■I )» 10~®M LHRH (111 ) or medium alone (□ ). Medium was
replaced after 2, 4, 6, 8 and 20 h.
Data shown represent cumulative totals (Mean +_ S.E.M., 10
follicles per group) of steroid production over the given time
period.
ND = Non-Detectable.




Androstenedione, testosterone, oestradiol and progesterone release from
follicles incubated with 10"8m LHRH agonist, 10"bM LHRH or medium alone
for 2 h periods up to 8 h and from 8-20 h.
Data are mean _+ S.E.M. (10 follicles/group). Values differ from those of M199
Controls a P n. 001; b P-^.0.01; c P-^0.05; NO = Non-Detectable.
Steroid Treatment
Time (h) pg/fol1icle



















































































Androstenedione (Fig. 7.5; Table 7.1) and testosterone (Table 7.1)
release were stimulated by 10*8m lhrh agonist and 10~6m lhrh
during each 2 h period up to 8 h, resulting in significant accumulation
after 2, 4, 6 and 8 h. The release of androgen from 8-20 h was not
significantly greater than that of control over this time period (Table
7.1) but the cumulative total at 20 h was still increased (Fig. 7.5).
Progesterone was not detectable until after 6-8 h incubation when
both LHRH and LHRH agonist raised concentrations to detectable levels.
Both peptides stimulated progesterone release between 8-20 h (Table 7.1;
Fig. 7.5).
Oestradiol release was signi ficantly stimulated by 10~8m LHRH
agonist during each 2 h period up to 8 h, and by 10_6|V| LHRH at 2-4 h,
4-6 and 6-8 h (Table 1) but not 8-20 h. The cumulative total showed no
net effect of either peptide on oestradiol levels after 20 h.
A 100 fold higher concentration of LHRH (10~^M) was required to
cause a response similar to that achieved with lO'^M LHRH agonist.
7.3.6 Comparison of LHRH-stimulated and hCG-stimulated steroidogenesis
Method:- In order to compare the stimulatory effects of LHRH with
those of hCG, an experiment was performed similar to that described in
7.3.4, with 4 groups of 10 follicles being incubated with either medium
alone, lO'^M LHRH, 10~8m LHRH agonist or 50 mlU hCG, for 20 h.
Medium was replaced with fresh, containing the same hormonal additions,
after 2, 4, 6, 8 and 20 h.
Results:- Incubation with lO'^M LHRH agonist resulted in the
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FIGURE 7.6 Time course of androstenedione, progesterone and oestradiol
release from follicles incubated either with (E3) or without
(□ ) 50mIU hCG. Medium was replaced at 2, 4, 6, 8 and 20 h.
Data represents cumulative totals (Mean + S.E.M., 10 follicles
per group) of steroid production over each time period.
ND = Non Detectable.
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oestradiol release being stimulated at each 2 h time period upto 8 h. A
lower dose (10*8m) of LHRH was used, so as expected, the stimulatory
effect on androstenedione was less than that of lO'^M LHRH agonist,
and oestradiol release was unaffected (Table 7.2).
50 mlU hCG resulted in significant stimulation of all steroids
(androgen, oestradiol and progesterone) at each 2 h time point up to 8 h
(Table 7.2; Fig. 7.6). This is in contrast to the stimulation with LHRH
where progesterone release was only stimulated after 6-8 h incubation
(Tables 7.1; 7.2). However, in agreement with the actions of LHRH,
androgen and oestradiol release were not observed during 8-20 h incubation
with hCG, whereas net progesterone release continued to occur (Tables 7.1;
7.2).
7.3.7. Summary
The experiments presented so far have shown:-
(1) LHRH and LHRH agonist stimulated basal androgen and progesterone
production.
(2) LHRH agonist was approximately 100 times more potent than LHRH.
(3) Stimulation was dose-dependent, the minimal effective doses being 5 x
10-10m for LHRH agonist, and 10~9M for LHRH.
(4) Stimulation of androgen production by LHRH agonist was immediate
(2-3 hrs), whereas that of progesterone was delayed (6-8 hrs).
(5) The magnitude of stimulation was small in comparison to that of 50
mlU hCG.
(6) Oestradiol production varied between experiments; either a
stimulation of production occurred or no change occurred from basal
1 eve!s.
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7.4 CHARACTERISTICS OF LHRH AGONIST STIMULATION
7.4.1 Effect of pre-incubation
Studies using rat Leydig cells had indicated that hCG-induced
stimulation of testosterone production would occur over a 4 h incubation
period in hormone-free medium subsequent to a 15 minute exposure to hCG
(Sharpe ft Cooper, 1982a). Thus the continued presence of gonadotrophs
was not essential for its stimulatory effects on steroidogenesis. The
following experiment set out to investigate whether this was the case for
LHRH agonist-stimulated steroid production in isolated rat follicles.
MethodOne Group of 20 follicles was incubated in the presence or
absence of 10~8m LHRH agonist, for 18 h. Another group of 20
follicles was pre-incubated for 3 h with LHRH agonist or medium alone
before being transferred to hormone-free medium for 18 h incubation.
Results:- The results shown in Fig. 7.7 indicate that after 18 h
continuous incubation with 10~8m LHRH agonist, androstenedione and
progesterone release were stimulated (P ^ 0.001). Incubation for 3 h
resulted in increased androstenedione release in the LHRH agonist-treated
follicles. Despite pre-incubation for 3 h with LHRH agonist, steroid
production during the subsequent 18 h period in medium alone was not
significantly different from the control value.
The continued presence of LHRH agonist was therefore necessary for
stimulation of basal steroid production.
7.4.2 Specificity of action
The ability of non-LHRH-rel ated peptides to stimulate basal
steroidogenesis was investigated.
Method:- Four groups of 10 follicles were incubated for 3 h followed
176
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FIGURE 7.7 Androstenedione, testosterone and oestradiol production from
follicles incubated in the presence (Ml ) or absence (Q ) of
10~8m LHRH agonist for 18 h or 3 h. After 3 h
pre-incubation, follicles were transferred to medium alone for
18 h (Right hand columns).
Data are Mean _+ S.E.M. (10 follicles per group).
* P-^.0.05; *** P-< 0.001 for treated compared to control
values at each time period.
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FIGURE 7.8 Testosterone, progesterone and oestradiol production from
follicles incubated for 3 h followed by 17 h in medium alone
(199) or in the presence of 10"8M LHRH agonist (LHRH/\),lOOOng thyrotrophs releasing hormone (TRH) or 1000 ng
somatostatin (GHIH).
Data are Mean _+ S.E.M. (10 follicles per group).
** ?•£. 0.01; *** P< 0.001 for treated compared to control
values at each time period.
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by 12 h with medium alone, 10~8m LHRH agonist, 1000 ng TRH or 1000 ng
somatostatin (GHIH).
Results10~8m LHRH agonist significantly stimulated basal
testosterone release after 3 h (P 0.001), and basal testosterone
(P-^C 0.001) and progesterone (P^C.0.01) production after 12 h. Neither
TRH or GHIH influenced basal steroid production (Fig. 7.8).
This result agrees with the LHRH receptor data (see Chapter 3)
indicating specificity of both the receptors and the steroidogenic
response for LHRH agonist. Non-related peptides did not interact with
LHRH receptors, nor did they influence basal steroidogenesis.
7.4.3 Effect of an LHRH antagonist
In order to assess further the specificity of LHRH actions, the
effect of an LHRH antagonist (DPhe^ phe^ DPbe^ LHRH) on LHRH- and
LHRH agonist-induced changes was examined.
Method:- Three groups of 20 follicles were incubated with medium
alone, 10"®M LHRH agonist or lO-^M LHRH, in the presence or
absence of 2 ^g (4 x 10~®M) LHRH antagonist for 3 h followed by 17 h.
Results:- Basal steroid production was unaffected by LHRH
antagonist, so the results from each group were pooled to give one control
group. The results for testosterone and progesterone production are
expressed as percentage increment over control values (Fig. 7.9). LHRH
and LHRH agonist induced the expected stimulation of testosterone release
after 3 h and 17 h, and of progesterone after 17 h incubation.
Concomitant treatment with LHRH antagonist reduced the stimulatory effects
of both molecules, being most potent in reducing the testosterone rejponse
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FIGURE 7.9 Percentage increment in testosterone and progesterone
production from follicles after 3 h followed by 17 h
incubation with 10"8m LHRH agonist (LHRH/\) or 10""M
LHRH in the presence (f=! ) or absence (□ ) of 2 /jg LHRH
antagonist.
Data are Mean +_ S.E.M. (10 follicles per group).
* P 2^ 0.05; *** P2L 0.001 for antagonist treated compared to
Non-antagonist treated values at each time period.
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inhibition was observed it could be suggested that the antagonist analogue
used was not potent enough to completely prevent interaction of LHRH with
its receptors.
Results from this and the previous experiment emphasise the specific
nature of the direct gonadal effects of LHRH and confirm receptor data
presented in Chapter 3.
7.4.4 Summary
(1) The continued presence of LHRH agonist was essential for expression
of its stimulatory effects.
(2) Stimulation was specific for LHRH and LHRH agonist; unrelated
peptides such as TRH and GHIH had no effect.
(3) LHRH antagonist reduced the stimulatory effects of LHRH and LHRH
agonist.
7.5 DOES LHRH AGONIST INHIBIT AROMATASE ?
Since oestradiol results were variable betv/een experiments it was
pertinent to investigate the possibility that the stimulatory effects of
LHRH on basal androgen production were due to an inhibitory effect on the
granulosa cell enzyme aromatase (which converts testosterone to
oestradiol), thus resulting in a passive build up of substrate by the
thecal cell. Since aromatase activity is located exclusively in the
granulosa cells of the rat (Dorrington, 1975; Erickson ft Hsueh, 1978) and
depends entirely on thecal androgen as its sole precursor, the ability of
LHRH agonist to influence the conversion of exogenously added testosterone
to oestradiol, was assessed in isolated granulosa cells.
7.5.1 Studies with isolated granulosa cells
Method:- Granulosa cells were isolated from ovaries of immature
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rats killed 48 h after the administration of 4 IU PMSG, by puncturing the
follicles with a fine needle to expel the cells. After centrifugation at
700 rpm for 15 minutes at 37°C and washing (with 3 x 1 ml incubation
medium) the cells were counted (viability, as assessed by trypan blue
exclusion, was 70-80%) and incubated in multiwell plates with
2.5 x 10~5 cells per well, as described for follicles, for 4 h.
Several inhibitors of aromatase have been used previously but 1 pg
5 OC dihydrotestosterone (DHT) has been suggested as the most effective
(Hill i er et al ., 1980). The effect of 10-8^ LHRH agonist on the
conversion of a range of doses of testosterone to oestradiol was assessed
and compared with that of DHT. Six groups of 10 wells (with
2.5 x 10~5 cells/well) were incubated with 0, 5, 10, 25, 50 or 100 ng
testosterone in the presence or absence of 10"8m LHRH agonist. An
additional group of 10 wells was incubated with 100 ng testosterone and 1
pg 5 (X DHT in the presence and absence of 10"^M LHRH agonist.
ResultsTestosterone resulted in a dose-dependent increase in
oestradiol production (Fig. 7.10). The oestradiol response was not
significantly affected by 10~8m LHRH agonist except in the presence of
100 ng testosterone, when LHRH agonist stimulated apparent aromatase
activity (P-^0.05). The potent aromatase inhibitor, 5 &L DHT, inhibited
(P<^C 0.05) the conversion of 100 ng testosterone to oestradiol in the
presence and absence of LHRH agonist.
LHRH agonist clearly had no inhibitory effect on the conversion of
testosterone to oestradiol, and did not behave in a manner similar to that
of an aromatase inhibitor.
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FIGURE 7.10 Oestradiol production from isolated granulosa cells incubated
for 4 h with various doses of testosterone and in the presence
of an aromatase inhibitor (1 /jg DHT) with (■ ) and without
fI 1 ) 10_8m LHRH agonist.
Data are Mean S.E.M. (5 observations per group).




Oestradiol production (pg/follicle) from isolated pre-ovulatory follicles
incubated for 3 h and 17 h with M199, 10_8M LHRH agonist, 100 ng
testosterone, 1 pg 5<x dihydrotestosterone (DHT) as shown.
Data represents mean + S.E.M. with 10 follicles per group. Values differ
from M199 controT or as indicated. a P^ 0.001; b P0.01
Time (h)
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7.5.2 Studies with whole follicles
Attempts at examining the effects of LHRH agonist on androgen
production in the presence of the aromatase inhibitor 5 DHT proved
unsuccessful. The rationale behind the experiments was to ascertain
whether inhibition of basal aromatase could be achieved in isolated
follicles by 5 c?<. DHT, and whether this would result in an increase in
androgen similar to that seen with LHRH. In addition it was hoped to
utilize this model to investigate whether LHRH would induce a further
increase in androgen production in the presence of 5 c*. DHT, thus
indicating a direct thecal site of action for LHRH.
Method:- Seventy follicles were incubated (10 follicles per group)
for 3 h and 17 h with medium alone, 10~8m LHRH agonist, 100 ng
testosterone (T), 1 jjg 5 oC dihydrotestosterone (DHT), LHRH agonist plus
100 ng T, 100 ng T plus 1 jjg 5 oC DHT or LHRH agonist plus 1 jug DHT.
ResultsOestradiol production is shown in Table 7.3. Oestradiol
production was increased in the presence of 100 ng T at 3 h and 17 h (P^~
0.01 and P 0.001 respectively; Table 7.3) and this increase was
inhibited (P 0.01) by 1 fig 5 (X DHT after 17 h incubation. Basal
oestradiol levels were unaffected by 5 DHT at 3 h or 17 h.
10"8m LHRH agonist had no effect on the oestradiol produced in the
presence of 100 ng T. Basal oestradiol levels were increased after 17 h
incubation with LHRH agonist (P^L. 0.001) and this increase was inhibited
by 5 DC DHT (PZ. 0.01).
These results confirm that the results seen in isolated granulosa
cells were applicable to isolated follicles, namely that LHRH agonist
failed to inhibit conversion of testosterone to oestradiol whereas a
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potent aromatase inhibitor, 5 ^DHT, reduced oestradiol production.
Since 1 jjg 5 OC DHT cross-reacted in the testosterone and
androstenedione assays, even after attempts at removing the inhibitor by
column chromatography, it was not possible to assess whether LHRH agonist
stimulated thecal androgen production in the presence of the aromatase
inhibitor.
7.5.3 Intact vs broken follicles
One other possible reason for the observed variability in the
oestradiol response of isolated follicles to LHRH was that LHRH may be
needed to exert direct granulosa cell effects and may be hindered by
having to be transported through thecal cells to the inner granulosa cell
layer. This could also be the reason why effects on granulosa
progesterone production were seen only after 6-8 h whereas those on thecal
androgen production were apparent after 2-3 h. The following experiment
attempted to investigate this by comparing the steroidogenic response to
LHRH agonist stimulation of intact and broken follicles.
Method:- Two groups of 20 follicles were incubated in the presence
or absence of 10~8m LHRH agonist. One group was incubated intact. In
the second group, follicles were ruptured using a fine needle while in
their individual wells. Incubations were carried out for 6 h.
Results:- Whole follicles showed the expected increased androgen
(P^L 0.001) and progesterone (P^C0.05) production in response to LHRH
agonist but oestradiol levels were unaffected (Fig. 7.11). Broken
follicles showed a similar androgen response (P^C 0.001), although the











































FIGURE 7.11 Testosterone, oestradiol and progesterone production from
isolated intact or broken follicles incubated for 6 h in the
presence (■ ) or absence (□ ) of lO'^M LHRH agonist.
Data are Mean _+ S.E.M. (10 follicles per group).
* P< 0.05; *** P< 0.001 for LHRH agonist treated compared to
controls in each group, or as indicated.
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in response to LHP.H agonist was markedly enhanced compared with whole
follicles [P^~ 0.001) and interestingly, oestradiol production was
stimulated (P 0.002). This is unlikely to be due to release of
follicular fluid oestradiol since freezing and thawing liberated 90%
oestradiol in both instances (see 7.3.2.2).
Thus LHRH agonist stimulated oestradiol production in broken but not
intact follicles. It could be suggested therefore that in the broken
follicles exogenous LHRH had immediate access to granulosa and thecal
cells, enabling stimulation of granulosa cell oestradiol production in the
presence of stimulated thecal cell androgen production.
7.5.4. Summary
(1) LHRH agonist had no effect on the conversion of testosterone to
oestradiol v/hereas an aromatase inhibitor (5 <X PHT) reduced
oestradiol production.
(2) 5 CX. DHT failed to reduce basal oestradiol release from isolated
fol1icles.
(3) Oestradiol release was stimulated by LHRH agonist after incubation
with ruptured, but not intact follicles.
7.6 DISCUSSION
7.6.1 Characteristics of LHRH stimulation of basal steroidogenesis
10"8m LHRH agonist consistently stimulated basal androstenedione
and testosterone release from isolated follicles over incubation periods
from 2-20 h, resulting in a 2-5 fold stimulation over basal levels. The
response to LHRH was dose- and time-dependent, significant stimulation
occurring with concentrations of LHRH agonist in the range 5 x 10~10M
to 10~8m and with concentrations of native LHRH in the range
188
10-9 _ io~6m. The greater potency of the agonist molecule was
also indicated by the 100 fold higher concentration of native hormone
(i.e. 10"6M) required to elicit stimulation comparable to that found
with lO-^M agonist. A similar phenomenon has been observed by others
(e.g. Hillier et al_., 1981) and is likely to be due to increased
resistance to degradation or to an increased binding affinity of the
analogue. The concentrations required to elicit stimulation were in the
same range as the Ka for ovarian LHRH receptors (e.g. Pieper et al ., 1981
and Chapter 3) suggesting that the effects were receptor mediated.
Dose-dependent stimulation of progesterone release occurred with both
LHRH and LHRH agonist after 18 h continuous exposure to the peptides. No
detectable stimulation of progesterone release was seen until after 6-8 h
of incubation. This is a longer period of incubation than that reported
by others, who found increases in progesterone production after 4-6 h
incubation with LHRH, both in isolated follicles (Hillensjo, 1981;
Hill ensjo et al ., 1982) and granulosa cells (Clark, 1982). The reason for
this difference is not known but may be related to the use of increased
numbers of follicles or cells during incubation with LHRH.
Basal oestradiol production in response to LHRH varied between
experiments. In some instances significant stimulatory effects were
detected while in others no change was observed.
This pattern of stimulation of basal steroidogenesis was specific for
LHRH since other peptides (e.g. TRH, GHIH) showed no effect. In addition
the effect on testosterone and progesterone production could be inhibited
using an LHRH antagonist.
The nature of the stimulatory effect of LHRH, compared with that of
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hCG, is interesting. Both hormones stimulated testosterone and oestradiol
production for periods up to 8 h, after which the follicles appeared to
lose the ability to respond to either hCG or LHRH. However, progesterone
release continued to occur after 8 h continuous exposure to either
hormone. These changes could be due to the incubation conditions, with
prolonged incubation resulting in receptor changes and subsequent
switching of action from a predominantly thecal to a predominantly
granulosa site, perhaps due to 1uteinization-1ike changes in granulosa
eel 1 s.
However, LHRH action differed from that of hCG in two parameters.
LHRH-stimulated progesterone production was evident only after an
incubation period of 6-8 h whereas incubation with hCG resulted in
immediate (2 h) stimulation of progesterone production. In addition,
whereas hCG-stimulated steroid production continued after pre-incubation
period (see Sharpe ft Cooper, 1982a) removal of LHRH agonist from the
incubation medium abolished the stimulatory effects of the peptide. Thus,
the continued presence of LHRH is required to elicit the stimulatory
effects on steroidogenesis. These differences between hCG- and
LHRH-stimulated steroidogenesis may reflect the characteristies of the
hormone-receptor interaction, that for LHRH being rapid (t| 20 minutes at
21° C) and that for hCG being slow (t\ 150 minutes at 37° C) as suggested
by Sharpe ft Cooper, (1982a). It could be postulated that the delayed
progesterone response to LHRH is due to a prolonged period required to
activate functional granulosa cell LHRH receptors. It is evident, however
that the characteristics of LHRH-stimul ated steroidogenesis, differ from
those of hCG.
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7.6.2 Possible sites of action for LHRH stimulation
Stimulation of basal progesterone production has been reported from
isolated granulosa cells (CI ark et al ., 1980). Since specific receptors
for LHRH have been demonstrated to be present on isolated granulosa cells
(e.g. Jones et al ., 1980) the most likely explanation for LHRH-induced
progesterone production in isolated follicles is that the increase is due
to a direct action of LHRH on granulosa cells.
However, since androgens can stimulate progesterone production (Lucky
et al ., 1977; Nimrod, 1977) it is possible that LHRH-induced progesterone
production from isolated follicles could be an indirect action via
increased thecal androgen production. In addition, since thecal cells
produce small amounts of progesterone (Terranova et al ., 1982) a thecal
source of progesterone cannot be excluded.
The mechanism by which LHRH-stimulated androgen production could
occur is less clear. Since in the rat, thecal cells provide the major
source of androgens (Fortune & Armstrong, 1977; Hamberger et al., 1978) it
is possible that LHRH exerts a direct action on thecal cells. Indirect
evidence suggested that specific receptors for LHRH may be present on
thecal cells. Thus LHRH was found to bind to residual follicular tissue
(presumably thecal/interstitial tissue) following the removal of granulosa
cells (Pieper et al ., 1981). In addition autoradiography revealed the
presence of ^25j_LHP.H agonist grains over thecal tissue (Chapter 3).
Moreover LHRH agonist had been reported to influence interstitial cell
steroidogenesis. (Magoffin et al ♦, 1981).
Although there is evidence for granulosa cell production of androgens
in some species e.g. hamster (Makris & Ryan, 1980), this is unlikely to be
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the case in the rat where there is no evidence for granulosa cell androgen
production.
Finally an apparent increase in androgen release could theoretically
be caused by an inhibition of granulosa cell aromatization resulting in
accumulation of precursor. While it is not possible to rule out this
possibility due to the variability of the oestradiol response to LHRH, it
seems unlikely for a number of reasons. Firstly, LHRH had no inhibitory
effect on aromatase activity in isolated granulosa cells. Indeed recent
studies have indicated that LHRH might stimulate aromatase activity
(Dorrington et al., 1982). Secondly, in no experiment did LHRH show an
inhibitory effect on basal aromatase; either no effect or a significant
stimulation was observed. It could be suggested that in the model system
used, under certain circumstances the aromatase enzyme may be incapable of
responding to such relatively small changes in substrate concentration,
especially since even known stimulators of aromatase (e.g. db cAMP) on
occasion failed to stimulate oestradiol production (see 7.8.1).
One possibility investigated was that, in order for oestradiol
production to occur in response to LHRH agonist-induced androgen
production, granulosa cells required direct exposure to LHRH agonist.
Since granulosa cells are separated from the outer medium by thecal cells,
perhaps LHRH transport to the centre of the follicle was impaired. This
could also explain the delayed progesterone increase. Oestradiol
production was stimulated by incubation of LHRH agonist with broken but
not intact follicles. Thus an additional effect of LHRH on the ability of
granulosa cells to aromatize androgen cannot be excluded.
Attempts at stimulating androgen production with LHRH agonist in the
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presence of an aromatase inhibitor proved unsuccessful due to interference
of the inhibitor in androgen radioimmunoassays. Several groups have
reported data utilizing isolated rat thecal preparations prepared from rat
pre-ovulatory follicles (e.g. Fortune & Armstrong, 1977 A 1978; Hamberger
et al ., 1978). However, attempts at preparing enriched cultures of rat
thecal cells proved unsuccessful due to technical difficulties and
granulosa cell contamination.
Thus, although the data presented implies a direct thecal action of
LHRH, until these observations are confirmed in isolated thecal
preparations the question of direct thecal effects of LHRH remains a
hypothesis only. Interestingly however, in a recent paper by Hi 11 ensjo et
al., (1983) experiments were cited as demonstrating a direct stimulatory
effect of LHRH on isolated rat thecal cells (Nordenstrom - in preparation,
cited in Hi 11 ensjo et al., 1983).
7.7 EFFECTS OF LHRH AGONIST ON hCG-INDUCED STEROIDOGENESIS
7.7.1 Effect on hCG dose response
The stimulatory effects of LHRH and LHRH agonist on basal
steroidogenesis were small in comparison to those seen with 50 mlU hCG
(see 7.3.5). Since LHRH had been shown to decrease the sensitivity of
granulosa cells to gonadotroph!n stimulation in long-term culture (see
Chapter 1 A Hsueh A Jones, 1981 for review) the ability of LHRH to
influence hCG sensitivity in short-term culture was assessed.
Method:- Six groups of 20 follicles were incubated with either
medium alone, 1, 5, 10, 25 or 50 mlU hCG in the presence or absence of
10"8m LHRH agonist. After 3 h, medium was removed to assess steroid
release and replaced with fresh medium with the same hormone additions and
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FIGURE 7.12 Stimulation of testosterone, oestradiol and progesterone
release from isolated follicles incubated with various doses
of hCG in the presence (a~a) or absence (•-•) of 10~8M
LHRH agonist for 3 h.
Each point represents Mean + S.E.M. (10 follicles per group).
* P 0.05; *** P^. 0.001 for LHRH agonist treated compared tocontrol values at each dose of hCG.
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FIGURE 7.13 Stimulation of testosterone, oestradiol and progesteroneproduction by isolated follicles incubated with various dosesof hCG in the presence (*-*) or absence (•—•) of 10"8MLHRH agonist for 17 h.
Each point represents Mean _+ S.E.M. (10 follicles per group).
* P<0.05; ** p<0.01; *** P <0.001 for LHRH agonisttreated compared to control values at each dose of hCG.
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incubated for a further 16 h.
Results:- The results of steroid release over the 3 h and 17 h
incubation periods are shown in Figs. 7.12 and 7.13.
Analysis of the results showed a significant effect of LHRH agonist
on hCG-stimul ated testosterone at 3 h (PxC 0.005) and 17 h (P 0.005).
Subsequent analysis showed significant stimulation by LHRH agonist
occurred with doses of 1 mlU and 5 mlU hCG at 3 h, and with 1 mil! at 17 h.
LHRH agonist however, had a significant effect on hCG-induced
oestradiol production [P (1.05) after 3 h but not after 17 h. LHRH
agonist stimulated basal oestradiol and that in the presence of 1 mlU hCG
after 3 h incubation.
LHRH agonist significantly increased hCG-induced progesterone
production at 17 h (P-^L.0.05) but not at 3 h, with stimulation of basal
and 1 mlU hCG induced progesterone production after 17 h incubation.
These data indicate that LHRH enhanced the sterodogenic response to
low doses of hCG, due to stimulation of basal and 1 mill hCG-stimul ated
steroid production. No inhibition of hCG stimulation was observed with
LHRH agonist treatment.
7.7.2 Effect on time course of hCG action
In order to examine whether LHRH exerts a transitory effect on hCG-
induced steroid production a detailed time course similar to that
described earlier (see 7.3.5) was investigated.
MethodFour groups of 10 follicles were incubated with medium
alone, lO'^M LHRH agonist, 50 mil) hCG or both 10*% LHRH agonist
and 50 mlU hCG. Medium was replaced with fresh containing the same


























FIGURE 7.14 Time course of androstenedione, oestradiol and progesterone
release from follicles incubated with medium alone (□ ),
10-8M LHRH agonist (■ ), 50mIU hCG (Q ) or 50mIU hCG and
10~8M LHRH agonist (^). Medium was replaced at 2, 4, 6
and 20 h.
Data represents cumulative totals (Mean +_ S. E.M., 10 follicles
per group) of steroid production over each time period.
ND = Non Detectable
* P <10.001 for LHRH agonist treated compared to non-LHRH











































































































































frozen at 20 h.
ResultsThe cumulative pattern of androstenedione, oestradiol and
progesterone release is shown in Fig. 7.14 and the steroid release per
time period in Table 7.4. Similar results to those attained previously
were seen with LHRH agonist or hCG alone, namely hCG stimulation of
production of all steroids after 2 h incubation, and LHRH agonist
stimulation of androgen production after 2 h but without effect on
progesterone until 6-20 h. LHRH agonist had no effect on the
steroidogenic response to 50 mlU hGG at any of the times studied (Fig.
7.14; Table 7.4).
7.7.3 Effect of Pre-incubation
Studies in luteal tissue and tissue from immature rat ovaries had
indicated that pre-incubation with LHRH agonist would result in a
decreased response to subsequent gonadotrophin exposure (Reddy et al♦,
1980; Hall et al ., 1981). The following experiment set out to determine
the effects of pre-incubation of isolated follicles with 10'% LHRH
agonist, on the subsequent steroidogenic response to 1 IU hCG.
Method:- Four groups of 20 follicles were pre-incubated either with
or without 10"% LHRH agonist for 1, 3, 6 or 18 h, before addition of
1 IU hCG.
Results:- Results for testosterone and oestradiol release are shown
in Table 7.5. Testosterone release was stimulated after each
pre-incubation period longer than 1 h, with LHRH agonist (P-< 0.001). No
such effect was seen for oestradiol. hCG stimulated both oestradiol and
testosterone production after 1, 3 and 6 h pre-incubation. Follicles


































































































































respond to hCG. Pre-incubation with lO^M LHRH agonist had no effect
on the subsequent response to 1 IU hCG.
7.7.4 Summary
(1) LHRH agonist had no effect on steroidogenic changes induced by 50 mlU
hCG over 2-20 h incubation.
(2) LHRH agonist had no inhibitory effect on tissue responsiveness to
hCG. The steroid response to extremely low (1 mIU) doses of hCG was
enhanced by LHRH agonist.
(3) Pre-incubation with LHRH agonist for 1-6 h had no effect on
subsequent hCG-induced changes.
7.8 EFFECTS OF LHRH AGONIST ON cAMP-INPUCEP STEROIDOGENESIS
7.8.1 Effect on dibutyryl cAMP-induced changes
Previous studies had indicated a variety of effects of LHRH on cAMP-
induced steroidogenesis with either an inhibition (e.g. Reddy et al .,
1980; Hillier et al ., 1981) or no effect (e.g. Harwood et al., 1980a;
Behrman et al ., 1980; Jones et al., 1982) being reported. High doses
( 10"3m) of the membrane-soluble cAMP analogue dibutyryl cAMP (db
cAMP) are toxic to cells, but a dose of 10"3m Was reported as being
maximally effective in stimulating steroidogenesis (Hillier et al., 1978).
The effect of LHRH on steroidogenesis induced by 1 mM db cAMP was
therefore assessed.
Method:- Two groups of 20 follicles were incubated with control
medium or 1 mM db cAMP in the presence or absence of 10"8m LHRH
agonist for 6 h, then transferred to fresh medium containing the same
additions for 12 h.














































FIGURE 7.15 Testosterone, oestradiol and progesterone production by
follicles incubated for 6 h then 12 h with M199 or 1 mM
dibutyryl cyclic AMP (db cAMP) in the presence (■) or
absence (□ ) of 10-8m LHRH agonist.
Data are Mean _+ S.E.M. (10 follicles per group).
** P-C.0.01; *** P 0.001 for LHRH agonist treated compared
to controls in each group, or as indicated.
202
LHRH agonist alone stimulated basal testosterone and progesterone release
(P^i_0.001) after 6 h and 12 h. Db cAMP also stimulated the accumulation
of testosterone and progesterone at both times. LHRH had no effect on the
db cAMP-induced testosterone increase at 6 h but stimulated over and above
that of db cAMP at 12 h (P 0.01) and after both 6 h and 12 h for
progesterone release (P^~ 0.001). Thus LHRH appeared to potentiate the
effects of db cAMP on testosterone and progesterone release and may
therefore exert stimulatory effects at events post-cAMP formation and/or
involve a mechanism independent of that of cAMP.
The absence of an effect of db cAMP on oestradiol production was
unexpected, particularly since testosterone was markedly increased.
However, this phenomenon seems to reflect one of the major problems
encountered during these studies, namely the variability of oestradiol
responses. These discrepancies are unlikely to be due to differences in
responses of individual animals to PMSG and it is not known why the
aromatase system seems unable to respond to the presence of precursor
under certain conditions but not others.
However, in complete contrast to earlier observations indicating no
effect or inhibition of cAMP-induced steroidogenesis, short-term exposure
of LHRH agonist to isolated rat follicles enhanced the progesterone and
testosterone response to 1 mM db cAMP.
7.8.2 Effect on caffeine-induced changes
Since methyl xanthenes such as caffeine are potent inhibitors of
phosphodiesterase (the enzyme responsible for cAMP breakdown), addition of
such compounds would be expected to raise endogenous cAMP levels. The













































































MethodFour groups of 10 follicles were incubated with M199, 4 mM
caffeine, lO'^M LHRH agonist or both caffeine and LHRH agonist, for *
17 h.
ResultsThe results obtained are shown in Table 7.6. LHRH agonist
alone stimulated both testosterone (P^c_ 0.001), progesterone [V 0.01)
and oestradiol (P«<0.01) levels. Caffeine alone had no effect on basal
levels of testosterone or oestradiol but increased basal progesterone
production (P< 0.001). Caffeine had no effect on LHRH agonist-stimulated
testosterone and oestradiol production. LHRH agonist stimulated
progesterone production over and above that found with caffeine alone.
Piscussion:- The results of the previous 2 experiments are
consistent with the theory that the stimulatory actions of LHRH agonist
are additional to those of cAMP, whether administered exogenously in the
form of db cAMP or after raised endogenous levels induced by caffeine.
Since gonadotrophic hormones are believed to exert their effects on
steroidogenesis by raising endogenous cAMP (see Marsh, 1975; 1976) it was
surprising that LHRH stimulated steroidogenesis over and above that seen
after db cAMP or caffeine treatment but had no effect on steroidogenesis
induced by high doses of hCG (see 7.7). The reason for this difference is
unknown. In the absence of measurement of endogenous cAMP levels it is
not possible to determine whether LHRH treatment alters cAMP. However, no
change in granulosa cell cAMP content was seen after treatment with LHRH
agonist despite increased progesterone release (CIark et al., 1980). In
addition, no change in cAMP content was seen in isolated follicles
incubated with LHRH agonist (Hillensjo _et al_., 1982). It is likely
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therefore that LHRH agonist-induced changes in steroidogenesis are in
addition to or independent from those of cAMP.
7.9 EFFECT OF LHRH AGONIST ON PROSTAGLANDIN-STIMULATED STEROIDOGENESIS
Prostaglandins have been postulated to be involved in the regulation
of follicular function, with PGF2 <X being implicated in follicular
rupture and PGE2 in 1uteinization (see Armstrong, 1979 for review). In
addition prostaglandins are likely to be involved in the induction of
ovulation, mediating the actions of LH (e.g. Dodson & Watson, 1977).
Incubation of isolated granulosa cells with 1 jjg PGE2 together with
LHRH for 48 h, resulted in inhibition of PGE2~induced oestradiol
production (Hsueh et al., 1980). This experiment set out to determine.the
short-term effects of LHRH agonist on steroidogenesis induced by PGE2
or PGF2OC.
Method:- Three groups of 20 follicles were incubated with M199, 1 pg
PGF20^ , or 1 jjg PGE2 in the presence of absence of lO'^M LHRH
agonist for 3 h followed by 17 h.
Results:- Control incubations showed LHRH agonist stimulating basal
androgen (3 h & 17 h) and progesterone (17 h) but not oestradiol
production.
PGEp: PGE2 stimulated basal androgen, oestradiol and progesterone
release after 3 h, and basal androgen and progesterone after 17 h
(Fig. 7.16). LHRH agonist inhibited the PGE2~induced increase in
progesterone after 17 h incubation (P/C. 0.05) and a small, not significant
decrease in oestradiol after 17 h, but had no effect on other steroids at
anytime.
PGFj?Ok : PGF2'^ stimulated basal androgen production at 3 h and 17 h.
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FIGURE 7.16 Testosterone, oestradiol and progesterone production by
follicles incubated for 3 h then 17 h with M199, 1 |ig
prostaglandin F2c* (PGF2C<) or prostaglandin E2 (PGE2)
in the presence (■ ) or absence (EZJ) of lO'^M LHRH
agonist.
Data are Mean +_ S.E.M. (10 follicles per group).
** P<0.05; ** P<0.01; *** P< 0.001 for LHRH agonist
treated compared to controls in each group, or as indicated.
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After 3 h incubation LHRH agonist enhanced the testosterone response
to PGF^X and raised progesterone to detectable levels, but had no effect
on oestradiol at any time.
These results confirm the stimulatory effect of prostaglandins on
steroidogenesis and show that short-term incubation with LHRH agonist can
inhibit the PGE2~induced progesterone production, after 17 h, and
stimulate PGF^-stimulated testosterone production, after 3 h.
7.10 EFFECT OF PROSTAGLANDIN SYNTHESIS INHIBITORS ON LHRH AGONIST-
STIMULATED STEROIDOGENESIS
A number of reports have indicated that LHRH stimulation of
progesterone production is associated with a rise in endogenous
prostaglandin production (PGE2 & PFG2^ ) in isolated granulosa cells
(CI ark et al., 1980) and PGE2 from isolated follicles (Hi 11 ensjo et al .,
1982). LHRH has also been shov/n to increase the levels of ovarian PGE2
in vivo (Ekholm et al ., 1982a). Since LHRH agonist stimulated ovulation
in hypophysectomized rats (Ekholm et al ., 1981; Corbin & Rex, 1981) and
this action was inhibited by indomethacin (Ekholm et al., 1982a; Dekel et
al., 1983) it seemed likely that prostaglandins were involved in mediating
the actions of LHRH agonist. The following experiment therefore set out
to determine the effects of the prostaglandin synthesis inhibitors,
indomethacin and aspirin, on LHRH agonist-induced stimulation of basal
steroidogenesis.
7.10.1 Effect of Indomethacin
Method:- Two groups of 20 follicles were incubated with M199 or 100
uM indomethacin with or without 10"^M LHRH agonist for 3 h and 17 h.




FIGURE 7.17 Testosterone, oestradiol and progesterone production by
follicles incubated for 3 h then 17 h with 100 |iM indomethacin
(indomet) or M199 in the presence (■ ) or absence (□ ) of
10-8M LHRH agonist.
Data represent Mean +_ S.E.M. (10 follicles per group).
* P<0.05; ** P<0.01; *** P<0.001.
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3 h and 17 h and decreased basal oestradiol production after 17 h. LHRH
agonist stimulated androgen production regardless of the presence of
indomethacin. No effect of LHRH agonist was noted in any group, on
oestradiol production. LHRH agonist-stimulated progesterone production
was prevented by indomethacin (Fig. 7.17).
7.10.2 Effect of Aspirin
Method:- Two groups of 20 follicles were incubated with medium alone
or 0.5 mM aspirin in the presence or absence of IO-Sri LHRH agonist.
Result:- Aspirin stimulated basal testosterone levels after 3 h
(P^C 0.05) and inhibited basal progesterone after 17 h {P^L 0.001; Fig.
7.18). LHRH agonist-stimulated progesterone production was prevented by
the presence of 0.5 mM aspirin. LHRH agonist-stimulated testosterone
production was decreased but not prevented by aspirin (Fig. 7.18).
Piscussion:- Both aspirin and indomethacin abolished the stimulatory
effect of LHRH agonist on progesterone production after 17 h incubation,
thus confirming the central role of endogenous prostaglandin in LHRH
stimulation of granulosa cell progesterone production (Clark et al .,
1980).
Interestingly, indomethacin appeared to inhibit basal aromatase and
this was accompanied by an increase in basal testosterone at 17 h (Fig.
7.17). In the presence of inhibited aromatase however, LHRH agonist
further stimulated testosterone production thus implicating a direct
thecal site of action.
In contrast to progesterone, LHRH agonist-stimulated testosterone
production occurred despite the presence of indomethacin or aspirin. It
is concluded therefore that the thecal action of LHRH, unlike the
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FIGURE 7.18 Testosterone, oestradiol and progesterone production by
follicles incubated for 3 h then 17 h with 0.5 mM aspirin or
M199 in the presence (■ ) or absence (□) of 10_8m LHRH
agonist.
Data represents Mean +_ S.E.M. (10 follicles per group).
* P-< 0.05; ** p<0.01; *** P< 0.001 for LHRH agonist
treated compared to controls in each group, or as indicated.
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granulosa action, does not involve endogenous prostaglandin production.
7.11 SUMMARY
1) LHRH agonist stimulated testosterone and progesterone production in
the presence of db cAMP or caffeine.
2) LHRH agonist inhibited PGE2-stimulated progesterone production, but
had no effect on other PGE2-induced changes.
3) LHRH agonist stimulated testosterone production in the presence of
PGF2^ after 3 h but had no effect on other steroids at any time.
4) LHRH agonist-stimulated progesterone was abolished by prostaglandin
synthetase inhibitors whereas LHRH agonist-stimulated testosterone
production was not abolished.
7.12 RESPONSIVENESS OF FOLLICLES TO LHRH AGONIST DURING DIFFERENT STAGES
OF DEVELOPMENT
In order to assess whether follicles from different stages of
development were capable of responding to LHRH agonist, the responsiveness
of follicles isolated from ovaries from immature untreated rats was
assessed together with that of follicles isolated from ovaries from
immature rats 24 h after exposure to 4 IU PMSG.
7.12.1 "Immature" follicles
Method:- Two groups of 20 follicles were isolated from immature rat
ovaries and incubated with M199 or 50 mlU hCG in the presence or absence
of 10"^M LHRH agonist, for 17 h.
Resul ts:- The follicles isolated were small, approximately half
(i.e. 0.5 - 0.8 mm) the diameter of those recovered 48 h after PMSG
treatment. Basal androstenedione and oestradiol levels were non-
detectable, the major steroid produced being progesterone. 50 mlU hCG
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TABLE 7.7
Steroid production from follicles isolated from immature rat ovaries
incubated for 17 h.




M199 ND ND 1201+439
lO'^M LHRH agonist ND ND 1535+343
50 mlU hCG 116+13 ND 4600jf928
50 mlU hCG +
10"8m LHRH agonist 90+17 ND 4325+796
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stimulated progesterone production and raised androgen to detectable
1 evel s.
LHRH agonist had no effect either on basal or hCG-stimulated
steroidogenesis (Table 7.7).
7.12.2 Dioestrous-type follicles
MethodTwo groups of 20 follicles were isolated from rat ovaries
24 h after treatment with 4 IU PMSG. Follicles were incubated with M199
or 50 mill hCG in the presence or absence of 10-8m LHRH agonist, for
17 h.
Results:- Follicles were slightly smaller (approximately | size)
than those isolated 48 h after PMSG (i.e. 0.7 - 0.9 mm diameter). The
steroidogenic response of these follicles was similar to that of
pro-oestrous follicles. LHRH agonist significantly increased basal
production of androstenedione, oestradiol and testosterone (P^CO.Ol; Fig.
7.19) but had no effect on hCG-induced steroidogenesis (Fig. 7.19).
7.13 DISCUSSION
In contrast to previous observations showing inhibitory actions of
LHRH and LHRH agonist on ovarian function (see Chapter 1) the data
presented in this chapter have indicated that the short-term effects of
LHRH and LHRH agonist on ovarian function are stimulatory as regards
progesterone, testosterone and occasionally, oestradiol production. Other
investigators have confirmed the stimulatory actions of LHRH agonist on
granulosa cell progesterone production both in vitro (CI ark et al., 1980;
Hillensjo et al ., 1982) and in vivo (Ekholm et al ., 1981). In addition
LHRH has been found to stimulate a variety of parameters such as
prostaglandin accumulation (Clark etal ., 1980), meiotic maturation of
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199 hCG
FIGURE 7.19 Androstenedione, oestradiol and progesterone production from
follicles isolated from rats 24 h after treatment with PMSG.
Follicles were incubated with or without 50 mlU hCG in the
presence (■ ) or absence (I I) of 10"8m LHRH agonist.
Data are Mean _+ S.E.M. (10 follicles per group).
** P«C0.01 for LHRH agonist treated compared to control
values in each group.
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oocytes in vitro and in vivo (Hillensjo & LeMaire, 1980; Ekholm et al.,
1981; 1982a) and oocyte respiration (Magnusson & LeMaire, 1981). LHRH and
LHRH agonists have even been reported to induce ovulation in
hypophysectomised pro-oestrous rats (Corbin & Bex, 1981; Ekholm et al .,
1981). In these actions LHRH appears to mimic the effects of LH; however
LHRH does not mediate the action of LH since LHRH antagonists inhibited
LHRH but not LH-induced oocyte maturation in isolated follicles (Ekholm et
al., 1982b; Dekel et al ., 1983). Since LHRH has no effect on maturation
of non-follicle enclosed isolated oocytes (Anderson & Hillensjo, 1982;
Hi 11 ensj'o et al., 1983), its effects on oocyte maturation are likely to be
secondary to the induced changes in follicular environment and/or to its
interruption of oocyte-corona cell contact (Erickson et al ., 1983).
Studies in the male have indicated that short-term incubation with
LHRH and LHRH agonist stimulated basal testosterone production in vitro
(Sharpe & Cooper, 1982b; Hunter et al ., 1982) and in vivo (Sharpe et al .,
1982b).
The stimulatory effects of LHRH agonist are small in comparison to
those of maximally or sub-maximally stimulating doses of hCG/LH. In
addition LHRH had no effect on the steroidogenic response to 10 mlU - 1 IU
hCG. This agrees with data of others, where LH-induced progesterone was
unaffected by LHRH agonist (Clark, 1982). However, since LHRH agonist
stimulated androgen production in the presence of low (1-5 mlU) hCG it may
be suggested that an endogenous LHRH-like factor could be involved in the
maintenance of steroid levels in the presence of low circulating levels of
a
gohjdotrophin. Moreover, studies in the male have indicated that LHRH
agonist enhances the testosterone response to low doses of hCG in vitro
216
(Sharpe & Cooper, 1982b; Hunter et al., 1982) and in vivo (Sharpe et al .,
1982b).
It is important to remember, however, that the isolated follicles
utilized in these studies have been exposed to gonadotropin'ns in vivo.
Since follicles incubated in medium alone continued to synthesize steroids
it could be suggested that this was due to residual gonadotrophs
stimulation and therefore that the term 'basal' steroidogenesis is a
misnomer; steroid production being effected by previous gonadotrophs
exposure.
That the actions of LHRH may be dependent upon prior exposure to
gonadotrophins is indicated by the preliminary data presented on the
responsiveness of 'immature' and 'dioestrous-type' follicles. LHRH
agonist had no direct stimulatory effects on the former follicles, whereas
marked stimulation was seen with follicles exposed for 24 or 48 h to PMSG.
Recent studies have indicated that in the male, LH regulates the
responsiveness of Leydig cells to LHRH agonist (Sharpe & Fraser, 1983); it
would be interesting to determine whether a similar phenomenon occurs in
the female i.e. if pre-exposure to LH determines the sensitivity of the
follicle to LHRH stimulation.
The mechanism of LHRH action on ovarian tissue is largely unsown.
Its stimulation of progesterone is unlikely to involve cAMP (Clark _et
_al_.,1980; Hi 11 ensjo et al ., 1982). It appears well established that LHRH
agonist-induced ovulation, like that of LH, is mediated by increased
ovarian prostaglandins (e.g. Ekholm et al ., 1982a). In addition LHRH has
been found to stimulate production of plasminogen activator, the enzyme
involved in follicular rupture (Wang, 1983). From the data presented in
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this chapter it appears that two separate mechanisms of LHRH action
mediate the effects on granulosa and thecal function. Thus LHRH agonist-
stimulated progesterone but not androgen production, was abolished by
prostaglandin synthesis inhibitors, indicating a role for endogenous
prostaglandins in LHRH agonist-stimulated granulosa but not thecal
function.
Recent studies however, have implicated a role for calcium in LHRH
stimulation. The mechanism by which LHRH stimulates pituitary function is
largely believed to be via alterations in cellular calcium metabolism (see
Conn et al., 1981b for review). Calcium has also been implicated in the
direct gonadal effects of LHRH (e.g. Ranta et al ., 1983). In addition
inhibition of calmodulin has been reported to abolish the stimulatory
effects of LHRH agonist on granulosa cell function (Hillensjd et al .,
unpublished observations cited in Rani et al ., 1983).
Recent studies have indicated that the initial cellular response
following LHRH binding is an incorporation of unlabelled phosphate into
phosphatidyl inositol (PI) in both pituitary (Snyder & Bleasdale, 1982;
Raymond et al ., 1982) and ovary (Naor & Yavin, 1982; Leung et al ., 1983;
Davis & Clark, 1983). The importance of these observations is the
suggested coupling of PI metabolism with that of cellular calcium (see
Putney, 1981; Berridge, 1981 for reviews). A cyclic nucleotide-
independent calcium- and phosphol ipid-dependent protein kinase exists
which is selectively activated by calcium and phospholipid (Kishimoto _et
al., 1980) and such an enzyme has been found in ovarian tissue (Davis &
Clark, 1982). The phosphatidic acid formed after PI breakdown may
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therefore acts as an endogenous calcium ionophore under neurohumoral
control (Putney, 1981) thus mediating the action of LHRH. Further
studies, particularly as regards thecal cells, are awaited with interest.
In conclusion therefore, the data presented in this chapter suggest
that the initial response of follicles to LHRH involves stimulation of
basal steroidogenesis. It could be suggested therefore that follicular
responsiveness to LHRH is biphasic, with short-term exposure leading to
stimulation, and more prolonged exposure resulting in desensitization and
an inhibitory response. This has been suggested by studies described
by Rani et al., (1983) when, after 8 h continuous exposure to LHRH, the
steroidogenic response as regards androgen and oestradiol production, was
abolished. In addition this has been suggested for LHRH-stimulated
progesterone production from isolated follicles (see Rani et al ., 1983).
The short-term actions of LHRH are likely therefore to mimic those of an
intra-ovarian peptide involved in the regulation of ovarian function as
suggested by Ying & Guillemin, (1979). The following chapter is concerned
with attempts at isolation of such a peptide.
7.14 CONCLUSIONS
1) LHRH and LHRH agonist stimulate basal steroidogenesis.
2) LHRH agonist does not influence tissue responsiveness to hCG.
3) The mechanism of LHRH agonist action is unlikely to involve cAMP.
4) LHRH agonist-stimulated progesterone production is likely to involve
endogenous prostaglandin production.
5) LHRH agonist-stimulated androgen production is likely to be
independent of endogenous prostaglandin production.
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Follicles isolated from immature rat ovaries do not respond to LHRH
agonist.
Follicles isolated 24 h after PMSG treatment show similar stimulatory
effects of LHRH to those seen in pre-ovulatory follicles.
The responsiveness of the ovary to LHRH may well be determined
therefore by prior gonadotropin exposure.
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CHAPTER 8
ATTEMPTS AT ISOLATING OVARIAN LHRH-LIKE MATERIAL
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8.3.3 Sources of Tissue
8.4 EXTRACTION METHODS, RESULTS AND PROBLEMS
8.4.1 Acid-ethanol extraction
8.4.2 Acid-ethanol followed by Ethyl ether acetate and butan-I-ol
extraction
8.4.3 Amicon ultrafi1tration
8.4.4 Solid phase purification using Sep-pak columns
8.4.4.1 Method A
8.4.4.2 Method B
8.4.5 Acetic Acid extraction
8.5 DISCUSSION
8.6 CONCLUSIONS AND FUTURE PROSPECTS
8.1 INTRODUCTION
As discussed in Chapter 1 LHP.H exerts direct actions on a variety of
extrapituitary sites. Since LHRH is rapidly degraded (e.g. Jeffcoate et
al., 1974) hypothalamic LHRH is unlikely to reach these sites in high
enough concentrations. It seemed likely therefore that an LHRH-1ike
material might be produced in extrahypothalamic areas. That this is
indeed the case has been shown by techniques utilizing specific antisera
for LHRH. Immunoreactive LHRH has been demonstrated by
immunohistochemistry in the pineal (Wheaton, 1980; Piekut & Knigge, 1982),
pancreas (Seppala et al., 1979) mammary tumours (Seppala & Wahlstrom,
1980), placenta (Khodr & Siler-Khodr, 1978b) and testis (Paull et al.,
1981).
Similarly, extraction of tissues and biological fluids for assay in
LHRH radioimmunoassays has revealed the presence of LHRH-1ike activity in
milk (Amarant et al ., 1982) and urine (Rettig et al ., 1982). In addition
a macromolecu Ie cross reacting with an LHRH antiserum has been localized
in extracts of rat liver, kidney, spleen and muscle (Barnea Ft Porter,
1975).
The first indication that the ovary contained an LHRH-1ike substance
was reported in 1979. During bioassay tests for the presence of
inhibin-like activity in follicular fluid a contaminating 'stimulin' was
found which stimulated LH release from isolated pituitary cells (de Jong
et al ., 1979).
In addition, these observations were confirmed by Ying Ft Guillemin
who coined the phrase "gonadocrinin" for an LH-releasing factor present in
ovarian follicular fluid (Ying & Guillemin, 1979b;1980). These studies
were subsequently extended with the reported isolation of a 3500 dalton
peptide from ovarian tissue with LHRH bioactivity but with immunological
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characteristics different from those of LHRH (Ying et al., 1981).
Similar evidence was emerging from studies in the male. Acid-ethanol
extracts of rat interstitial fluid not only displaced binding of LHRH
agonist in the rat Leydig cell radioreceptor assay, but also stimulated LH
release from hemipituitaries in vitro (Sharpe & Fraser, 1980b; Sharpe et
al., 1981). In addition this substance was immunochemically distinct from
LHRH (Sharpe et al ., 1982a; Fraser et al ., 1982; Sharpe & Harmer, 1983)
being recognized specifically by antiserum R103. This antiserum v/as one
of five raised against D-Ser-But6 des GlylO ethyl amide LHRH and
recognized a substance in testicular extracts, not recognized by LHRH
antisera (Sharpe'et al., 1981).
8.2. AIMS
The studies described in this Chapter v/ere designed to investigate:-
1) The optimum method for extracting LHRH-like activity from ovarian
tissue from a variety of sources.
2) The characteristics of such a factor as determined by radioreceptor
and radioimmunoassay.
8.3 ASSAY METHODS
Prior to assay, the pH of final extract was checked and if necessary
adjusted to pH 7.4.
8.3.1 Radioreceptor assay (RRA)
The ability of LHRH and LHRH agonist, but not unrelated molecules, to
displace binding of ^^5j_lhrH agonist from ovarian tissue (Chapter 3)
provided the basis for an RRA for the detection of LHRH-like factors.
Extracts of ovarian and control tissue were therefore tested for their
ability to displace binding in the rat ovarian RPA. The degree of
parallelism betv/een the displacement of binding induced by the extract and
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that induced by unlabelled LHRH agonist, providing a measure of the
similarity between the molecules in their receptor interactions.
8.3.2 Radioimmunoassay (RIA)
Three RIAs were selected to analyse the immunological characteristies
of the extracted material: (i) an assay specific for LHRH based on an
antiserum recognizing both ends of the LHRH molecule (i.e.
"conformational" antiserum) as described by Nett et al ., (1973); (ii) an
assay specific for the C terminal sequence of LHRH based on antiserum RO
(Jeffcoate et al., 1976); (iii) an assay specific for LHRH agonist (D-Ser,
But6 des GlylO ethyl amide LHRH) based on antiserum R103 (Fraser _et
al., 1983a).
8.3.3 Sources of tissue
Bovine and porcine follicular fluids were aspirated from follicles
obtained from ovaries from the local abbatoir. Ovaries were kept on ice
and arrived between 1-6 h after removal from the animal.
Human follicular fluid was obtained from patients undergoing oocyte
aspiration for the IVF programme and was kindly supplied by Dr. 0.
Djahnbakhch with the informed consent of the patient. After immediate
transportation to the laboratory the fluid was placed on ice prior to
extraction.
Rat tissue was obtained from Sprague Oawley rats from the laboratory
colony, either from immature (26 day old) rats or from immature rats
killed 48" h after induction of follicular development with 50 IU PMSG.
Tissue was extracted immediately after removal from the animal (within 2-5
minutes after death by CO2 asphyxiation).
Control Serum was either of human origin (pooled from a number of
normal patients) or bovine origin (from a castrate bull). Serum was
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stored in 20 ml aliquots at -20°C prior to extraction.
8.4 EXTRACTION METHODS, RESULTS AND PROBLEMS
8.4.1 Acid-ethanol extraction
A method similar to that used to extract hypothalamic LHRH (Wheaton ft
McCann, 1976) and testicular LHRH-like activity (Sharpe ft Fraser, 1980b)
was used. Preliminary tests indicated that the following procedures would
recover 70-75% of 1_lHRH agonist added to serum samples.
Biological fluids from a variety of sources were extracted using an
excess (10-fold) of cold 0.1 N acetic acid/ethanol solution (1:40 v/v) at
-20°C. After thorough mixing at -20UC for at least 30 minutes the
precipitated proteins were removed by centrifugation, at 2500 rpm for 30
minutes at 4UC. The ethanol supernatant was decanted off and evaporated
to dryness using a rotary evaporator. The residue was taken up in the
appropriate assay buffer (10mM Tris HC1 for RRA, 0.1% BSA PBS for RIA, or
distilled water if further extraction was involved) to a final
concentration 3 times (Human follicular fluid) or 6 times (bovine, porcine
follicular fluid and serum) that of the original volume.
Results:- Bovine follicular fluid aspirated from large ( 7^0.5 cm
diameter) or small 0.5 cm diameter) follicles, extracted as described
displaced binding of 125j_|_hrh agonist in the rat ovarian PRA (Fig.
8.1). Bovine serum also displaced binding.
Similarly extracted human follicular fluid and human serum also
displaced binding in the rat RRA (Fig. 8.2).
Problem:- Apparent LHRH-like activity was present in serum controls
as well as follicular fluid extracts.
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FIGURE 8>1 Displacement of 125i.LHrH agonist binding to rat ovariantissue by LHRH agonist (•—•), by acid-ethanol extracts (o-o)of bovine follicular fluid from small (SF) or large (LF)follicles, or by bovine serum (B.S.).
Each point represents mean of duplicate observations.
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FIGURE 8.2 Displacement of 125j_LHRH agonist binding to rat ovarian
tissue by LHRH agonist (•—•), by acid-ethanol extracts (Ck-°)of human follicular fluid (HFF), and human serum (HS) or afterethyl ether acetate and but-an-l-ol extracted (a—a) porcinefollicular fluid (PFF) and serum (S).
Each point represents mean of duplicate observations.
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8.4.2. Acid-ethanol followed by ethyl ether acetate (EEA) and butan-1-ol
extraction
In an attempt to eliminate non-specific interference, a fat
extraction and a crude desalting step were included after the acid/ethanol
procedure. After taking up the residue, left after evaporation of the
ethanol , in 2 ml distilled water, samples were vortexed with 2 mis EEA.
The organic layer was discarded and the aqueous layer extracted using an
equal volume of butan-l-ol to dissolve peptides and leave ionic salts in
the aqueous phase. The organic layer was decanted, taken to dryness under
nitrogen and resuspended in assay buffer. These procedures led to the
recovery of 44% of added 125i_lhRH agonist tracer.
Results:- Porcine follicular fluid (from random sized follicles) and
serum were extracted to final concentration 6 times the original volume.
Both follicular fluid and serum displaced binding in the RRA (Fig. 8.2).
Problems:- 1) Low recovery of ^25j_lHRH agonist due to multiple
extraction steps.
2) Serum extracts also displaced binding.
8.4.3 Amicon ultrafiltration
In a further attempt to remove potential salt interference within the
assay systems a selective molecular separation technique was used. Since
Diaflo UM05 filters have a molecular weight cut-off of 500 daltons,
LHRH-like molecules should thus be retained while salts should be
gradually diluted out via continuous dilution of the solution with fresh
solvent washing the permeating species through the membrane.
The filters were washed prior to use with distilled water, to remove
glycerin used in storage, and soaked overnight in 5% BSA to reduce
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FIGURE 8.3 Cross reactivity of LHRH (4-A) and acid-ethanol extracts of
human follicular fluid (HFF), bovine follicular fluid (BFF)
and human serum (HS) after Amicon ultrafiltration, in an RIA
based on antiserum RO.
Each point represents mean of duplicate determinations.
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jjI SAMPLE ADDED
FIGURE 8.4 Cross reactivity of LHRH (Ar-A) and acid-ethanol extracts of
human follicular fluid (HFF), bovine follicular fluid (BFF)
and human serum (HS) after Amicon ultrafiltration, in an RIA
based on the Nett antiserum.
Each point represents mean of duplicate determinations.
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FIGURE 8.5 Cross reactivity of LHRH agonist (•—•) and acid-ethanol
extracts of human follicular fluid (HFF), bovine follicular
fluid (BFF) and human serum (HS) after Amicon ultrafiltration,
in an RIA based on antiserum R103.
Each point represents mean of duplicate determinations.
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each of 8 wells in the Amicon apparatus.
Samples of human and bovine follicular fluid, with human serum as a
control, were extracted using acid-ethanol (see 8.4.1). The residue v/as
taken up in distilled water and subjected to ultrafiltration. The
osmolality of the eluate was determined at various time intervals using an
osmometer and the samples removed only when a value similar to that
obtained from distilled water alone was reached. In practice this took
6-9 hours. The contents of the v/el 1 s were then lyophilized and
reconstituted in assay buffer to a final concentration of 1 ml :6 mis
original sample volume.
ResulLs:- Despite pre-soaking in 5% BSA the Amicon filters were
found to adsorb 40% of added 1 ^5j_|_hrH agonist.
Both human and bovine follicular fluid extracts displaced binding in
all 3 assays (Figs. 8.3; 8.4; 8.5); serum extracts were negative in RO and
Nett assays (Figs. 8.3; 8.4) but interfered in the R103 assay (Fig. 8.5).
Problems1) Adsorption of ^^5j_lhRH on filters.
2) Prolonged extraction time at room temperature.
3) Presence of LHRH-like and LHRH agonist-like material
in follicular fluid extracts.
4) Serum interference in R103 assay.
8.4.4 Solid phase purification using Sep-pak columns
A relatively simple, rapid method for the extraction and purification
of peptides had been described using the ability of octadecasilyl silica
to adsorb peptides from large volumes of aqueous solution and then release
them into solvent mixtures such as methanol (Bennett et al ., 1977).
Two methods were adopted and both enabled extraction of 80% of
125i_lhrh agonist from serum.
231
8.4.4.1 Method A
This method had been utilized successfully to extract peptide
fragments from somatostatin and corticotropin from both fluid and tissue
samples (Bennett et al ., 1977; 1978). Rat ovarian tissue (from immature
and PMSG-treated rats) and liver tissue were homogenized on ice (10 mls/g)
in a solution of 5% formic acid, 15% trifl uoroacetic acid (TFA as a
deproteinizing agent) in IN hydrochloric acid (HC1). After centrifugation
at 2500 rpm for 30 minutes at 4°C to pellet the proteins and tissue
debris, 5 ml samples of supernatant were applied slowly (5 minutes loading
time) to a Sep-pak 1 ml disposable column (Millipore Waters Assoc., Mass.
U.S.A.). The column had been pre-washed with methanol and distilled
water. The eluate was passed through the column a second time.
After sample loading the column was washed through with 5 mis 1% TFA,
and the eluate, from the final wash with 5 mis of methanol :water:TFA
(80:19:1 v/v) solution was collected and evaporated to dryness under
nitrogen. The residue was taken up in assay buffer for RIA using antisera
RO and R103 to a final concentration equivalent to 200 mg wet weight of
tissue per ml. A control solution of extracted distilled water was
also assayed. This had been passed through the column as described.
Results:- None of the extracts cross-reacted in the RO assay and
only the data from R103 is shown in Fig. 8.6. Control fluid was negative
but both ovarian and liver extracts cross-reacted with the antiserum.
Problem:- Liver 'control1 tissue cross-reacted in R103 assay.
8.4.4.2 Method B
This method had been employed for the extraction of met-enkephalin
from human plasma and cerebrospinal fluid (Clement-Jones et al., 1980).









































































different elution procedure was utilized.
10 ml samples of bovine follicular fluid or serum were acidified with
0.1 ml formic acid and centrifuged at 2500 rpm for 30 minutes at 4°C. The
supernatant was applied to a Sep-pak column. The column had been
pre-washed in sequence with 1 ml 1% TFA, 1 ml methanol :TFA:water (80:1:19
v/v) solution, 1 ml 1% TFA and 1 ml 1% formic saline with 1.6% glycine in
INHC1. After sample loading the column was washed with 1% formic acid
followed by 1 ml 1% TFA and the sample eluted with 1 ml TFA:methanol:water
solution. After evaporation to dryness the residue was taken up in assay
buffer to a final concentration 6 times the original volume.
Results:- Neither of the extracts cross-reacted in R0 assay. Roth
follicular fluid and serum extracts cross-reacted in the R103
radioimmunoassay (Fig. 8.6).
Problems:- 1) No cross-reactivity in R0 assay (compare Fig. 8.3).
2) Serum interference in R103 assay.
8.4.5 Acetic Acid extraction
This method had been successfully utilized to demonstrate the
presence of testicular LHRH-like material (Sharpe & Fraser, 1980b). Rat
ovarian (from immature or PMSG primed rats) and liver tissues were
homogenized in 10 mis of either 0.3 N or 0.02 N acetic acid immediately
after removal from the animal and boiled for 15 minutes to inactivate any
remaining functional enzymes. After centrifugation at 2500 rpm for 30
minutes at 4°C the supernatant was lyophilized and the residue taken up in
assay buffer to a final concentration equivalent to 200 mg wet wt/ml.
Results:- Control extracts of boiled, lyophilized acetic acid were
without activity in all assays (Figs. 8.7; 8.9). Roth liver and ovarian








































































































































































































































FIGURE 8.10 Displacement of 1^5j-LHRH agonist binding to rat ovarian
tissue by LHRH agonist (•—•) and 0.3 N acetic acid extracts of
ovaries from immature rats (I) or from rats 48 h after PMSG
treatment (0) and rat liver (L) with acid control (C).
Each point represents mean of duplicate determinations.
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and R103 (Fig. 8.8) assays, but not in the Nett assay (Fig. 8.9).
Ovarian tissue extracted with 0.3 N acetic acid cross-reacted in P.O
(Fig. 8.7) and R103 (Fig. 8.8) assays, liver extracts gave minimal
displacement. Only extracts of immature ovaries showed a minimal
displacement in Nett assay (Fig. 8.9).
These extracts were also tested in the ovarian RRA (Fig. 8.10). Both
liver and acid controls showed no displacement whereas both ovarian
extracts displaced binding.
Problems1) Non-parallel displacement of binding in assays.
2) Repeatability of results. Additional experiments
using these procedures (i.e. 0.3 N acetic acid) gave
either essentially the same result or no activity at
all in any of the assays.
3) Immature ovarian tissue totally abolished binding in
R103 and RO but not Nett or RRA.
8.5 DISCUSSION
The results presented in Figs. 1-10 are an illustration of some of
the problems encountered whilst attempting to demonstrate the existence of
a specific LHRH-like peptide in ovarian tissue. The most common problem
was that of interference of 'control' extracts from liver or serum.
Several methods were tried in an attempt to extract the peptide. Since
concentrating may have increased non-specific interference such as salt,
methods to remove salt were tried. The only techniques which resulted in
minimal 'control' interference were, UM05 ultrafiltration and 0.3 N acetic
acid extraction. The latter method appeared to be the most promising,
extracts indicating the presence of LHRH-and LHRH agonist-like material
(cross-reactivity in P.O and R103 assays) non-identical to LHRH (no effect
in Nett assay) in ovarian, but not liver tissue. Immature ovarian tissue
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obliterated binding in P.103 and RO assays which may indicate a high
concentration of material in this tissue compared with PMSG primed tissue.
However, another major problem encountered with 0.3 N acid extraction was
that of repeatability. The same procedure was repeated numerous times,
either revealing a similar pattern to that described or no activity at all
in any extract. Thus no concrete data was obtained as to the presence or
nature of a putative LHRH-like factor in the ovary.
Several points must be borne in mind when assessing data on LHRH-like
factors:-
1) Ovarian LHRH receptor concentrations are 25% those of the pituitary
(see Chapter 3). Therefore since it is likely that a putative
endogenous ligand is present in very small quantities, extraction
procedures consequently need to utilize large amounts of tissue. Use
of the subsequent 'concentration' of crude extracted material
inevitably risks inducing abnormally high levels of non-specific
substances such as salt which may interfere with the assay systems
used. It is therefore essential to include data from control
extracts in order to assess the tissue specificity of the data
presented. In the experiments reported, tissue was concentrated to a
final level equivalent to 200 mg wet wt/ml and fluids concentrated
3-6 times. It could be suggested either that these levels were
insufficient to provide enough peptide material or that the
concentration factor was too great to exclude non-specific
interference. Relatively few studies in the literature have included
data on control extractions (Table 8.1).
2) If the putative intragonadal LHRH-like factor is a small locally
produced and acting peptide it is likely to be degraded rapidly, thus
240
hampering extraction efficiency. This may explain the variability in
the data obtained (Figs. 1-10). Degradation was minimized in these
studies by performing all rat tissue extractions immediately after
removal from the animal under enzyme-inactivating or protein-
denaturing conditions. However, with the follicular fluids obtained
from slaughter house or hospital sources there was considerable delay
between removal of the follicular fluid from the female, and
extraction. Degradation of peptides by endogenous peptidases had
most likely occured prior to extraction of these samples.
3) The current available data suggests that extra-hypothalamic factors
are LHRH-like. The majority of extraction procedures utilized have
been based on the assumption that the molecule of interest is a small
molecular weight peptide (see Table 8.1). However, this may not be
the case. It is already clear from a number of studies that
hypothalamic LHRH is present in a number of molecular forms, assumed
to be precursor or prohormones, and is therefore a heterogeneous
n
molecule (Rarnea & Porter, 1975; Steijberger et al ., 1981; Gautron et
al., 1981). The same characteristic has been suggested for
testicular LHRH. Dutlow R Millar (1981) have suggested the presence
of multiple forms of LHRH-like activity from acid-extracts of the
testis which, when subjected to affinity chromatography and Sephadex
G100 separation gave 4 immunoreactive peaks with apparent molecular
weights ranging from <4.4,000 to 100,000. Two forms of testicular
LHRH with widely differing molecular weight were also suggested by
Bhasin et al., 1983.
Thus, since the chemical identity of the putative endogenous ligand
is uncertain, the extraction procedures employed in these experiments
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may be inappropriate for the nature of the ligand.
4) Although it is of primary importance to rule out the possibility that
the observed characteristics of extracted material are due to
non-specific factors, it is uncertain what appropriate 'control'
tissues to include. Serum has been indicated to contain
immunoreactive LHRH (e.g. Miyake et al., 1980; Sarda et al., 1981).
A macromolecule cross-reacting with LHRH antisera has been located in
liver (Barnea & Porter, 1975) and direct effects of LHRH have been
reported in kidney (Lecomte et al ., 1982) and adipose tissue (Murthy
& Modesto, 1974). LHRH receptors have been reported in the adrenal
gland (Bernardo et al ., 1978).
In addition, since LHRH may be a neurotransmitter in the sympathetic
nervous system (see Chapter 1) detection of LHRH-like material in
tissues may only reflect sympathetic innervation of that tissue.
8.6 CONCLUSIONS AND FUTURE PROSPECTS
From the data presented in this Chapter it is evident that many
problems were encountered during the investigation of gonadal LHRH-like
peptides and no firm conclusions could be made as to the existence of an
intragonadal LHRH-like factor.
Other investigators have attempted to isolate ovarian LHRH and repeat
the observations of Ying & Guillemin (1980) but have met with little
success. Thus immunohistochemical localization of ovarian LHRH-like
material has been unsuccessful (Moss et al ., data reported in Smith-White
& Ojeda, 1983) as have further radioimmunological methods (Ojeda,
unpublished observations cited in Smith-White & Ojeda, 1983). However,
LHRH bioactivity has been suggested to be present in dextran-charcoal


















































































































































provides a summary of some of the data presented in the literature on
LHRH-1ike peptides, with a number of studies failing to include 'control'
data.
Due to the pitfalls inherent in RIA and P.RA methods, particularly
interference by non-peptide molecules, perhaps a more promising approach
wou 1 d be to utilize an ovarian bioassay for ovarian extracts, namely
isolated follicles (Chapter 7). The bioactivity as regards stimulation of
basal androgen and progesterone could be assessed together with the
ability of LHRH antagonists and/or peptidases to inhibit the effect.
The problems encountered in the experiments detailed earlier have
been echoed by a recent report concerning the observations of Ying et al .,
1981. The group has failed to repeat the demonstration of a
"gonadocrinin" (Esch et al ., 1983). They report "occasional evidence" for
activity (see 8.4.5) and similar activity was found to be present in
'control" tissues, lung and kidney, even after purification by HPLC. (A
similar problem has been encountered with testicular extracts following
HPLC - see Sharpe & Harmer, 1983). In addition, activities similar to
LHRH and LHRH agonist were reported (Esch et al ., 1983; Sharpe & Harmer,
1983).
Esch et al ., (1983) suggested several explanations for their data.
Firstly that the rat ovary contains two molecules, LHRH and LHRH agonist
(although reservations were expressed as to the biological equivalent of
DTrp). Secondly, that activity in 'control' tissues represents
insignificant production of minute amounts of the molecule due to
occasional derepression of the gene. Finally that the data published
previously on the isolation of gonadocrinin was an artefact due to
contamination of the extracts with LHRH (Esch et al., 1983). They
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concluded "it may thus be still true that gonadal tissues do contain
LRF-1ike peptides. If this should eventually be proven beyond doubt, our
early conclusions would deserve no scientific credit since we can not
exclude the possibility that we are dealing with an artefact".
In conclusion, therefore, evidence for the existence of an intra-
ovarian LHRH-like factor is not convincing. This chapter has attempted to
indicate some of the pitfalls inherent in its isolation and assay. To
date, no adequate character!"zation of such ovarian material has been
achieved and in the majority of reports so far published, the contribution







9.1 PITUITARY LHRH RECEPTORS
9.2 OVARIAN LHRH RECEPTORS
9.3 DIRECT OVARIAN ACTIONS OF LHRH AND LHRH AGONIST
9.1. PITUITARY LHRH RECEPTORS
The first part of this thesis was concerned with a consideration of
the mechanisms governing changes in LHRH receptors. Pituitary LHRH
receptor concentrations were markedly altered by experimental regimes
associated with an interference with endogenous LHRH release, such as
immunoneutralization of LHRH. It was therefore suggested that receptor
autoregulation was an important means of controlling pituitary LHRH
receptors (Chapter 4). However, the relevance of these observations as
regards the antifertil ity effects of LHRH and LHRH agonist or the control
of pituitary responsiveness under physiological conditions is unclear.
One of the mechanisms suggested to explain the antifertility effects
of LHRH agonist was a decreased pituitary responsiveness due to decreased
or down-regulation of LHRH receptors (Chapter 1). Chronic administration
of a range of doses of LHRH agonist resulted in an impairment of
reproductive function despite the fact that pituitary LHRH receptors were
within the cyclic range (Chapter 4). It seemed unlikely therefore that
receptor down-regulation could explain the noted antifertil ity effects.
This conclusion is supported by examination of the doses of LHRH agonist
required to elicit receptor down-regulation compared with those causing
antifertility effects. Decreased pituitary receptor concentrations (a net
loss of only 32%) occurred only after 6 day infusion with 30 ng LHRH
agonist (Clayton, 1982) and thus the 'threshold' for receptor
down-regulation appears to be extremely high. In contrast, much lower
doses of LHRH agonist 0.2 ng, Arimura et al ., 1980 and 1 ng (Johnson _et
asl_., 1976a; Vi 1 chez-Marti nez et al ., 1979) per day have been reported to
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inhibit reproductive function. In conclusion, antifertil ity effects of
LHRH agonist are not invariably correlated with decreased pituitary LHRH
receptors. However, pituitary responsiveness is clearly impaired
following prolonged LHRH administration, as was shown by the failure of
oestrogen to induce an LH surge in treated ewes (e.g. Rippel et al.,
1974). In addition, the ability of the pituitary to respond to exogenous
oestrogen-induced positive feedback was abolished, delayed or reduced in
macaque monkeys treated chronically with LHRH agonist (Fraser, 1981b). It
is likely therefore that decreased pituitary responsiveness can occur by
mechanisms other than LHRH receptor down-regulation, e.g. post-receptor
mechanisms involved with synthesis and secretion of gonadotrophins.
The relevance of receptor down-regulation in the control of pituitary
LHRH receptors under physiological conditions is also questionable.
Removal of endogenous LHRH did not result in an increased receptor
concentration indicative of removal of a negative regulator. In addition,
abolition of the pro-oestrous surge of LHRH by immunoneutralization,
failed to prevent the receptor decrease at oestrus (Chapter 4). It is
likely therefore that reduced LHRH receptor numbers under physiological
conditions are due, either to the influence of heterologous ligands such
as steroids (as implicated by Giguere et al ., 1981; Adams et al ., 1981a)
or to removal of LHRH as a positive regulator of its own receptors.
Endogenous LHRH concentrations are unlikely to reach the high threshold
values necessary for receptor down-regulation, under physiological
conditions.
The majority of evidence presented in this thesis and in the
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literature suggests that LHRH autoregulation is primarily one of up-
regulation i.e. a maintenance or increase in receptor numbers. Thus
administration of more physiologically representative doses of LHRH or
LHRH agonist resulted in increases in pituitary receptor numbers both in
vivo (e.g. Frager et al., 1980; Dal kin et al ., 1981; Naess et al ., 1981;
Heber et al ., 1982; Marchetti et al., 1982; Clayton, 1982; Pieper et al.,
1982) and in vitro (Loumaye & Catt, 1982; Smith et al ., 1983). In
addition, receptor changes appeared to mirror those of known or assumed
changes in endogenous LHRH levels; thus when pituitary exposure to
endogenous LHRH was reduced (by active or passive immunization against
LHRH), LHRH receptors were reduced, and conversely when LHRH output was
assumed to be elevated, e.g. after castration receptor numbers were
increased (Chapter 4).
Whereas the mechanism by which receptor down-regulation can occur is
largely acknowledged to be via receptor mediated endocytosis and
degradation of the hormone-receptor complex (see Goldstein, 1979), the
mechanisms for receptor up-regulation are unknown. Since LHRH receptors
are known to be internalized after exposure to LHRH (see Chapter 3) the
fact that receptor numbers are unchanged or even increased following LHRH
administration, implicates a rapid receptor turnover. Application of
cycloheximide with LHRH, resulted in a decreased receptor levels below
that of controls, indicating continual synthesis and turnover of LHRH
receptors under normal conditions (Smith et al ♦, 1983).
Several mechanisms can be postulated to account for increased
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FIGURE 9.1 Diagramatic representation of suggested mechanisms by which
interaction of LHRH (^ ) with its pituitary receptor (• )
could cause increases in the concentration of receptors seen
at the cell surface. For details see text.
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diagramatical ly in Fig. 9.1. The first mechanism involves LHRH
stimulation of cellular protein synthesis (a phenomenon noted by Hsueh &
Jones, 1982b) and production of its own receptors (Fig. 9.1a). Since
cycloheximide abolishes receptor up-regulation in vitro (Smith et al .,
1983) this mechanism is clearly a valid one. It would be interesting to
determine whether or not the dioestrous to pro-oestrous receptor rise is
due to de novo synthesis of receptor protein.
Secondly, a more rapid response could be envisaged if interaction of
LHRH with its receptor resulted in unmasking of other membrane receptors,
either due to removal of an impeding molecule (Fig. 9.1b) or to changes in
membrane fl uidity mobil izing and exposing receptors (Fig. 9.1c). Finally,
since LH receptors have been suggested to be present on membranes of
exocytotic secretory granules (Suter et al ., 1980) and since pituitary
uptake of LHRH occurred as long as LH release continued (Duello & Nett,
1980) it could be suggested that LHRH receptors are present on the
membranes of LH-secretory granules, being incorporated into the plasma
membrane as LH is secreted (Fig. 9.Id). In agreement with this
hypothesis, LHRH receptors have been located on the limiting membrane of
secretory granules (Sternberger & Petrali, 1975).
It is important to realise however that although LHRH receptor up-
regulation occurs, changes in receptor numbers are not invariably
correlated precisely with endogenous LHRH levels. For example, during the
oestrous cycle, receptor numbers increase from the afternoon of dioestrus
one, well before the endogenous surge of LHRH in portal blood (see Fig.
9.2). Since immunoneutral ization of LHRH at this time prevented the
receptor rise (Chapter 4) it could be suggested that LHRH up-regulation
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involves the qualitative pattern of LHRH release as well as the
quantitative amounts released. This may also be the reason why the post-
castration receptor increase (see Chapter 4) precedes that of the reported
increase in endogenous LHRH (e.g. Sarkar & Fink, 1980).
It is a generally accepted principle that where tissue receptors are
present in excess, changes in receptor numbers will alter, not the maximum
potential response, but the responsiveness of that tissue to the ligand
(e.g. Catt et al ., 1979 for review). Initial studies confirmed a
correlation between pituitary LHRH receptors and pituitary responsiveness
to LHRH (reviewed in Chapter 4). However, a number of more detailed
studies have implied that the relationship is not a simple one. Thus as
discussed earlier the decrease in pituitary responsiveness following
chronic LHRH agonist administration, was not correlated with decreased
receptors. In addition, studies in the male rat, described in Chapter 4,
showed no close correlation between pituitary LHRH receptors and serum LH,
following passive immunization against LHRH. Receptor recovery preceded
that of serum LH and testosterone.
Similar observations can be made from a more detailed look at the
correlation between receptor concentrations and pituitary responsiveness
to LHRH during the rat oestrous cycle. Fig. 9.2 details data (centred
round the time of the LH surge) on receptor numbers (from Clayton et al.,
1980), endogenous LHRH release (from Levine Ft Ramirez, 1982) and pituitary
responsiveness to a set dose (50 ng/100 g wt) of exogenously administered
LHRH (from Aiyer et al., 1974a). Receptor numbers are maximal at the time
of maximal responsiveness (namely pro-oestrus) and minimal at the time of
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FIGURE 9.2 Summary of data obtained from a number of sources on changes
during the rat oestrus cycle in pituitary LHRH receptors (from
Clayton et al., 1980), endogenous LHRH output (from Levine &
Ramirez, 1982) and pituitary responsiveness to a 50 ng dose of
LHRH as regards LH release (Aiyer et al., 1974a).
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receptor numbers are increased to pro-oestrous levels on dioestrus day 2,
yet pituitary responsiveness is low. This data also indicates that
pituitary responsiveness is not invariably correlated with changes in LHRH
receptors and implies that other factors are involved.
This conclusion has been reached by a number of others. Pituitary
cells isolated from rats from different stages of the oestrous cycle
showed the expected differences in responsiveness to LHRH. However,
similar differences in the amount of LH released in response to a
different secretagogue, namely potassium (K+), were found. This data
also indicated that pituitary responsiveness, as regards LH release, is
independent of LHRH receptor changes (Speight & Fink, 1981).
Pituitary desensitization occurred after continuous exposure to LHRH
in vitro (Smith & Vale, 1981; Badger et al., 1983). This was not due to
depleted LH stores since further LH release could be induced by K+
(Smith & Vale, 1981). It was expected therefore that this phenomenon was
due to loss of LHRH receptors similar to the loss of epidermal growth
factor (EGF) receptors noted after continuous exposure of cells to EGF
(Heldin et al., 1979; see Catt et al ., 1979). A number of studies have
attempted to correlate the two parameters using isolated pituitary cells
for simultaneous measurement of receptor concentrations and LH release.
Initial studies showed a coincidence of pituitary desensitization
with loss of LHRH receptors after continuous exposure of isolated cells to
LHRH (Zilberstein et al ., 1983). However, this was by no means a general
finding. Thus receptor numbers decreased during culture, whereas
responsiveness increased (Naor et al., 1980). Pituitary desensitization
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induced by continuous exposure to LHRH, was accompanied by an increase in
receptors (Smith & Vale, 1983). This latter observation, namely low
responsiveness in the absence of receptor decrease, has also been shown in
vivo (Heber & Swerdloff, 1980) and is analogous to the situation described
on dioestrus two. In addition, the converse has been shown since the
self-priming effect of LHRH was reported to be accompanied by a decrease
rather than an increase in LHRH receptors (Ferland et al., 1981).
It is likely therefore that post-receptor events are important in
determining pituitary gonadotroph!"n release (Heber & Swerdloff, 1980;
Speight & Fink, 1981; Smith & Vale, 1983). These phenomena have been
described for other systems e.g. insulin receptors (Heaton & Gelehrter,
1981) and alpha adrenergic receptors (Takeyasu et al ., 1981).
However, these observations detailing a lack of correlation between
receptor numbers and responsiveness, are based on two assumptions, namely
that the receptor assay used determines the total number of available
receptors and that these receptors are all functional. These criteria may
not be valid in all cases. Thus, measurement of receptor numbers in
homogenates may include internal receptors and give different values from
those estimated from whole cells. However this is unlikely, since similar
receptor changes have been observed using either isolated cells or
homogenates during the oestrous cycle (see CIayton et al ., 1980; Meidan &
Koch, 1981). Alternatively decreases in receptor numbers may be apparent,
(rather than representing true receptor loss), due to receptor occupancy
by endogenous or added ligand (e.g. Smith-White & Ojeda, 1983). Finally
it is possible that receptors are present in several forms within the cell
membrane. It could be envisaged that receptors capable of binding LHRH
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(and thus giving an apparent high receptor concentration value) are not
functionally linked to the gondotrophin-releasing apparatus. In addition,
receptors may be non-randomly distributed over the cell surface.
Responsiveness could therefore be controlled by regulating the
distribution and relative proportions of coupled and uncoupled receptors
without altering total receptor concentrations. These possibilities might
explain why receptor down-regulation is not invariably associated with
periods of decreased responsiveness and why, likewise an increase in
receptors does not necessarily confer increased responsiveness. Thus the
receptor assay is unlikely to distinguish between functionally active
receptors, or between changes in receptor microaggregation or coupling to
calcium mobilizing proteins.
Moreover, it must be remembered that 'pre-receptor' regulatory
mechanisms may be equally important in determining pituitary
responsiveness to LHRH in vivo. A synthetic peptidase substrate was
suggested to compete for binding to LHRH receptors (Kuhl & Raumann, 1981),
an observation which may indicate the presence of plasma membrane-
associated degrading enzymes regulating the effective concentrations of
LHRH (whether of endogenous or exogenous origins). In this regard it is
important to remember that the 125j_LHRH agonist receptor assay only
detects changes in numbers of high affinity LHRH receptors. The low
affinity receptors, present in greater concentrations (see Chapter 3) may
represent enzymes degrading LHRH, therefore changes in the concentrations
of these receptors may also regulate pituitary responsiveness to LHRH in
vivo.
In conclusion, although LHRH is clearly important for the maintenance
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and 'up-regulation' of its pituitary receptors, the relative contributions
of changes in receptor concentrations, together with pre- and post-
receptor mechanisms in the regulation of pituitary responsiveness to LHRH
in vivo, remain to be established.
9.2 OVARIAN LHRH RECEPTORS
Despite extensive investigations on the biochemical nature and
characteristics of ovarian LHRH receptors (see Chapter 3) surprisingly
little is known either about their physiological significance in terms of
ovarian function, or their regulation. It was evident from data presented
in Chapter 5 that ovarian LHRH receptors were not controlled in parallel
with those of the pituitary. This is not particularly surprising in view
of the widely different functions of both receptors.
The distribution of ovarian LHRH receptors revealed one of the
underlying difficulties in assessing receptor changes - namely their
distribution between all ovarian compartments (see Chapter 3). The
limited data available on changes in receptor concentrations in individual
cell compartments suggested that granulosa cell receptors were altered
during puberty (Smith-White & Ojeda, 1983) and were regulated by both LHRH
and FSH (Ranta et al ., 1982). In addition, since active immunization
against LH or LHRH resulted in increased receptor concentrations (Chapter
3) a role for LH in the long-term regulation of ovarian receptor
concentrations was implicated. As yet however, no data is available on
relative changes of receptor concentrations between individual ovarian
compartments.
In addition, no studies have attempted to assess changes in the
sensitivity of ovarian cells to LHRH. It is interesting to note that one
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of the periods of highest receptor concentration (namely, during
immaturity see Smith-White & Ojeda, 1981) was also a period when no short-
term stimulatory effects could be determined in isolated follicles
(Chapter 7), thus implicating either a role for post-receptor regulation
or the presence of non-functional receptors at this time.
9.3 DIRECT OVARIAN ACTIONS OF LHRH AGONIST
Although direct effects of LHRH have been demonstrated on both
follicular and luteal tissue (see Chapters 1 & 7) these studies have
almost entirely utilized model systems to induce formation of ovarian
tissue. Only one study has provided evidence for direct ovarian effects
of LHRH in cycling rats, namely that of Corbin & Bex, (1981) showing
induction of ovulation in hypophysectomized pro-oestrous rats. It would
be of considerable interest to determine the steroidogenic responsiveness
of rat follicles isolated during different stages of the oestrous cycle.
Limited data reported in Chapter 7 indicated that follicles isolated from
untreated immature rats were not responsive to LHRH agonist whereas those
of a "dioestrous" of "pro-oestrous" type were. Ovarian responsiveness to
LHRH may therefore vary during the life of the rat. In addition a recent
report from Hi 11 ensjo et al ., (1983) suggested that LHRH stimulated oocyte
maturation in oocytes of small antral follicles but not pre-antral
fol1icles.
Data presented in Chapter 7 emphasised a stimulatory role of LHRH and
LHRH agonist with regard to both thecal and granulosa cell function
(summarized in Fig. 9.3). These stimulatory effects were on basal rather





FIGURE 9.3 Summary of some of the stimulatory actions of LHRH on ovarian
follicular function involving stimulation of basal androgen
(A) progesterone (P) and possibly oestradiol (E2)
production.
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inhibitory action seen in previous studies (see Chapter 1 and Fig. 1.1).
Several differences are evident between the earlier studies indicating an
inhibitory action of LHRH, and the data presented on stimulatory effects.
Firstly, inhibitory effects were noted after prolonged incubation
(^>24 h) and were on gonadotrophin-induced events, basal changes not
being reported (Table 9.1). In contrast, stimulatory effects were noted
in short-term incubations { ^L. 20 h). Secondly, demonstration of
inhibitory actions of LHRH on rat granulosa cell function have been
confined exclusively to the model system of the immature rat (usually
hypophysectomized) treated with diethyl sfcilhjestrol (DES) (see Hsueh &
Jones, 1981 for review). This model is known to induce pre-antral
follicle development yielding large numbers of relatively undifferentiated
granulosa cells, with minimal gonadotroph!'n stimulation (Hillier et al.,
1977), by a direct effect of PES on the ovary, together with augmentation
of subsequent ovarian responses to gonadotropin ns (Meyer & Bradbury,
1960). In contrast, demonstration of stimulatory effects of LHRH or LHRH
agonist have been confined exlusively to follicles or granulosa cells
after follicular development had been induced by PMSG (Table 9.1). It
could be suggested therefore that the responsiveness of follicular tissue
to LHRH depends on prior exposure to gonadotrophins. Prior to and after
initial exposure to gonadotrophins (in growing pre-antral follicles) LHRH
exerts inhibitory actions, whereas after adequate gonadotrophs priming
(e.g. in pre-ovulatory follicles) LHRH actions are stimulatory (see Fig.
9.4). This hypothesis ha£ been confirmed by very recent studies by Naor
















































































































































































FIGURE 9.4 Schematic diagram indicating a possible role for LHRH as an
intra-ovarian regulatory factor, derived from studies on
responses to LHRH and LHRH agonist. Diagram from Fraser et
al., 1983b.
261
ovulation was found to depend on the follicular stage of development
rather than the dose or duration of exposure to LHRH. A non-gonadotrophin
primed follicle was inhibited by LHRH agonist whilst a PMSG-primed
follicle was stimulated (Naor et al ., 1983).
Luteal tissue has been studied either as "granulosa-1uteal" cells
prepared by sequential treatment of granulosa cells (from
hypophysectomized DES treated immature rats) with FSH and hCG (Jones _et
al., 1980) or from luteal tissue induced by PMSG/hCG treatment (Clayton et
al., 1979a; Harwood et al ., 1980; Rehrman et al ., 1980; Hall et al.,
1981). LHRH has been found to be inhibitory to both basal- and hCG/LH-
stimulated events using either model. It appears therefore that a
fundamental difference exists between the responsiveness of luteal and
follicular tissue. Prior to ovulation, LHRH appears to induce either
stimulation or inhibition, after ovulation LHRH actions are entirely
inhibitory (Fig. 9.4).
However, it must be emphasized that almost all the studies on direct
ovarian actions of LHRH have utilized model systems in which specific
ovarian states have been artificially induced. The physiological
significance of these observations on the control of follicular growth,
atresia and luteal function in vivo during the events of a normal oestrous
cycle remain speculative.
The relevance of direct gonadal actions of LHRH to species other than
the rat is unclear. Isolated mouse Leydig cells failed to respond to LHRH
(Hunter et al ., 1982). However, FSH-induced increases in progesterone and
cAMP from porcine granulosa cells were inhibited by LHRH agonist
(Massicotte et al., 1980). LHRH agonist stimulated progesterone
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production from perfused rabbit ovaries in vitro (Koos et al ., 1982) and
inhibited LH-stimulated progesterone synthesis in isolated bovine luteal
cells (Milvae A Hansel, 1980). Whether such direct effects occur in
primates is unclear. Although no binding or direct effects have been
reported in monkey corpora lutea (Asch et al ., 1980; 1981) a recent report
by Knecht cited unpublished evidence for a direct inhibitory effect of
LHP.H on progesterone production in cultured granulosa cells from FSH-
treated monkeys (Knecht et al., 1983).
Data presented in Chapter 6 indicated the presence of specific
binding sites for LHRH in human luteal tissue. These sites may also be
present on human granulosa cells and mediate the LHRH agonist inhibition
of progesterone production (Turek et al., 1982). Although the affinity of
these human luteal binding sites was relatively low, and therefore their
physiological significance uncertain, they may be activated by high levels
of exogenously administered LHRH and LHRH agonist used clinically.
Finally, the question whether the gonad contains LHRH-like material
was assessed in Chapter 8. No satisfactory data were obtained, and the
question as to the existence of a specific intra-ovarian LHRH-like peptide
remains unsolved. A new approach is required to investigate this
phenomenon in view of problems encountered in the procedures described in
Chapter 8. The most promising direction for the future lies with
techniques of molecular biology. With the isolation of mRNA for rat
hypothalamic LHRH (Curtis & Fink, 1983) it would be possible to produce a
complementary, cDNA copy to utilize as a specific probe for the detection
of such mRNA in a wide variety of tissues. Only when the existence,
source and pattern of release of the postulated intra-ovarian LHRH-like
molecule is known can the physiological significance of the direct ovarian
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